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Microglia are a tissue-resident immune cell of the central nervous system known to possess 
functions involved in immune surveillance and tissue homeostasis. Transcriptomics has 
characterised microglia and enabled discovery of microglial heterogeneity in addition to core 
microglial transcriptional programmes. However, investigation of microglia during severe 
inflammatory contexts has been challenging because no markers reliably discriminate them 
from the monocyte populations that ingress during inflammation. Nonetheless, candidate 
markers have been identified; these show promise in specific microglial identification yet 
remain to be widely validated. 
Within the literature, there are conflicting reports on how microglia regulate or promote 
inflammation depending on the tissue insult. However, it is well-recognised that the 
homeostatic state of microglia is altered yet it remains unknown if this state is restored post-
resolution. Furthermore, understanding the plasticity of microglial responses to both acute and 
persistent inflammation within the eye will help to determine the extent to which different 
pathways are perturbed. 
The purpose of this thesis was to investigate the transcriptional changes that occur in retinal 
microglia in response to inflammation and whether the homeostatic threshold remains 
perturbed after acute and/or chronic inflammation. 
The data presented herein demonstrates how an ultra-low input mRNA-Seq approach was 
optimised and validated to permit transcriptomic assessment of low numbers of cells isolated 
from individual retinas. The Cx3cr1CreER:R26-tdTomato mouse line was then validated as 
microglial-specific during inflammation. mRNA-Seq was utilised to profile the temporal 
kinetics of the microglial transcriptome in the acute endotoxin-induced uveitis (EIU) model. 
Restoration of the microglial homeostatic state was confirmed, and key marker changes were 
orthogonally validated. Furthermore, C5AR1 was validated as a marker for differentiating 
microglial subsets during inflammation. The next steps have begun to examine microglial 
behaviour in experimental autoimmune uveitis (EAU), a model of chronic inflammation, and 
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Bst2 Bone marrow stromal antigen 2 precursor 
BV Brilliant Violet 
BWA Burrows-Wheeler aligner 
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CC BY Creative Commons ‘Attribution’ licence 
CC BY-NC Creative Commons ‘Attribution’ licence (non commercial) 
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cDNA Complementary DNA 
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CSF1R Colony stimulating factor 1 receptor 
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 
CX3CL1 C-X3-C motif chemokine ligand 1 
CX3CR1 C-X3-C motif chemokine receptor 1 
CXCL C-X-C motif chemokine 
Cy7 Cyanine-7 
DAM Damage-associated microglia 
DAMP Damage-associated molecular pattern 
DAVID Database for annotation, visualization and integrated discovery 
DC Dendritic cell 
DCQ Digital cell quantification 
Dd(H2O) Double-distilled water 
DEG Differentially-expressed gene 
DESeq Differential expression analysis for sequence count data 
DGEA Differential gene expression analysis 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 




EAE Expeirmental autoimmune encephalomyelitis 
EAU Expeirmental autoimmune uveitis 
ECM Extracellular matrix 
EDASeq Exploratory data analysis and normalization for RNA-Seq 
edgeR Empirical analysis of DGE (digital gene expression) in R 
EDTA Ethylenediaminetetraacetic acid 
eGFP Enhanced GFP (green fluorescent protein) 
EIU Endotoxin-induced uveitis 
ELM External limiting membrane 
EMBL-EBI European bioinformatics institute 
ENCODE Encyclopedia of DNA elements 
ER Oestrogen receptor 
ERCC External RNA controls consortium 
ERG Electroretinogram 
ERK Extracellular signal-regulated kinase 
FACS Fluorescence-activated cell sorting 
Fas Fas cell surface death receptor 
FDR False discovery rate 
FISH Fluorescence in situ hybridisation 
FITC Fluorescein isothiocyanate 
FMO Fluorescence minus one 
FPKM Fragments per kilobase of exon model per million reads mapped 
FPR False positive rate 
FPS Frames per second 
G (e.g. 25G) Gauge (refers to needle diameter) 
GCL Ganglion cell layer 
GEO Gene expression omnibus 
GFP Green fluorescent protein 
GO Gene ontology 
GPCR G protein-coupled receptor 




GSEA Gene set enrichment analysis 
GSNAP Genomic short-read nucleotide alignment program 
GTEx Genome tissue expression 
GUI Graphical user interface 
HISAT Hierarchical indexing for spliced alignment of transcripts 
HLA Human leukocyte antigen 
IFN Interferon 
IL Interleukin 
ILC Innate lymphoid cell 
ImmGen Immunological genome project 
INL Inner nuclear layer 
IPA Ingenuity pathway analysis 
IPL Inner plexiform layer 
IRBP Interphotoreceptor retinoid-binding protein 
IS Rod and cone inner segment 
KEGG Kyoto encyclopedia of genes and genomes 
Lair1 Leukocyte-associated immunoglobulin-like receptor 1 
LCM Laser capture microdissection 
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lncRNA Long non-coding RNA 
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1.1 Intraocular Inflammation  
Chapter I: Introduction 
Intraocular inflammation, commonly described as uveitis, refers to a spectrum of autoimmune-
autoinflammatory diseases of the eye and infection locally to the eye [1]. Non-infectious uveitis 
is relatively rare, having estimated incidence rates of 17–52 individuals per 100,000 per year and 
prevalence rates of between 40–400 individuals per 100,000 [2-5] (or 1 in 250–2,500 individuals). 
It is more common in females than males [6-8]. The large variability in these estimates between 
studies could be due to the year of sampling, geographical region, or other bias in the sample 
population. Nonetheless, uveitis is estimated as the commonest cause (1 in 10 cases) of blindness 
in 20–60 year-olds (the “working-age” population) [9] and the fourth commonest cause of 
blindness overall in developed countries [1]. Visual impairment is well-characterised to restrict 
participation in daily activities [10] and lower quality of life [11], as well as increase the risk of 
mortality by more than two-fold [12]. As a common cause of blindness, uveitis represents a 
significant health problem. 
Describing and classifying uveitis has historically been ambiguous and non-standardised, 
making interpreting or comparing historical work by different authors difficult. In 2005 the 
standardisation of uveitis nomenclature (SUN) working group (a group of 45 international 
uveitis specialists) published a report of classifications, descriptors, and grading scores for 
uveitis and definitions to address these issues [13]. Uveitis is predominantly classified based on 
the primary site of inflammation (e.g. anterior, intermediate, posterior, or pan-), but a variety 
of other descriptors and grading schemes (e.g. acute, recurrent, or chronic) are important so 
that information from human studies are more readily comparable. Uveitis has a variety of 
aetiologies; these can be grouped into categories such as infectious or non-infectious, and 
systemic or local. There are at least 28 major causes of non-infectious uveitis [14, 15] and the 
majority of cases (~80%) are not associated with other systemic diseases (often referred to as 
idiopathic autoimmune uveitis) [16]. HLA-B27 is an important allele that associates with both 
idiopathic forms of anterior uveitis and some systemic-associated forms of uveitis which 
coincide with diseases such as ankylosing spondylitis, inflammatory bowel disease, and psoriatic 
arthritis [17]. The other systemic diseases most frequently associated with uveitis include 
sarcoidosis, Behçet disease, juvenile idiopathic arthritis, Vogt-Koyanagi-Harada syndrome, and 
multiple sclerosis [18]. Despite the large number of causes, it is well-recognised that 
commonality exists in disease mechanism i.e. the immune system is dysregulated, that similar 
or identical cell types participate, and patients typically have some form of persistent 
inflammation. 
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The clinical features of uveitis are primarily determined by the anatomical region in which the 
active inflammation is occurring, and therefore which tissues and structures are most likely 
altered. It can affect one or both eyes and usually has a rapid and sudden onset. Common 
symptoms include pain, redness, photophobia, and blurring or other alterations to vision. In 
severe cases cystoid macular oedema, cataracts (opacification of the lens), synechiae (adherence 
of the iris to the cornea or lens) and ultimately loss of visual acuity can occur [19, 20]. 
The National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summary 
(CKS; it represents the United Kingdom’s [UKs] standard national health service [NHS] policy) 
states that glucocorticoids (steroids) are the first-line treatment for uveitis. Whilst these are 
efficacious in 60–70% of patients [21], they are well-known to cause a multitude of side effects 
that coalesce into Cushing’s syndrome, making their long-term use inappropriate. If the 
aetiology is believed to be infectious, then an appropriate antimicrobial agent would also be 
administered. Other interventions, such as cycloplegic-mydriatics, tumour necrosis factor 
(TNF) inhibitors, laser phototherapy, cryotherapy, or vitrectomy may also be administered [22]. 
Much work has recently attempted to establish where and when to use the various treatments 
available at an ophthalmologist’s disposal [23]. Nonetheless, current management of uveitis 
could be enhanced and further developed. 
Development of therapeutics that are more efficacious, and potentially have fewer side effects, 
requires a better understanding of the physiology of the eye and pathophysiology of uveitis; this 
would allow for the selection of a therapeutic target that is more specific than the generalised 
immunosuppression that glucocorticoids and other existing treatments exhibit. 
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1.2 The Eye 
The eye is a highly specialised organ dedicated to photoreception – the detection of light energy 
from the environment by rod and cone cells (types of photoreceptors). Photons of light can 
interact with these rod and cone cells (the latter being stratified into 3 subtypes in most 
humans) and become transformed into electrical signals by the process of visual 
phototransduction. This can ultimately be interpreted by specialised regions of the brain that, 
along with the eyes (including structures required for accommodation, miosis, mydriasis, 
and/or those which supporting and nourishing the visual structures) and connecting pathways 
(e.g. optic nerve [ON]), form the visual system [24]. Sight is relied upon as a principal sensory 
mechanism in a large number and variety of species, humans included, and has clear 
evolutionary advantage [25]. In humans, sight is hugely important to participation in daily 
activities [10]. 
The eye is a spheroid structure consisting of segments of two spheres. The anterior (and smaller) 
sphere has a boundary comprised primarily of the cornea and lens, whilst the posterior is 
contained within the sclera; they contain fluids termed the aqueous humour and vitreous body 
(formerly humour; VB) respectively [26]. The contents are surrounded by three layers: the 
corneoscleral (fibrous) coat, uvea (comprising the iris, ciliary body, and choroid), and the retina 
(neural layer) [27]. A diagram, highlighting key components of the human eye, is shown in 
Figure 1.2.1. 
Light is refracted by both the cornea and lens to focus an image on the retina. The cornea has a 
fixed refractive power, whilst the lens is variable and can be controlled by tension (or slack) of 
the suspensory ligaments (also known as the lens zonules or zonules of Zinn) ultimately 
controlled by the contractile state of the ciliary body – a process termed accommodation [28]. 
The size of the pupil (aperture) is altered by the iris sphincter muscle or the iris dilator muscle, 
for miosis and mydriasis respectively, and can be manipulated with pharmacological agents 
[29]. Aqueous humour is produced by the ciliary body epithelium and drains via the canal of 
Schlemm [24]. When observing a fundus image (taken from an anterior position), the optic disc 
(blind spot), fovea (and surrounding macula), and blood vessels (as well as the orange-pink 
colour of the retina) are apparent [27]. 
The retina, along with many other structures in the eye, is a complex tissue comprised of 
multiple cell types and structures. It is stratified into 10 different layers which are visualised in 
Figure 1.2.1 and 1.2.2 [30]. Each of these layers is briefly summarised in Table 1.2.1.  





Figure 1.2.1. A schematic diagram representing the structure of the eye (top) to include 
cells and layers within the retina (bottom). Abbreviations: NFL – nerve fibre layer, GCL – 
ganglion cell layer, IPL – inner plexiform layer, INL – inner nuclear layer, OPL – outer plexiform 
layer, ONL – outer nuclear layer, IS – rod and cone inner segment, OS – rod and cone outer 
segment, RPE – retinal pigment epithelium, BM – basement membrane. Adapted from [31]. 
  






Figure 1.2.2. A histological section of the retina and choroid highlighting the different 
segments and their appearances with haematoxylin and eosin staining. Haematoxylin 
stains the nuclei purple whilst eosin stains the cytoplasm and extracellular matrix pink. 
Abbreviations: NFL – nerve fibre layer, GCL – ganglion cell layer, IPL – inner plexiform layer, INL 
– inner nuclear layer, OPL – outer plexiform layer, ONL – outer nuclear layer, ELM – external 
limiting membrane, IS – rod and cone inner segment, OS – rod and cone outer segment, RPE – 
retinal pigment epithelium, BM – basement membrane. Adapted from [32] and used under licence 
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Layer Primary Components Function Reference 
NFL Ganglion cell axons 
Transmit action potentials towards the 
brain (ultimately via the ON) 
[33] 
GCL Ganglion cell bodies 
Components of the visual system 
(relating to electrophysiology) 
[26] 
IPL 
Synapses between bipolar cells and 
ganglion/amacrine cells 
INL 
Cell bodies of the amacrine, bipolar, 
and horizontal cells 
OPL 
Synapses between PRs and 
bipolar/horizontal cells 
ONL Photoreceptor cell bodies 
ELM 
Junctional complexes between PRs 
and MCs 
Mechanical strength and barrier [34] 
IS/OS PRs 
Light detection and conversion into an 
electrochemical signal 
[35] 
RPE Simple cuboidal epithelium 
Barrier, and control of substance 
movement in/out of retina 
[34] 
BM Extracellular matrix (collagen) Structural integrity [36] 
Table 1.2.1. Primary components of the retinal layers and their basic function. Abbreviations: NFL 
– nerve fibre layer, GCL – ganglion cell layer, IPL – inner plexiform layer, INL – inner nuclear 
layer, OPL –plexiform layer, ONL – outer nuclear layer, ELM –external limiting membrane, PR 
– photoreceptor, MC – Müller cells, IS/OS – inner/outer segments, RPE – retinal pigment 
epithelium, BM – basement membrane. 
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In addition to the cells which detect light, convert it into an electrochemical signal, and transmit 
this to the brain there are several other cell types present in the eye important for maintenance 
of physiological conditions. Microglia and macroglia (astrocytes and Müller cells) are important 
for supporting neurons in a multitude of ways which have been extensively reviewed recently 
[37]. Furthermore, there are an abundance of different tissue-resident immune cells, or 
sentinels, which observe the environment for danger. When required, they can manage threats 
or escalate by initiating a cascade of events which promote the infiltration of peripheral immune 
cells to assist. Tissue-resident macrophages and dendritic cells have been observed in the 
cornea, choroid, iris, and ciliary body, whereas tissue-resident mast cells have been observed in 
the iris, ciliary body, and choroid of some species [38-40]. Microglia possess an immune 
function, in addition to their supporting roles, and are discussed in greater detail later in this 
chapter [41]. The retinal pigment epithelium (RPE) also plays an important role in immune 
responses and modulation [42]. 
In addition to this, it is typical to also observe non-tissue resident lymphocytes and other 
immune cells within non-inflamed retinas; in the absence of inflammation a very small number 
can still infiltrate and egress without apparent damage or clinical features [40]. Furthermore, it 
appears possible for tissue-resident T lymphocytes to be present within normal eyes in some 
species, or for the development of tertiary (or ectopic) lymphoid structures in eyes that have 
undergone persistent inflammation [43, 44]. 
The delicate structure of the eye, and its highly important role in daily activities, has meant that 
investigation using invasive techniques in humans is greatly limited [16]. To overcome these 
challenges, investigations utilising model organisms have been performed. Mice are commonly 
employed to model human diseases of the eye and are a prime organism of choice with a variety 
of models and transgenic lines (relevant models of intraocular inflammation and transgenic 
lines are discussed later). However, it is noteworthy to highlight key differences between human 
and mouse exist as they are separated by roughly 87 million years of evolution and around 300 
genes are unique to one species or the other [45-47]. With respect to eyes, mice do not possess 
a macular or fovea, their eye is a single spheroid (still containing both the anterior and posterior 
chambers), and the lens is considerably larger (Figure 1.2.3) [48]. Nonetheless, human and 
mouse eyes exhibit a lot of similarities and many advancements in our understanding of eye 
biology have originated from studies in the mouse. 
  




Figure 1.2.3. Schematic diagrams of sagittal sections of the human (top) and mouse 
(bottom) eyes to highlight their similarities and differences. The primary differences 
include a relatively larger lens in the mouse in addition to an absence of both fovea and macula. 
The mouse eye more closely represents a single spheroid as well. Abbreviation: RPE – retinal 
pigment epithelium. Adapted from [48] and used under licence (CC BY 4..0). 
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It is also relevant, at this point, to highlight that mouse and human immune systems also exhibit 
discrepancies despite many similarities. Generally, human blood has a high proportion of 
neutrophils whilst in the mouse lymphocytes predominate. Mice have considerably more 
bronchus-associated lymphoid tissue, and haemopoietic stem cells express markers (e.g. c-kit 
and flt-3) to varying degrees between the species [47]. Whilst many new drugs and targets have 
translated from mouse to man many others have failed, highlighting underlying differences 
between the species and/or poor disease modelling [49]. Whilst it would be self-confounding 
to experiments, there is even data to suggest specific pathogen free (SPF) conditions alter the 
mouse immune response – with data showing some bystander infections confer resistance to 
otherwise lethal infections [50]. However, it remains pragmatic to utilise mouse models in 
situations where no better alternative currently exists, and to try and normalise conditions (and 
include the proper controls) so experiments are more readily comparable – meaning that 
control of environmental pathogens and bystander infections is a necessary compromise to 
reduce confounding within experiments. 
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1.3 Murine Models of Uveitis: 
An early paper describing ocular reactions to exogenously administered substances was 
published in 1943 [51]. However, it wasn’t until the 1980s that the first models of uveitis were 
developed (in rabbits and rats): experimental autoimmune uveitis (or uveoretinitis; EAU) and 
endotoxin-induced uveitis (EIU), induced by immunisation and endotoxin respectively [52-54]. 
Since then, these models have been adapted for the mouse and multiple new variations have 
emerged: novel vaccination peptides, adoptive transfer (AT) of uveitogenic cells, transgenic 
mice which develop uveitis spontaneously, infection models with cytomegalovirus or 
M.tuberculosis, and alternative administration routes or substances (for EIU) [55, 56]. Each 
model generates a different clinical phenotype which can help in modelling different aspects of 
uveitis and correlation to patient phenotypes. However, none of these models accurately 
recapitulates human disease [57]. Despite a diverse range of induction approaches, some 
common effector mechanisms exist to cause disease [57]. 
1.3.1 Experimental Autoimmune Uveitis 
EAU is a model of local non-infectious posterior uveitis, mediated by cluster of differentiation 
(CD) 4+ T cells primarily via the T-helper 1/17 (Th1/17) axis [1]. It was first described in the mouse 
in 1988 [58]. EAU is conventionally induced by immunising the mouse against retinal antigens. 
To achieve this, a mouse is required that has a permissive background (to include possession of 
a susceptible haplotype) such as a B10.RIII or C57BL/6 strain, but also an encouraging 
environment so that autoimmune disease can develop [59]. The environment is generated by 
three major components: complete Freund’s adjuvant (CFA), pertussis toxin (PTX – this 
component is optional, but its use increases the rate of successful induction), and the 
immunising autoantigen. The peptide is not usually an exact match of a mouse retinal antigen 
and therefore this system could be considered similar in mechanism to molecular mimicry in 
terms of how it models autoimmunity. The environment is administered only once and poorly 
simulates both the burden of infection (or multiple acute events) over the lifetime of an 
organism and the relapsing nature of uveitis (see Section 1.4). 
CFA contains heat-killed and dried Mycobacterium tuberculosis of the strain H37Ra dissolved 
in paraffin oil and mannide monooleate. Adjuvants are used in vaccines and immunisation 
models as they enhance the immune response to a particular antigen; in the case of CFA, cell-
surface antigens of the M.tuberculosis strain activates TLR2, leading to MAPK/ERK activation 
and expression of TNF-α, leading to acute activation of the innate immune system and up-
Chapter I: Introduction 
12 
 
regulation of TLR2 and TLR4 [60]. Knockout of the TLR adapter protein, MyD88, results in 
resistance to EAU induction [61]; however, single or paired TLR2/4/9 knockouts did not induce 
disease resistance [62] suggesting redundancy within TLR-signalling. Interleukin-1 receptor (IL-
1R)-deficient mice are resistant to EAU induction, implying an essential role [61]; IL-1β is a pro-
inflammatory cytokine produced by monocytes, macrophages, dendritic cells, and microglia in 
response to TLR stimulation, and it causes enhanced endothelium permeability to infiltrating 
cells such as T lymphocytes [63], highlighting the vital role myeloid cells play in the initiation 
of EAU. However, TLR agonists have been shown (compared to TLR-knockout mice) to enhance 
disease severity [62], especially in less-susceptible strains or where low concentrations of 
antigen are used. This highlights how the local context can influence the sensitivity tuning of 
the T cell receptor (TCR). 
PTX is primarily useful for autoimmune disease induction in the eye because the eye is relatively 
immune privileged under physiological circumstances. PTX has multiple subunits, organised in 
a typical A-B structure. PTX raises the permeability of the blood-brain barrier (BBB) [64], which 
the blood-retinal barrier (BRB) is an extension of, enhancing temporary access of immune cells 
to the eye. The primary mechanism of action of PTX is to inhibit Gi proteins via ADP-
ribosylation via the A-promoter, although it is recognised that PTX has other pharmacological 
properties too [65]. For example, the B-oligomer acts as an adjuvant, binding to and activating 
TLR4 to enhance immune responses [66]. PTX has been shown to enhance many CD4+ T cell 
responses [67], in particular Th1 and Th17 cells indicated by increased interferon-γ (IFN-γ) [68] 
and IL-17 [69] expression. As M.tuberculosis up-regulates TLR4 expression [60], it is likely to 
have a synergistic interaction with PTX with respect to enhancing immune responses. 
The final component, the antigen, is specific to the target the mouse is being immunised against. 
The antigen chosen, the mass required, and the amino acid residues varies depending on the 
strain used because their genetic background (primarily major histocompatibility complex 
[MHC] haplotype) alters susceptibility. For example, the immunisation protocols used by our 
group for B10.RIII strains utilise RBP-3161-180 (retinol binding protein-3, also known as human 
inter-photoreceptor retinoid-binding protein [hIRBP]) whilst in C57BL/6 strains RBP-31-20 or 
RBP-3629-643 are used in a much greater final concentration instead. 
EAU is a model where, after active immunisation, the first clinical signs of disease (generally 
swelling and brightening of the optic disc) are observed around days 12–14, followed by 
perivascular sheathing and the development of spots and/or lesions – which by peak of disease 
(days 21–27) covers the vast majority of vessels in the C57BL/6 mouse. It is followed by further 
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structural damage described as a “secondary progression” or resolution phase [70, 71]. In the 
B10.RIII strain, disease develops earlier and more aggressively. Whilst EAU was originally 
considered to model posterior uveitis, features of anterior uveitis have also been observed [72]. 
Since the report of the original model, several variations have since emerged. These can include 
immunisation against different peptides or different regions of an already identified uveitogenic 
peptide [71, 73-77]. However, other variants of EAU include the AT model where lymphocytes 
with antigen-specificity for retinal peptides are injected into recipient mice [78]. The AT model 
enables the investigation/delineation of retinal-specific T cells and endogenous T cells which 
have not (before disease) been selected for retinal antigen activity, especially if allelic markers 
(such as CD45.1 and CD45.2) are used to differentiate them. The AT model generally has a much 
faster onset and severity of disease, peaking around day 11 as a more acute form of EAU. Further 
variants include induction of anterior uveitis using melanin [79, 80], humanised EAU models 
(these mice have their murine MHC-II replaced with human HLA, with a spontaneous model 
using HLA-A29 mice – which in humans has a very strong genetic association with birdshot 
chorioretinopathy [81-83]), other spontaneous models through knockout of the AIRE gene (an 
important gene for central tolerance as described later) [84]. Lastly, models which mimic 
infection (linking both the innate and adaptive immune responses), partially diverge in effector 
mechanism, and therefore are considered separate models to EAU include both primed 
mycobacterial uveitis (a more anterior disease; PMU) [85] and cytomegalovirus (CMV) infection 
in immunodeficiency [86]. Generally, the induced models of uveitis tend to have a more acute 
and greater severity of disease whereas spontaneous models initiate earlier, last longer, and 
result in a greater loss of retinal function (as measured by electroretinogram [ERG]) [87]. The 
different peptides used to induce EAU in rodents (and their protocols) have already been 
comprehensively reviewed [88]. 
1.3.2 Endotoxin-Induced Uveitis 
Endotoxin-induced uveitis (EIU) is another model of uveitis; it was originally induced by 
subcutaneous or intraperitoneal injection of lipopolysaccharide (LPS – a potent activator of the 
immune system and component of the outer membrane of gram-negative bacterial that is 
recognised by TLR4 [89]). It leads to an acute short-lived monophasic reaction that was 
originally considered synonymous to anterior uveitis [52]; however, it is now recognised to 
exhibit clinical features that are analogous to posterior uveitis as well [90]. 
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New variations on the EIU model have since emerged, such as administering LPS intravitreally 
[91]; this approach would simulate local uveitis as opposed to systemic, whilst also greatly 
reducing the amount of LPS used to induce disease in each mouse eye. Other variations include 
using different immunostimulatory molecules (such as other TLR agonists) to induce 
intraocular inflammation [92]. Comparisons between peripheral and local administration of LPS 
have been made, showing that in the mouse (in which less severe disease is seen with respect to 
the rat – the originally-described organism for this model) cellular infiltrate is poor when 
administered systemically, but alterations in cytokine levels that were broadly similar to local 
administration were observed [93]. It is also recognised that the amount of LPS required 
systemically for EIU has a multitude of serious adverse effects in the mice that is considered 
unnecessary suffering – use of local administration in addition to titrating the amount of LPS 
(or other molecule) administered is a refinement (one of the 3Rs – a framework for more 
humane animal research [94]) of the model. It is also known that a reduced disease severity 
could predictively enrich the treatment effect of potential therapies tested downstream [95]. 
This could be coupled with the recent advancements in analysis of retinal disease models via 
the development of high resolution in vivo imaging platforms and general analytical approaches 
for images (such as image segmentation [96]) that provide greater ability and sensitivity for 
detecting and classifying disease in all ocular models. For example, scoring of EIU using optical 
coherence tomography (OCT)-based methods has been recently reported [97]. Table 1.3.1 
summarises multiple different mouse models of uveitis. 
  








EAU Induced Original EAU mouse model, 
immunisation against RBP-3. 
Multiple variants against other retinal 





DR Tg mouse) 
Induced Mice with Tg (human) HLA become 
susceptible to uveitis induction 
[81] 
EAU (AT) Induced Injection of uveitogenic CD4+ T cells 
generated from donor mice 
[78] 





Induced AT of TCR Tg lymphocytes (against HEL) 
into Tg mice where lens expresses HEL 
[98] 
PMU Induced Systemic priming with M.tub Ag followed 
by local M.tub Ag. Repeated injections 
possible for a more chronic disease form 
[85] 
CMV Induced Local administration/infection with CMV [86] 
AIRE KO Spontaneous Failure of central tolerance leads to 
systemic autoimmunity 
[84] 
HLA-A29 Spontaneous Insertion of HLA-A29 from birdshot 
chorioretinopathy patient 
[82] 
RBP-3 R161H Tg 
mouse 
Spontaneous Spontaneous EAU in mice with Tg auto-




Spontaneous Spontaneous EAU, utilising HEL system, 
by crossing melanocyte-specific-HEL 




Spontaneous Spontaneous EAU, utilising HEL system, 
by crossing IRBP-HEL mice with HEL-
specific-TCR CD4+ T cells 
[101]  
EIU (LPS systemic) Induced Systemic LPS dosing causes widespread 
acute inflammation 
[52] 
EIU (LPS local) Induced Local LPS dosing to the eye causing acute 
inflammation 
[91] 
EIU (non-LPS) Induced Dosing with PRR agonists (such as to 
TLRs) causing acute inflammation 
[92] 
Table 1.3.1. A summary and comparison of mouse models of uveitis. Since EAU and EIU were 
first described in 1988 and 1980 respectively, many variants have since emerged. Abbreviations: 
AT – adoptive transfer, CMV – cytomegalovirus, EAU – experimental autoimmune uveitis, EIU 
– endotoxin-induced uveitis, HEL – hen egg lysozyme, HLA – human leukocyte antigen, LPS – 
lipopolysaccharide, PMU – primed mycobacterial uveitis, PRR – pattern recognition receptor, 
RBP-3 – retinol-binding protein 3, Tg – transgenic, TLR – toll-like receptor. 
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1.3.3 In Vivo Clinical Assessment of Intraocular Inflammation 
The eye permits non-invasive repeatable in vivo clinical imaging to monitor disease across a 
time course and assists in understanding changes in tissue integrity, immune cell recruitment 
and activation, and assessment of retinal function. 
Live imaging techniques have improved dramatically in the last 15 years. Before imaging 
techniques, it was usual to score retinal disease using semi-quantitative approaches such as 
histology which was a terminal assay [70]. This greatly increased the number of required mice 
for an experiment, with exponential increases as more timepoints were used. As individual eyes 
could not be tracked through disease, this also meant that greater numbers were required to 
draw conclusions with confidence due to the inherent variability of the disease models. With 
improvements, approaches such as slit-lamp examination were utilised. The slit lamp is 
effectively a microscope coupled to a light source which can be focused to shine a thin layer of 
light into the eye. It permitted scoring in the same mouse across time and cross-correlation of 
terminal assays to disease within the same mouse [102]. Scoring was based exclusively on 
anterior features, is both coarse and subjective, and performed only by the researcher(s) 
completing the examination [103]. It also means that validation of scores by other researchers is 
not possible, meaning it could be confounded by bias. 
Further developments in imaging has enabled retinal diseases to be monitored by acquiring 
images of the posterior retina (fundal imaging) using topical endoscopic fundus imaging (TEFI 
– [70, 104, 105]) or by commercial imaging platforms such as the Micron IV [106]. TEFI, put 
simply, is the attachment of an endo-otoscope to the end of a single lens reflex (SLR) camera 
but also to a light source (via fibre optic cable) for image capture and retinal illumination, 
respectively. The Micron IV is a commercial retinal imaging solution (essentially a widefield 
microscope with condensing lenses) optimised for rat and mouse imaging. These imaging 
techniques are especially pragmatic as they allow for repeated imaging and monitoring of the 
same animal, facilitating a reduced requirement in terms of numbers, but also correlation to 
other ex vivo assessments (e.g. flow cytometry and immunohistochemistry) and an ability to 
remove confounding mice before or during an experiment (i.e. through baseline imaging to 
identify abnormalities, or confirmation of disease induction before allocation to treatment or 
control groups in the case of models such as EAU [107]). Additionally, the Micron IV imaging 
platform enables acquisition of other data in addition to brightfield fundus images: it has the 
capability to perform OCT (“in vivo histology”) and utilise filters for fluorescent imaging. In 
combination with cell tagging approaches (e.g. carboxyfluorescein succinimidyl ester [CFSE] or 
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transgenic reporter lines), it would be possible to track specific cell types during disease to 
better understand their dynamics during disease, and correlation to observed tissue damage or 
other (terminal) assays. 
Additionally, with fundal imaging it is possible to score EAU disease severity using multiple 
different reviewers who can readily be blinded to treatment groups to prevent potential 
confounding through bias (without blinding, treatment effect magnitude is estimated to 
increase by nearly 20% [108]). The convenience of digital images makes it easier to blind images 
and have multiple reviewers. This makes comparisons and tests of reliability and validity much 
simpler to perform. Furthermore, other emerging approaches for image analysis have been 
described. For example, it is possible to use OCT as an unbiased linear approach for scoring 
retinas during EIU [109]. Briefly, it utilises counts or volume measurements of objects 
(presumably immune cells) observed inside the vitreous body during inflammation. There is 
potential for application to EAU and other models where immune cell infiltration occurs as well. 
Whilst the imaging techniques allow for in vivo analysis, there are limitations in the information 
they can provide. At the cellular/molecular level, they can provide only minimal information 
(due to resolution limits – in the Micron IV, this is roughly 2 µm), thus facilitating the need for 
other ex vivo assessment. Nonetheless, the imaging techniques are especially useful in indicating 
successful induction of EAU, allowing for selection of mice that were successfully induced 
(incidence of EAU is typically 89-100% [110]) but also selection at a given time-point of the 
disease (early, peak, late as there can be great variability in the kinetics) so that molecular 
techniques and/or therapeutic interventions are performed on well-controlled samples. 
Baseline imaging can also exclude mice with anomalous eyes before use in an experiment. This 
ultimately means that fewer animals are required in each group to demonstrate significance at 
a statistical level. Imaging across a time-course also permits determination of good endpoints 
for an investigation, so that expensive or complicated assays can be performed at the correct 
time in future/repeat experiments. 
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1.4 Immunity and Inflammation 
The immune system spans the entire organism to maintain health, with well-known functions 
including protection from infectious diseases and aberrant host cells that have or could form a 
tumour but additional roles that include tissue morphogenesis, tissue homeostasis, removal of 
foreign/waste substances (scavenging), wound repair, and many more [111-115]. Underpinning 
all of these functions is the ability of the immune system to recognise and respond appropriately 
to self and non-self; where this fails autoimmunity, immune deficiency or other immune 
disorders such as autoinflammation can arise [116]. 
The immune system is divided into two arms at the cellular level: innate and adaptive. Key 
stages of the differentiation of haematopoietic cells (to include leukocytes, erythrocytes, and 
platelets), in addition to their localisation during these stages, is shown in Figure 1.4.1. The 
innate immune system is comprised predominantly by cells of the myeloid lineage and is the 
first arm of the immune system to respond to infection or damage. It does this via pattern 
recognition receptors (PRRs) which can detect the presence of damage to cells or tissues 
(damage associated molecular patterns [DAMPs]) or generalised cell-surface molecules which 
associate with foreign cells i.e. those found on a pathogen (pathogen associated molecular 
patterns [PAMPs]). Whilst these have a fixed and limited repertoire, each receptor will 
nonetheless act in a specific fashion. For example, TLR4 recognises lipopolysaccharide (LPS) – 
a major component of the outer membrane of gram-negative bacteria. 
In response to activation, innate immune cells perform functions such as phagocytosis and the 
secretion of chemokines/cytokines to recruit other immune cells and transiently increase 
immunological activity in that locale; the response can also enhance immunological surveillance 
across the body. PAMPs often have critical roles in the survival and function of these foreign 
cells and therefore cannot be lost or made redundant from them [117]. This partially explains 
how the innate immune system has retained effectiveness whilst pathogens would be under 
selection pressures against expression of these molecules (from an immunological perspective). 
The repertoire of receptors enables the recognition of many different pathogens and damage 
signatures but nonetheless is limited as there are a finite number of them, pathogens may be 
capable of altering other surface receptors, and a vast diversity of pathogen species exist. 
Therefore, innate immune responses are effective, but evolution has also driven the 
development of adaptive immunity which can combat continually evolving pathogens. 
The adaptive immune system, comprised by cells of the lymphocytic lineage (mainly T and B 
lymphocytes), has the capability to recognise an almost unlimited repertoire of molecules 
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(termed antigens) and overcomes shortfalls in innate immunity. T lymphocytes act directly on 
targets whereas B cells typically are associated with differentiating into plasma cells that 
synthesise antibodies (or immunoglobulins); in short, both major types of lymphocyte assist in 
target neutralisation. In addition, the adaptive immune system has the capacity for generating 
immunological memory – where the immune system mounts both a faster and stronger 
response to subsequent antigenic exposure. However, an effective initial adaptive immune 
response takes considerably longer to mount than an innate response, and crosstalk can occur 
between the two arms via mechanisms such as antigen presentation. That said, memory has also 
been observed in innate immune cells (controlled by epigenetic changes) that can last long-
term [118-120].




          [121] 
Figure 1.4.1. Developmental summary 
of blood cells (haematopoiesis) to 
include their localisation and 
maturation during key stages. The 
common lymphoid progenitor gives rise 
to multiple adaptive immune cells, whilst 
the common myeloid progenitor gives 
rise to multiple innate immune cells. 
Taken from [121] and used under licence 
(CC0 1.0). 




1.4.1 Innate Immunity 
Once a foreign cell overcomes anatomical barriers (i.e. the skin and other epithelia), it enters 
the body. Many mononuclear phagocytes act as sentinels for pathogen entry, residing within 
the tissue and sensing for danger. They can be found throughout a wide variety of, if not all, 
tissues of the body and include microglia (brain and eye), Kupffer cells (liver), splenic, lymph 
node, stromal, cardiac, lung, peritoneal, ileal, and colonic macrophages to name a few [122, 123]. 
Many types of innate immune cell are also continually circulating within the bloodstream and 
possess the ability to enter injured or infected tissue as required. 
With PRRs, they can recognise generalised patterns of foreign cells or damage and enact initial 
responses. There are four major sub-families of PRR: TLRs, nucleotide-binding oligomerisation 
domain (NOD)-leucin rich repeats (LRR)-containing receptors (NLRs), retinoic acid-inducible 
gene 1 (RIG-1)-like receptors (RLRs), and C-type lectin receptors (CLRs; Figure 1.4.2) [124]. The 
different types of receptor, ligand they recognise, and their signalling pathways have already 
been extensively reviewed [125-129]. Furthermore, the context of pattern recognition (e.g. 
external surface [commensal] or internal [invading pathogen], local damage to tissues, or 
systemic spread) is utilised to determine the threat level and therefore the required magnitude 
of the immune response [130]. 
An alternative initiating mechanism of innate immunity is the complement system (Figure 
1.4.3). The main functions of complement include promoting inflammation, phagocytosis, and 
the formation of membrane attack complexes (MACs). MACs are required for the killing of 
particular species of pathogen (e.g. Nesseria meningitidis) and may enable the passage of 
degrading enzymes such as lysozyme [131]. Three pathways for complement activation exist: the 
classical, lectin, and alternative pathway. With differences in initiation, they all have the same 
downstream effects of chemoattraction, opsonisation, and the formation of MACs via a common 
signalling pathway from C3 [132]. The classical pathway is activated by antibody-antigen 
complexes, the lectin pathway activated by lectins (via receptors for unique carbohydrate 
signatures present on bacteria and fungi), and the alternative pathway initiates by spontaneous 
hydrolysis of C3 [133]. 
  




Figure 1.4.2. Pattern recognition receptors (PRRs) and downstream signalling elements. 
The four major sub-families of PRRs and their signalling adapters are shown: C-type lectin 
receptors (Dectin-1), Toll-like receptors (TLRs), nucleotide-binding oligomerisation domain 
(NOD)-leucin rich repeats (LRR)-containing receptors (NLRs), and retinoic acid-inducible gene 1 
(RIG-1)-like receptors (RLRs). All PRRs couple to an important pro-inflammatory transcription 
factor: NF-κβ. Taken from [134] and reproduced with permission from Springer Nature. 
  




Figure 1.4.3. A schematic of the complement system, highlighting the three initiating 
pathways and subsequent signalling cascade. The classical pathway is activated by binding 
to specific carbohydrates associated with pathogens. The alternative pathway is activated by 
spontaneous activation and binding of C3b to a pathogen, foreign material, or damaged tissues. 
Both C3a and C5a act as chemoattractants for leukocytes. Endogenous inhibitors of different 
components of the pathway are indicated in red. Adapted from [135] and used under licence (CC 
BY 4.0). 
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After activation, innate immune cells produce effector functions – i.e. phagocytosis of foreign 
material and pathogens – in addition to secretion of cytokines and chemokines to modulate the 
immune response and assist with recruitment of other (peripheral) immune cells to that locale 
respectively (Figure 1.4.4). With regards to effector functions, cytoskeletal changes permit the 
internalisation and subsequent formation of a phagosome. This fuses with lysosomes, forming 
a phagolysosome, and ultimately assist in killing the pathogen utilising reactive oxygen species 
(ROS) and lysosomes [136, 137]. With regards to secreted molecules, these can not only promote 
inflammation and attract immune cells, but also influence how other immune cells specialise 
(or polarise) in dealing with the cause of inflammation – both have been extensively reviewed 
recently [138-140]. Some chemokines are presented on the surface of endothelial cells in addition 
to other cell-adhesion molecules [141]; these assist in the binding of leukocytes and ultimately 
their ingress to the inflamed tissue – a process termed extravasation (Figure 1.4.5) [142, 143]. 
Furthermore, expression of chemokines control the homing of leukocytes between primary 
lymphoid organs in addition to secondary lymphoid organs and the periphery [144, 145]. It is 
also appreciated that leukocytes modulate expression of chemokine receptors at different stages 
of development and activation to facilitate homing. 
Phagocytes can process fragments of peptide from the killed pathogen, load it into the MHC 
and, along with expression of required co-stimulatory receptors/ligands to indicate a 
danger/damage context, present the fragment to T lymphocytes (Figure 1.4.4) [146]. This process 
is made feasible through the formation of an immunological synapse and, in addition to 
activating a T lymphocyte with a complementary TCR to the peptide, assists with T lymphocyte 
activation and polarisation towards a particular subset [147]. The overall process of loading 
peptide and exhibiting it to a T lymphocyte is termed antigen presentation, and typically occurs 
in lymphoid tissues. It is possible for exchange of peptides between different antigen-presenting 
cells [148], enabling peptide acquired by the initial response of tissue-resident cells to be 
processed in the lymphoid tissues. Lymphocytes inherently traffic via lymphoid tissue and 
therefore the probability of a productive interaction (i.e. an interaction/affinity between loaded 
peptide and TCR that results in activation of the lymphocyte) is greatly increased.  





Figure 1.4.4. Innate immune responses to pathogen-associated molecular patterns 
(PAMPs) and the interplay with adaptive immune cells. Phagocytes can recognise pathogens 
via PAMPs via their pattern recognition receptors (PRRs), and this causes cytoskeletal re-
arrangement and engulfment of the pathogen (phagocytosis). The newly formed phagosome can 
then fuse with a lysosome to enable degradation of the pathogen. At the same time, signalling 
cascades (via PRR activation) leads to the expression and secretion of cytokines and chemokines 
that leads to inflammation. After degradation of the pathogen, fragments of peptides can be loaded 
into the major histocompatibility complex (MHC) and presented to T cells which, along with 
secreted cytokines, enables activation and polarisation towards a specific T cell subset upon 
successful interaction. Taken from [149] and reproduced with permission from the American 
Society of Nephrology. 
  






Figure 1.4.5. An overview of the extravasation process. Leukocytes are well-documented to 
bind and roll alongside the endothelium under physiological circumstances, but when 
inflammation is occurring locally the presence of chemokines on the endothelium surface activate 
them and initiate a cascade of events the ultimately leads to their ingress within the tissue. 
Permission for use of this figure has been sought from the Author. Adapted from [150]. 
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Whilst many phagocytes can present antigen to an experienced T cell (one that has previously 
been activated), only the mononuclear phagocytes (monocytes, macrophages, and dendritic 
cells) and B cells have the capability to present antigen to a naïve T cell and induce activation – 
often leading to their description as professional antigen-presenting cells (APCs) [146, 151]. This 
means they are critical to initiating adaptive responses. Each of these cell types can be stratified 
into different subsets with differential responses to stimuli and function. For example, in 
humans three subsets of monocytes have been identified: classical, intermediate, and non-
classical. Classical monocytes are highly phagocytic, intermediate monocytes produce ROS and 
perform antigen presentation, and non-classical monocytes are considered mobile and often 
described as “patrolling” monocytes which search for sites of injury [152]. In the mouse, these 
subsets have also been identified but the markers used for identification are different to those 
used in humans and do not necessarily align perfectly with the human monocyte subtypes and 
function [153]. Monocytes also express markers such as C-C motif chemokine receptor 2 (CCR2), 
C-X3-C motif chemokine receptor 1 (CX3CR1), and many other chemokine receptors to varying 
degrees across the subtypes [154]. They possess the capability to differentiate into both 
macrophages and dendritic cells (DCs; these are sometimes referred to as myeloid DCs), 
although DCs and macrophages can be generated via other lineages also [155, 156]. Non-
monocyte-derived DCs are stratified into two main subtypes: conventional DCs and 
plasmacytoid DCs. It is suggested that monocyte-derived DCs are most similar to inflammatory 
DCs (a rarer and less well-understood subset) [157]. 
Macrophages comprise the majority of tissue-resident immune cells, in addition to 
differentiating from monocytes that have ingressed during inflammation; they were originally 
described as comprising two subsets: M1 (pro-inflammatory) and M2 (wound healing). 
However, it is becoming increasingly recognised that macrophages can possess sub-
specialisations depending on the tissue they localise to, and that the M1/M2 classification 
system does not fit all of the inflammatory phenotypes particularly well – with one study 
highlighting unique profiles of macrophages to many individual stimuli [158-164]. 
1.4.2 Of Monocytes and Macrophages 
As previously mentioned, monocytes are grouped into three main subsets – classical, 
intermediate, and non-classical – after discovery within humans. Whilst not perfect, broadly 
similar subsets have also been identified in the mouse. Classical (inflammatory) monocytes 
predominate in humans, and subsets are typically differentiated based on CD14 and CD16 
expression (Figure 1.4.6) [165]. In the mouse, subsets can be differentiated based on markers 
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including Ly6C, CCR2, and CX3CR1, all of which are also differentially-expressed between the 
human subtypes [166, 167]. Monocytes develop from (common) myeloid precursors located 
within the bone marrow (Figure 1.4.1), influenced by cytokines such as colony stimulating factor 
1 receptor (CSF-1; also known as macrophage colony stimulating factor [M-CSF]). Furthermore, 
multiple studies have utilised labelling techniques (some in conjunction with transfer of these 
labelled monocytes) to demonstrate that monocyte subsets retain plasticity, at least in a 
trajectory from a classical to non-classical phenotype [168-170]. 
Based on observed expression patterns (both at the gene- and protein-level), the monocyte 
subsets are believed to possess partial specialisation towards specific innate immune functions 
[171, 172]; these are summarised in Figure 1.4.6. Furthermore, specific monocyte subsets associate 
with differentiation preference: classical monocytes associate with macrophage differentiation, 
non-classical monocytes are argued as capable of macrophage differentiation, and intermediate 
monocytes are considered biased towards DC trajectories [173-176]. Despite differentiation 
potential, monocytes also play an important role in responding to both infection and 
dysregulation within the body and can remain as monocytes during the course of inflammation. 
For example, monocytes assist in apoptotic cell clearance in addition to degradation/removal of 
β-amyloid plaques (in the brain) and abnormal connective tissue [177]. Nonetheless, monocyte 
responses to injury can also exacerbate dysregulation as evidenced through their role in 
atherosclerosis development (by forming foam cells), tumour progression (acting as myeloid 









Figure 1.4.6. Monocyte subsets, defining markers, and functions. Three subsets of 
monocytes emerge from human bone marrow and are typically discriminated based on CD14 and 
CD16 expression. Classical monocytes (CMs) express proteins associated with phagocytosis and 
anti-microbial responses, whereas non-classical monocytes (NCMs) associate with directed 
phagocytosis; intermediate monocytes (IMs) possess functions relating to antigen presentation. 
Taken from [177] and used under licence (CC BY 4.0). 
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During inflammation, monocytes can differentiate into macrophages. However, macrophages 
are also recognised to develop in the bone marrow independently of monocyte-derived origin 
under the control of the transcription factor PU.1 [179, 180]. Beyond immediate inflammation, 
many macrophages are found as tissue-resident sentinels and can be found as Kupffer cells 
(liver), splenic, lymph node, stromal, cardiac, lung, peritoneal, ileal, and colonic macrophages 
to name a few [122, 123]. Many of these tissue-resident macrophages develop from embryonic 
progenitors (not monocytes or the bone marrow), are long-lived, and capable of self-replication 
[181]. 
Infiltrating macrophages have classically been described as M1 (pro-inflammatory) or M2 
(wound healing), after these polarisations were discovered in vitro [182]. M1 macrophages 
canonically express IL-1β, IL-6, and TNF-α (pro-inflammatory cytokines) whereas M2 
macrophages are associated with expression of IL-10 and arginase [183]. The two phenotypes are 
summarised in Figure 1.4.7. For these subsets to form, the macrophage requires cytokine signals: 
priming with IFN-γ and then stimulation with LPS assist in producing an M1 phenotype whereas 
M2 polarisation is considered dependent on IL-4 [184, 185]. Nonetheless, multiple studies have 
highlighted the problems associated with this simple two-state model (or even considering 
them polar ends of a spectrum) in that even in vitro macrophages receiving different stimuli fit 
the classification system poorly; some have argued for abandonment of this classification system 
in favour of a more multidimensional system which is more representative of the highly variable 
response to stimuli [186, 187]. Others have recommended more standardised nomenclature and 
reporting of the macrophages and their generation, to better describe them and try to overcome 
some of these shortfalls [188]. Lastly, 2 new macrophage phenotypes have also been described: 
regulatory macrophages (also called myeloid-derived suppressor cells [MDSCs]) and “hybrid” 
macrophages similar to both M2/wound-healing and regulatory macrophages [187]. MDSCs 
appear important in immunosuppression within the context of cancer, enabling tumours to 
develop and progress; they may also play a role in other chronic inflammatory environments 
[189]. However, these phenotypes have not been widely adopted, nor other classification 
systems beyond M1/M2. Therefore, it is evident that current classification systems leave much 
to be desired and research is required to develop them into something more reflective of in vivo 
macrophages. 
Beyond general phenotypes observed during active inflammation, it is well-recognised that the 
microenvironment can also influence the macrophage phenotype. For example, tissue-specific 
factors in addition to the disease-specific microenvironment can play a role in shaping both 
tissue-resident and infiltrating macrophages (Figure 1.4.8) [190, 191].  
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Figure 1.4.7. A proposed framework for describing M1/M2 macrophages for better 
comparability between studies. A) There are several methods for generating or isolating 
macrophages and their subsets, facilitating the need to clearly describe key features such as 
isolated cells and cytokine/s used in their generation. In the case of ex vivo macrophages, the 
anatomical location of source in addition to markers/reagents used for their identification would 
be beneficial. B) A variety of different markers (grouped based on general function) are attributed 
with varying degrees to M1- or M2-type macrophages. Taken from [188] and reproduced with 
permission from Cell Press. 
  





Figure 1.4.8. The effect of homeostatic tissue signals alone and in conjunction with 
activation of pattern recognition receptors (PRRs). Macrophages located in different 
tissues will all express typical macrophage genes (including general markers such as CD45 and 
CD11b) but also genes associated with their local microenvironment (such as Clec4f, Vcam1, 
Itga6, Runx3, and others [192]). When PRRs bind their ligands and transduce pro-inflammatory 
signals, the combination of this with the homeostatic signals in the microenvironment cause the 
macrophages to adopt distinctive pro-inflammatory gene expression programmes as opposed to 
a fixed universal programme. Taken from [190] and reproduced with permission from Springer 
Nature. 
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It is well-recognised that tissue-resident macrophages are found in many tissues throughout the 
body, differentiate from embryonic progenitors (unlike peripheral monocytes and 
macrophages), and act as sentinels – observing the local environment for danger signals via 
PRRs and using chemokines and cytokines to recruit and prime peripheral immune cells when 
required to combat infection and/or tissue dysregulation. Transcriptomic assessment of tissue-
resident macrophages can identify genes differentially-expressed based on anatomical location 
of tissue residency [180]. Nonetheless, core sets of genes expressed by tissue-resident 
macrophages from different anatomical regions have also been observed [193]. Epigenetic 
analysis has suggested that the intracellular changes responsible for these observed differences 
in gene expression are primarily due to alterations in enhancer activity; AT techniques have 
shown that the vast majority of these epigenetic alterations are shaped by the 
microenvironment rather than differences during development i.e. it is the context and 
environment which conditions the macrophage phenotype [192]. 
The alterations in gene expression allow tissue-resident macrophages to adopt additional 
functions beyond immune surveillance, enabling contribution towards tissue homeostasis. 
Additional roles have been observed in many different tissue-resident macrophages and are 
summarised in Table 1.4.1. 
  




Location Function Reference 
Bone (via osteoclasts, a myeloid 
lineage cell) 
Regulation of bone remodelling [194] 
Bone marrow Erythropoiesis and iron recycling [195, 196] 
Brown adipose tissue Thermogenesis [197] 
Heart Regulating cardiomyocyte 
electrical activity 
[198] 
Lung Surfactant homeostasis and 
particle clearance 
[199] 
Spleen/Liver Iron recycling [196, 200] 
White adipose tissue Insulin sensitivity [201] 
Table 1.4.1. Specialised region-specific functions of tissue-resident macrophages. In addition to 
immune surveillance throughout the body, many tissue-resident macrophages have adopted 
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Beyond providing additional functions in homeostasis, macrophages can be influenced by the 
microenvironment to generally reduce the propensity for inflammation/activation i.e. immune 
thresholding. It is believed these immunosuppressive/thresholding functions are important in 
preserving tissue homeostasis and in minimising inflammation-mediated damage to tissues 
[202]. For example, tissue resident macrophages have been shown to extend membrane 
processes around apoptotic cells to inhibit neutrophil activation, and that clearance of apoptotic 
cells by such resident macrophages does not activate them or promote inflammation [203, 204]. 
This enables them to manage low-level threats and infrequent occurrences of cell death (in low 
numbers) within the tissue. It is regulated by the presence of factors within the 
microenvironment, often derived from other cells in the tissue. For example, in the lung alveolar 
macrophages are regulated by IL-10, surfactant proteins, CD200R, and transforming growth 
factor β (TGF-β) [205]. Knock-out of CD200R can lower immune activation thresholds and 
reduce susceptibility to secondary bacterial infections [206]. However, lack of CD200R during 
influenza infection leads to greatly increased collateral damage and greatly impaired resolution 
post-infection [207]. This highlights the importance of localised adaptations and immune 
thresholding. Within the gastrointestinal tract, macrophages exhibit inflammatory anergy that 
is orchestrated, at least in part, by TGF-β. Additionally, they possess metabolic adaptations that 
enable utilisation of locally abundant resources such as glutamine [208, 209]. However, 
immunosuppression and immune thresholding can extend beyond the tissue-resident 
macrophages. Kupffer cells (located within the liver) are recognised to express high amounts of 
membrane-bound TGF-β upon activation, and this can suppress both antigen-specific and 
antigen-nonspecific CD4+ T cell proliferation in the context of inflammation with infiltrating 
CD4+ lymphocytes [210]. 
1.4.3. Adaptive Immunity 
The adaptive immune system is comprised predominantly of two major types of cell: B and T 
lymphocytes. As with other haematopoietic cells, their progenitors reside within the bone 
marrow. B cells complete their development here, whereas T cell precursors will migrate to the 
thymus. Post-development, they enter the bloodstream and circulate through the peripheral 
lymphoid tissues (lymph nodes, spleen, and other organ-associated lymphoid tissue [e.g. Peyer’s 
patches]) [211]. There are two main types of T lymphocyte: CD4+ and CD8+ T lymphocytes, which 
can interact with MHC class II and I respectively. They both recognise targets via their TCR. 
Canonically, the CD4+ T cell is associated with orchestrating clearance of extracellular 
pathogens whereas CD8+ T cells are associated with clearance of intracellular pathogens and 
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tumour cells. CD4+ T cells will typically promote or suppress inflammation by secreting different 
cytokines required for the infectious context and its resolution. Following productive 
interaction with an APC, CD4+ T cells are polarised into several different T helper (Th) lineages 
differing in phenotype and function. They derive from a common precursor but are defined by 
expression of signature cytokines under the control of a master regulator (transcription factors). 
Various subsets of CD4+ T cell have been identified to include Th1, Th2, Th9, Th17, Th22, Tfh, and 
Treg (Figure 1.4.9) [212, 213]. It should be recognised that T cells exhibit plasticity between these 
subtypes [214]. CD8+ T cells can secrete cytokines but also directly target infected or aberrant 
cells through the use of perforin and granzymes, as well as induce apoptosis in cells [215]. On 
the other hand, B cells express a B cell receptor (BCR), can perform phagocytosis, but when 
activated (via BCR engagement) can differentiate into plasma cells which produce soluble 
versions of the BCR termed antibodies [216]. Antibodies can have a variety of roles, to include 
activating complement and enhancing the efficiency/speed of phagocytosis. Both B and T cells 
possess the capability to generate memory cell subsets, which are long-lived and enable a rapid 
and more robust immune response upon secondary exposure to the same antigen [217]. Both B 
cells and T cells possess mechanisms that enable random changes/rearrangement of their 
receptor during and/or after development to generate novel receptor structures with different 
affinities; this enables the adaptive immune system to respond to a nearly infinite repertoire of 
molecules that it may encounter, and ensures that pathogens with novel antigens could still be 
targeted by the immune system [218]. 
 




Figure 1.4.9. Currently known Th cell subsets. Summary information about their differentiation, function, and expression of key markers highlights 
differences between them and their differentiation. Taken from [213] and used under licence (CC BY 4.0). 
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1.4.4 Immunological Challenges 
One challenge that makes the immune system different to many other bodily systems is that it 
is evolving under the influence of multiple directional pressures that can often be at odds with 
one another. Evolving to become better at killing pathogens risks greater collateral damage to 
self. Furthermore, hijack of built-in inhibitory mechanisms to protect the host from collateral 
damage can enable pathogens to survive [219]. This delicate balance of killing and suppression 
is highlighted by numerous reports identifying the side effects of autoimmunity or other 
immune-related adverse events caused by immunotherapies aimed at enhancing an anti-
tumour response using mechanisms such as checkpoint inhibition, cytokine administration or 
adoptive immunotherapy – many of which were targeted to a single molecule [220-222]. 
Therefore, a balanced response is required to both control infection and maintain homeostasis, 
and inappropriate responses (both mistargeting and excessive reaction) results in damage to 
self. 
Furthermore, the interaction between pathogens, commensals (i.e. the microbiome), and host 
and their evolution is highlighted in many examples: the complex nature of the immune system, 
with a wide variety of cell types and subtypes, complex pathogens that utilise a multitude of 
immune evasion mechanisms and frequent antigenic variation (e.g. CMV and influenza), and 
the presence of retrovirus DNA, transposons, and other elements in the genomes of many 
organisms [223-227]. This highlights the requirement for multiple compensatory mechanisms 
of activation, to cope with the wide diversity of pathogens, and the need for inherent flexibility 
(i.e. generation of an almost infinite TCR/BCR repertoire via the processes of combinatorial and 
junctional diversification, and somatic hypermutation [228]) to ensure adequate responses can 
be generated against novel antigens. However, inherent flexibility in antigenic recognition 
generates a new problem: how does the immune system cope with randomly generated 
receptors that recognise self? 
1.4.5 Tolerance 
As summarised above, it is inevitable that self-reactive lymphocytes will form in an organism 
during its lifetime. Therefore, the body requires mechanisms to ultimately prevent damage 
caused by these self-reactive lymphocytes; these are collectively termed tolerance. The first 
mechanism, which removes these autoreactive cells, is described as central tolerance and occurs 
during cell development and maturation into a naïve state (in the bone marrow and thymus [for 
B and T lymphocytes respectively]). In B cells, they can undergo apoptosis, anergy (a state of 
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permanent unresponsiveness to their antigen) or further receptor editing to see if autoreactivity 
can be ablated; where central tolerance fails immunologically ignorant B cells (which are 
autoreactive) can be generated [229, 230]. In the case of T cells, selection is a little more complex 
because the TCR must be able to interact with MHC molecules (either MHC-I or MHC-II) so 
that the TCR could activate when a foreign peptide is presented, termed positive selection. 
However, if the interaction is too strong (i.e. high avidity) then these cells undergo apoptosis or 
become regulatory T cells (Treg). This is because they will react to either MHC complexes loaded 
with self-peptide or unloaded MHC complexes [231]. There is debate in the field about whether 
T cells can undergo receptor editing if they are responsive to self-antigens [232, 233]. It is 
however evident that a single transcription factor, AIRE (autoimmune regulator), is critical in 
central tolerance and enabling expression and presentation of a wide variety of tissue-restricted 
self-peptides in medullary thymic epithelial cells (mTECs) during lymphocyte development; its 
knock-out results in spontaneous autoimmunity in mice (in humans, mutation of the AIRE gene 
leads to autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy). However, the 
symptoms and autoreactive cells generated are not invariable and highlights the stochastic 
nature of autoimmune disease [234]. It suggests any peptide not expressed, expressed in low 
quantities (i.e. cryptic self-epitopes), or spliced (or other amino acid side-chain modifications) 
so those epitopes are not present, by the mTECs could result in escape of autoreactive T cells 
from central tolerance mechanisms [235, 236]. Furthermore, low-avidity autoreactive T cells 
have been shown to routinely escape negative selection [237]. Some of this could be attributed, 
in part, to the high level of cross-reactivity of the TCR (recognition of up to 106 different 
peptides) [238], although there is evidence of TCR sensitivity tuning to nullify the effect of a 
peptide with weak binding affinity in the periphery which would (at least partially) overcome 
this, at least in naïve contexts [239]. 
Beyond lymphocyte development, multiple other mechanisms of tolerance are also observed, 
collectively termed peripheral tolerance because it occurs post-development (i.e. in the 
periphery with respect to their site of development). For example, T and B cells require 
signalling to be able to activate – from cytokines such as IL-1β, IL-6, and IL-12 to co-stimulatory 
molecules such as CD80/86 and CD40/C3b (for T and B cells respectively) – and in the absence 
of these they can undergo activation-induced death, become anergic, or differentiate into a Treg 
cell [240-246]. For expression of pro-inflammatory cytokines and co-stimulatory molecules, 
activation of PRRs that recognise PAMPs or DAMPs (by innate immune cells) is required. 
Other tissue-specific immunoregulatory mechanisms are also present. For example, certain 
regions of the body (e.g. the eye and brain) are relatively inaccessible to lymphocytes under 
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normal circumstances and it would not be possible for them to therefore engage their respective 
receptors (TCR/BCR) and induce autoimmunity – these sites are termed immunologically 
privileged, and in these regions tissue grafts or transplants can survive for extended lengths of 
time [247]. Likewise, some local environments (i.e. the microenvironment) will include factors 
that can help to prevent inflammation by functional deviation. In the retina and brain, TGF-β 
is one such factor that performs this role [248]. Additionally, tissue-resident immune cells (such 
as the microglia) also play a role in modulating responses and promoting an anti-inflammatory 
state, at least in naïve circumstances (see the microglial section of this chapter). 
Treg cells have the potential to suppress effector cells targeting the same cell or tissue (i.e. 
spatially-proximal to one another irrespective of antigen specificity) through cytokines such as 
IL-10, IL-35, and TGF-β, by inducing expression of ligands for co-inhibitory signals on antigen-
presenting cells (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4]), but also through 
other routes such as killing of effector cells with granzymes, metabolic interruption via 
hydrolysis of adenosine triphosphate (ATP) to adenosine to signal via adenosine 2A receptor, 
and a plausible but controversial mechanism of competing with effector T cells for IL-2 [249-
251]. 
1.4.6 Autoimmunity and Autoinflammation 
When tolerance mechanisms fail, it creates an environment that is permissive for autoimmunity 
(such as evasion of central tolerance and survival of autoreactive cells). Likewise, a failure of 
tolerance at a checkpoint could directly lead to autoimmunity (failure to correctly abrogate an 
autoreactive lymphocyte peripherally). 
Autoimmunity is a state in which discrimination between self and non-self fails (i.e. tolerance 
mechanisms) and the immune system reacts against healthy cells or tissues. It is well-recognised 
that autoimmunity is stochastic both in humans and some animal models – it is not a 
guaranteed event even with a permissive environment or genetic predisposition. For example, 
people who possess the human leukocyte antigen-B27 (HLA-B27) allele have a 26-fold increased 
relative risk of uveitis, but nonetheless it is not inevitable [252]. Therefore, other environmental 
factors are at play for enabling autoimmunity in a permissive environment. For example, it is 
common for someone diagnosed with autoimmune disease to have a history of recent illness. 
With inflammation comes an increased density of all peptide-MHC complexes, co-stimulation 
which alters the functional TCR responses, and changes in the proteasome that could result in 
generation of novel peptide fragments for presentation [239, 253]. Changes in tissue-resident 
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immune cells can also occur, even if they are distal to the infection or site of injury [254]. 
Nonetheless, once established many autoimmune disorders undergo a relapsing-remitting 
pattern, suggesting phases of activation and subsequent immune regulation [255]. 
It was originally believed that TLRs were completely specific for PAMPs and were an ideal way 
of discriminating self from non-self. However, new evidence indicates it is possible for DNA 
fragments from apoptotic cells to activate TLRs [124] and suggests a possible role for this in 
autoimmunity – specifically systemic lupus erythematosus [256, 257]. The C-type lectin CLEC2D 
can also recognise histones released from necrotic cells and stimulate TLR9 [258]. Similarly, 
when one eye sustains injury it is possible for inflammation to occur in the contralateral eye – a 
condition termed sympathetic ophthalmia. In very rare circumstances (considering currently 
available treatments) the injured eye can be enucleated to prevent damage in the contralateral. 
This highlights how local processes such as cell death and release of DAMPs could enable the 
activation of autoreactive lymphocytes and differentiation into effector/memory phenotypes to 
drive disease in the contralateral eye [259]. Sympathetic ophthalmia can occur at least as late as 
66 years post-injury, highlighting the stochastic nature of autoimmunity and how multiple 
environmental factors – in addition to autoreactive cells – are required for its development 
[260]. Presumably in this case occurring 66 years post-injury, the initial injury generated 
memory cells which did not re-encounter the antigen (an unknown retinal antigen) until 
decades later due to anatomical sequestering. For sympathetic ophthalmia to develop, perhaps 
both co-stimulation and entry of an autoreactive T cell (or several) into the contralateral eye is 
required to induce inflammation – in addition to a failure of other tolerance mechanisms 
simultaneously (which itself becomes easier to overcome once memory cells are generated). 
It is plausible that the presence of a pathogenic organism can lead to co-stimulation of both 
pathogen-specific and autoreactive lymphocytes due to its non-specific nature [261]. The 
presence of systemic infection can activate lymphocytes which have better access through 
barriers (such as the BRB) enabling temporary lymphocyte access where it was unavailable 
previously [262]. This could also explain why many people diagnosed with autoimmune illness 
have a recent history of illness. However, activation of an autoreactive cell in this context 
depends on a vital assumption: that the antigen encountered peripherally had a 
sequence/structural similarity to a self-antigen (termed molecular mimicry or cross-reactivity) 
that would enable the T cell to be autoreactive in the first place, or that an activated antigen-
presenting cell presented a retinal-specific self-antigen (presumably in addition to pathogen 
antigens) and interacted with a lymphocyte in the periphery [263]. In the case of HLA-B27 
associated autoimmunity (ankylosing spondylitis), it has been shown that several bacterial 
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antigens exhibit molecular mimicry to a portion of HLA-B27 and that HLA-B27 itself can be 
presented – explaining why possessing a HLA-B27 allele does not guarantee development of 
autoimmunity but with certain environmental factors can lead to it [264]. 
Additionally, it is plausible that autoimmunity can be triggered by other events. For example, it 
is possible that infection locally and self-antigens being presented can trigger autoreactive 
lymphocytes – a phenomenon termed bystander activation [265]. In the case of more persistent 
inflammation, it is possible that T cells specific for other self-proteins can become activated as 
the tissue is damaged, releasing more antigen; this is termed epitope spreading [266]. A last 
mechanism includes persistent infection and activation of B cells, leading to immune complex 
formation from the various antibodies generated – as observed with hepatitis C virus infection 
and cryoglobulinemia [267]. The relationship between infection and autoimmunity was 
summarised in 10 points by Kivity et al. [265] listed below: 
1. “Infections can cause autoimmune diseases. 
2. Different infectious agents (viruses, bacteria, fungus and parasites) can trigger 
autoimmunity. 
3. An infection can trigger an individual with an underlying immune dysregulation to 
express an overt autoimmune disease. 
4. Infectious agents can determine the presence of disease-specific auto-antibodies and 
clinical manifestations. 
5. In many cases, it is not a single infection, but rather the ‘burden of infections’ during life 
that is responsible for induction of autoimmunity. 
6. Infections during childhood can be implicated in the development of autoimmune 
diseases in adulthood. 
7. Infections can protect individuals from some autoimmune diseases. 
8. The same infectious agent can induce one specific autoimmune disease and protect from 
another autoimmune disease. 
9. Molecular mimicry, epitope spreading, bystander activation and polyclonal activation 
can induce autoimmunity after infections via innate and adaptive immune responses. 
10. Genetic susceptibility might explain why only a subgroup of individuals will develop 
autoimmunity after infections.” 
In relation to point 10, genetic susceptibility refers to MHC haplotype, but also any other 
immune regulators (such as the inflammasome) – whether they be costimulatory, inhibitory 
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receptors, or have other involvement [255]. Current genetic studies implicate small independent 
effects on susceptibility of several hundred different genetic loci [268]. 
Autoinflammation refers to a group of disorders where, much like autoimmunity, the immune 
system is dysregulated. In contrast to autoimmunity (where primarily the adaptive immune 
system causes damage), autoinflammation refers to diseases (e.g. Behçets or Crohn’s disease, or 
Blau’s syndrome) where primarily the innate immune system responds in the absence of an 
infection and causes injury [269]. However, as both the innate and adaptive immune systems 
interact, and it is possible for dysregulation of both simultaneously (not necessarily to the same 
degree) this means that autoimmune-autoinflammatory disorders are generally considered a 
spectrum with frequent overlap as opposed to two discrete entities [14, 15]. IL-1β is emerging as 
a good therapeutic target for some autoinflammatory disorders due to its pivotal role in 
inflammation caused by myeloid cells [270]. However, new pathways and genes associated with 
autoinflammatory disorders – such as the stimulator of interferon genes (STING) pathway and 
deficiency of adenosine deaminase 2 (Ada2) – highlight other ways in which autoinflammation 
can manifest [271]. 
Whilst autoimmune-autoinflammatory diseases in isolation are generally relatively rare, overall 
they have a prevalence of around 1 in 20 (5%) and it is becoming increasingly recognised that 
they have common underlying mechanisms of disease, highlighting the significant burden they 
represent to society as a whole [272]. 
1.4.7 Innate Immune Memory, Adaptation, and Para-Inflammation 
Innate immune memory describes “a change in the reactivity in innate immune cells previously 
exposed to various stimuli” [273]. It is generally considered a short-term phenomenon and has 
also been described “trained immunity”. However, long-lived memory phenotypes of innate 
immune cells, with a common memory transcriptional/epigenetic programme to lymphocyte 
memory cells, have also been described [119]. It is proposed, therefore, that immunological 
memory phenotypes emerged in ancient innate immunity and was inherited when adaptive 
immunity evolved [274]. Irrespective of origin, various terms have been used to describe innate 
immune memory and its surrounding phenomena with the potential to cause confusion. 
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Phenomenon Old Terms Proposed Terms 
Innate immune memory Innate memory Innate immune memory 
Trained innate immunity 
Induction of innate memory Priming 
Innate immune reprogramming 
Pre-conditioning 
Priming 
Innate immune reprogramming 
Memory-induced decreased 
responsiveness 
Tolerance Tolerance, trained tolerance 
(global phenomenon) 





Non-specific acquired resistance 
Potentiation, trained potentiation 
(global phenomenon) 
Enhancement, increase (individual 
effectors) 
Table 1.4.2. Innate immune memory terminology. It describes different phenomena and terms 
previously used to describe them, as well as suggested new terminology to minimise confusion. 
Taken from [273]. 
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Innate immune memory has been known about for a long time in the form of priming or 
tolerisation (primarily with regards to LPS) [275-277], but the mechanisms underpinning it 
(epigenetic modifications) have only been recently discovered [278-280]. LPS tolerance has been 
well-studied and reviewed in great detail recently [279]. 
In the context of peripheral immune cells (with the exception of the possible but rare memory 
phenotype/subsets), these effects would be short-lived (in the absence of chronic inflammation) 
as these cells are replaced as part of haematopoietic turnover [281]. Alterations of the progenitor 
stem cells located within the bone marrow are possible [282]. Furthermore, innate immune 
memory has the potential for long-lasting or semi-permanent effects on long-lived innate cells 
such as tissue-resident macrophages or where peripheral immune cells are kept alive by 
inflammation-associated signals. 
Immune adaptation (or differentiation) is considered “a form of adaptation through long-term 
changes in the functional program of a system (including immune response), determined by a 
constant change in the environmental conditions or due to a chronic insult (e.g., a chronic 
infection), leading to a new functional state” [274]. It differs from conventional innate immune 
memory in that the new functional state is not transient but persists until it is set to a different 
level. The similarities and differences between the two forms of memory are shown in Figure 
1.4.10. 
  




Figure 1.4.10. Immune memory and immune adaptation. A) Immune memory describes 
where the response intensity to a stimulus is altered due to previous stimuli (this can be increased 
or decreased i.e. priming and tolerance, respectively. The innate immune cells return to a state of 
homeostasis between stimulation. B) Immune adaptation describes a long-term change in the 
innate immune response which can be altered again in the future. Importantly, the innate immune 
response does not return to baseline between stimulation. Adapted from [274] with permission 
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Currently, most studies investigating innate immune memory have done so in vitro or 
systemically in vivo. A small number have identified differential memory responses depending 
on compartmentalisation [283, 284]. However, it is suggested that innate immune memory 
could play an important role in chronic diseases (such as atherosclerosis) in addition to 
autoinflammation/autoimmunity [280, 285]. 
Para-inflammation is a different phenomenon that is considered a range of inflammation 
between a full-blown infection response and complete homeostasis; it is believed to be an 
adaptive response to tissue injury or malfunction [286]. It differs from immune adaptation in 
that there is continual low-level inflammation occurring in para-inflammation, whereas in 
immune adaptation only the response to a stimulus is altered. Nonetheless, para-inflammation 
has been shown as an important process that helps to drive the formation of a wide range of 
tumours, whilst in the eye can develop into a more chronic inflammation that causes age-related 
macular degeneration (AMD) [286, 287]. In the eye, this could be triggered by necrotic cell 
death, ROS (which are generated as part of physiological cell processes), advanced glycation 
end products, and hyaluronan fragments to name a few [288, 289]. Many age-dependent/para-
inflammatory changes have been observed in the eye, such as increases in IL-1β and TNF-α (pro-
inflammatory cytokine) concentrations, breakdown of the BRB, increased complement 
activation, as well as changes in regulatory cell localisation and morphology [289-291]. 
It is possible that the “burden of infection” (believed important in autoimmune disease [265]) 
and/or ongoing changes with age could increase the para-inflammatory state and potential for 
progression to full-blown autoimmunity or autoinflammation (as barrier integrity is 
compromised and the microenvironment becomes more pro-inflammatory), increasing the 
probabilities of leukocyte entry and costimulation of a self-reactive T cell. Furthermore, innate 
immune memory/adaptation, para-inflammation, and autoimmunity/autoinflammation could 
represent part of a spectrum of accruing changes/dysfunction to the tissue-resident immune 
cells and microenvironment (Figure 1.4.11). Whilst this is conceptualised as a spectrum, it should 
be appreciated that a para-inflammatory state is not necessarily a pre-requisite for 
autoinflammation or autoimmunity nor is it a guaranteed progression. It is intended to suggest 
how different severities/degrees of immune dysregulation from homeostasis may link to one 
another. 




Figure 1.4.11. Immune adaptation, para-inflammation, and autoinflammation/autoimmunity may represent a spectrum of immune 
dysregulation and tissue dysfunction. Repeated challenges over time can lead to adaptation, predisposing to collateral damage and further 
adaptation, para-inflammation, and/or autoimmunity. It is possible that steps may be omitted due to other (stochastic) factors such as infection 
(leading to breakdown of anatomical barriers and expression of co-stimulatory molecules) and genetic risk. Equally, it could be possible for the tissue 
to regress or return to a homeostatic state.
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1.4.8 The Eye and Immune Regulation  
Despite multiple tolerance mechanisms to promote safe activation of the immune system 
(outlined above), the eye contains many unique features which further aid in shaping the 
immune system and pushing towards regulation – a phenomenon broadly described as immune 
privilege. For example, it is well-recognised that tissue grafts in the eye can survive for extended 
periods of time (rejection would occur at other sites) [247]. Furthermore, after a successful graft 
on the cornea it is possible to administer similar cells/tissues elsewhere in the body without 
rejection/reaction [292]. Antigens administered to the corneal surface can be tracked to 
draining lymph nodes and alloreactive T cells specific for these antigens can be detected 
systemically [293]. Yet, despite the presence of these alloreactive T cells immune responses are 
not generated. This atypical response (or deviation) has been termed anterior chamber-
associated immune deviation (ACAID) [294]. In other studies, xenografts of human uveal 
melanoma cells form considerably more hepatic micrometastases when administered via the 
posterior compartment of the eye as opposed to tail vein injection, providing further evidence 
that eye-specific systemic immune deviation mechanisms exist [295]. It is unclear whether 
ACAID itself is a physiological phenomenon or purely artificial. However, it highlights that 
immune-regulating mechanisms are present within the eye. 
As described earlier, the eye contains anatomical barriers (i.e. the BRB) which considerably 
limits the entry of leukocytes and the potential for local immune activation/reactivity. It is likely 
that considerable local damage and/or microglial activation is required for the breakdown of 
these barriers to occur to permit large-scale immune infiltration (see 1.5.2 and 1.5.4) and possible 
collateral damage. However, it is also hypothesised that relative inaccessibility (to leukocytes) 
limits the effectiveness of peripheral tolerance within the eye (i.e. allows B and T lymphocytes 
to remain immunologically ignorant) and therefore, ironically, this second defence mechanism 
could also hypothetically permit autoimmunity within the eye [296] (in conjunction with other 
circumstances such as local damage/danger context, genetic predisposition, or others as 
described earlier). 
The third main pillar of immune privilege within the eye is the microenvironment, containing 
a variety of secreted molecules (e.g. TGF-β or TRAIL, the latter promoting apoptosis), expressed 
receptors (e.g. CX3CL1 by neurons), highly-specialised tissue-resident immune cells (i.e. 
microglia, see later) or other cells capable of immune regulation (e.g. the RPE), constitutive 
expression of complement inhibitors, and the extracellular matrix – all of which help shape both 
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tissue-resident and infiltrating immune responses towards regulation or anergy [297-304] (see 
[305] for a recent review of retinal immune suppression). 
In summary, the eye has multiple additional mechanisms that help to promote anergy or a 
regulatory environment to avoid excessive inflammation and collateral damage – presumably 
because of both the delicate nature of the eye and the critical role it plays in survival. 
  




Microglia are long-lived tissue-resident macrophage-like cells of the CNS, including the eye. 
They reside within the retina in addition to many regions of the brain each with varying 
densities and marker expression, presumably to assist in additional sub-function specialisations 
[306]. Nonetheless, all microglia express conventional myeloid cell markers. However, despite 
expression of myeloid markers they have a different origin (they are derived from the embryonic 
yolk-sac as opposed to haematopoietic progenitors) to other myeloid cells [307]. They exhibit a 
ramified morphology (unlike the amoeboid morphologies of macrophages) and are well-
recognised to express a unique TGF-β-dependent transcriptional profile different to 
macrophages [308]. Microglia can self-replicate when required but under physiological 
conditions this is to a low degree. They are incredibly versatile, known to provide immune 
surveillance of the brain and eye (via movement of the ramified processes [309]), as well as 
general homeostasis via processes such as synaptic pruning – with dysregulation of the latter 
linking to schizophrenia [115, 310]. Many microglial functions are summarised in Figure 1.5.1, 
highlighting a plethora of sub-specialisations beyond immunosurveillance that explains how 
they differ from macrophages. Furthermore, complement-dependent synapse elimination by 
microglia is required for the loss of memories, with complement knock-out resulting in reduced 
cognitive decline in mice [311]. It is well-recognised that microglia, under homeostatic 
conditions, contribute to an immunosuppressive environment that helps to prevent 
unnecessary inflammation and/or autoimmune disease [312]. 
  





Figure 1.5.1. Microglia possess a variety of important roles relating to both immune 
surveillance/protection and maintenance of tissue homeostasis. Microglia play an 
important role in regulating the CNS as highlighted by their repertoire of functions. Overall, they 
are critical to maintenance of the CNS. Abbreviation: CNS – central nervous system. Taken from 
[313] and used under licence (CC BY-NC 4.0).  
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Microglia have been identified in a variety of vertebrates and invertebrates, including mammals, 
birds, frogs, fish, molluscs, and insects [314-320]. This suggests the existence of microglia 
predates the Nephrozoan divergence of organisms (into Protostomia and Deuterostomia – that 
gave rise to molluscs and insects, and chordates respectively) that dates ~600–700 million years 
ago [321, 322]. Microglia have not been observed in organisms that predate the Nephrozoa (i.e. 
in Xenacoelomorpha, a clade forming alongside the Nephrozoa from the common ancestral 
clade of Bilateria), implying their origin in Nephrozoa [323]. Furthermore, neuropeptides (NPs), 
which are well-characterised to modulate microglial activity [324-327], saw a major expansion 
in Bilaterians [328]. These events are summarised in Figure 1.5.2. and predate the development 
of complex nervous system architectures, implying microglia are a critical component or 
prerequisite for their development and maintenance, and that by extension microglial 
regulation is critical to homeostasis of the brain but also eye. 
  





Figure 1.5.2. Phylogenetic relationships and the sequence of evolution predating complex 
nervous system architectures. Significant developments are highlighted in the boxes below, 
with an indication of which branch it formed within. Adapted from [329] and used under licence 
(CC BY 4.0). 
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Microglia development in mammals occurs in three distinct stages: “early microglia” (until E14), 
“pre-microglia” (E14 to a few weeks after birth), and “adult microglia” (from weeks after birth 
henceforth) corresponding broadly to cell cycle, synapse pruning, and immune surveillance 
functions respectively [330]. During their development, perturbation of microglia can lead to 
severe consequences. For example, administration of Poly(I:C) (a TLR3 agonist [331]) causes 
psychopathology when administered during critical gestational time-windows [332]. 
Furthermore, depletion or alterations in the microbiome can also influence microglia – whether 
induced by acute changes caused by antibiotics or long-term changes caused through the use 
of germ-free mice [333, 334]. Additional studies highlight that microglial depletion during 
development or early post-natal stages can lead to defects in both mouse behaviour and brain 
physiology [335], cementing some of their critical roles beyond immune surveillance within the 
central nervous system (CNS). 
In adult microglia a core gene expression programme – including Sall1, Mertk, purinergic 
receptor P2Y12 (P2ry12), and triggering receptor expressed on myeloid cells 2 (Trem2) – was 
observed across species spanning roughly 450 million years of evolution (from leeches to 
humans, and 16 species between). Additional expression programmes exclusive to large 
mammals and humans were also identified. It highlighted both similarities but divergences in 
microglial function in these organisms, and provided implications in the origin of particular 
neurodegenerative diseases (specific to large mammals and/or humans) and their links to 
microglia [336]. 
1.5.1 Microglial Phenotypes 
Classically, microglia were considered to possess similar phenotypes and expression patterns to 
macrophages due to expression of common myeloid markers during a naïve state. However, 
recent evidence indicates that microglia have distinctive expression patterns and phenotypes 
that poorly fit “classic” phenotypes of macrophages (i.e. M1 and M2 [158]). An investigation to 
determine differences in adult microglial expression patterns showed that microglia isolated 
from the eye were distinctive to microglia isolated from other regions of the CNS, but also that 
microglia isolated from defined anatomical brain regions have subtle differences suggesting 
localised functional adaptation [308]. Furthermore, sex differences have been observed in brain 
microglia and their reactivity; sex differences in microglia are believed important in neurological 
disorders, many of which have a sex bias in incidence [337, 338]. 
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Microglia can be classified generally as primed or acute: an acute microglia is responding to 
acute injury (such as infection), whereas in contrast a primed microglia is one which exhibits a 
greater and more prolonged response to challenge (i.e. immune adaptation) – the latter being 
observed in ageing and neurodegeneration [158, 339]. A core of primed microglial genes was 
identified, where overlap/consensus between several different models was observed. 
Nonetheless, model-specific changes were also noted [158]. Furthermore, accumulating 
evidence suggests the presence of damage- or recovery-associated microglia (DAM or RAM, 
respectively) in addition to possible transitionary phenotypes and quiescent microglia during 
disease [340-343]. Formal classification and identification of these phenotypes (e.g. specific 
marker changes) remains to be investigated, although these subpopulations are already being 
associated to core sets of gene expression changes [344]. Nonetheless, recent efforts have 
resulted in the development of a 33-module classification system of microglial expression 
patterns. It was developed using microglial responses to 96 different single stimuli in vitro and 
shows promise in both characterisation and comparability with enough dimensions to resolve 
multiple hypothetical microglial states [345]. 
A microglial homeostatic transcript signature has been identified by several groups, with a lot 
of consensus between them [158, 308, 346-351]. Highly-enriched markers that have been 
identified in common by multiple groups (such as Cx3cr1, transmembrane protein 119 
[Tmem119], and P2ry12) have become the focus of research efforts in generating transgenic 
mouse lines and antibodies for specific microglial identification. However, it is increasingly 
recognised that this signature may only be representative of homeostatic microglia as 
downregulation has been observed in a variety of disease models [158, 341, 342, 352, 353] (for 
more detail on microglial identification see Chapter IV). More recent work has characterised 
homeostatic and “reactive” microglia (as separate entities) against macrophage populations, and 
may assist in the identification of markers specific to microglia in both homeostatic and 
pathophysiological circumstances [354]. 
In Alzheimer’s disease (AD), plaque-associated myeloid cells have recently been confirmed as 
deriving from resident microglia [355]. During disease, they cluster into three main groups: 
naïve, stage 1 DAM, and stage 2 DAM. The initial key receptors and pathways which trigger stage 
1 in this model is unclear, but progression to stage 2 has been shown to be dependent on TREM2 
[340]. This dependence on TREM2 for progression was also observed in amyotrophic lateral 
sclerosis (ALS; also known as motor neurone disease) [353]. In humans, TREM2 variants (which 
decreased or markedly increased TREM2 binding affinity to its ligands) can predispose to AD 
[356]. Downstream of TREM2 signalling, expression of apolipoprotein E (Apoe) and other genes 
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associated with lipid metabolism occurs. Apoe deletion resulted in considerable normalisation 
of the transcript signal and suggests this as a specific pathway in neurodegeneration as its 
upregulation was not observed after stimulation of microglia in vivo with E.coli or zymosan 
particles [353]. Expression of Apoe was also observed in microglia during other acute and severe 
neurodegenerative models (the facial nerve axotomy [FNX] and CK-p25 models respectively) 
[343, 357]. A human allele, Apoe2, has been shown to reduce pathology in an AD mouse model 
(synucleinopathy) compared to Apoe knock-out and insertion of other human Apoe alleles, 
including those which have genetic associations to cognitive decline (Apoe4). Furthermore, 
Apoe4 had considerably more phosphorylated α-synuclein than knockout or Apoe3 mice (not 
detected in Apoe2), although the total α-synuclein burden was similar across alleles and raised 
in Apoe knock-out [358]. This highlights the dual functionality of some genes, where knock-out 
can simultaneously be better and worse than possessing a functional gene (depending on the 
allele present) – showing how some alleles confer protective function and others a gain of toxic 
function. Apoe has been implicated in amyloid-β (Aβ) aggregation and clearance, being at least 
partially accountable for >99% of late-onset AD cases [359]. 
Furthermore, lipid-droplet-accumulating microglia (LDAM; they are associated with ageing, 
but also after LPS stimulation) have been shown (using CRISPR-Cas9 screening) to be regulated 
by genes associated with neurodegeneration. They produce high levels of reactive oxygen 
species (ROS), proinflammatory cytokines, and exhibit defective phagocytosis. Furthermore, 
LDAMs were found to be increased in a dementia model [360]. It is currently unclear if the 
microglia can reset to a completely homeostatic state after these changes have occurred. As 
Apoe has functions in lipid metabolism and is important in AD pathology [361], it is likely that 
LDAMs and Apoe (known to be important in AD onset) are part of the same mechanism of 
microglial dysfunction. These LDAMs could represent a critical link between the “burden of 
infection” and autoimmunity (and perhaps also the microbiota) [265], as the immune response 
threshold – “the level of immunogenic stimulation required to elicit an immune response” – and 
the strength of response (i.e. immune adaptation) is altered by accumulating damage [362, 363]. 
However, it should be appreciated that the TREM2 pathway and lipid-accumulation is 
neuroprotective (at least in some contexts) as its loss results in increased neurone loss in the 
cuprizone model (a multiple sclerosis model that bypasses the autoimmune component) [364]. 
Therefore, it is suggestive that LDAMs themselves are protective short-term by correcting local 
abnormalities (that would otherwise cause damage) and that they could represent a microglial 
marker for accumulating damage. However, the altered microglial immune thresholds for 
activation caused by this process could then predispose towards pathology long-term. These 
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alterations could represent a key initiator of para-inflammation, although the root mechanisms 
causing LDAMs remain to be elucidated. Well-designed experiments will be required to 
demonstrate what is associated with damage (acting as a recovery portion) and what is driving 
damage in these different contexts/scenarios. 
In other AD models (and in humans) nucleic acids associated with β-amyloid plaques have been 
shown to activate microglia and induce the expression of a type-I interferon (IFN) response, and 
that exogenous interferon (irrespective of β-amyloid) is able to activate microglia and cause 
synapse loss via a complement-dependent pathway [365]. Complement component 5a receptor 
1 (C5AR1) knock-out results in improved clinical outcomes in AD models, suggesting the IFN 
response as important in AD pathology and microglial-mediated damage [366]. The 
complement system also has strong genetic associations to retinal diseases such as age-related 
macular degeneration (AMD) with most functional implications suggesting loss of inhibitory 
signals or increased activity [367] – suggesting increased synaptic pruning by microglia as 
fundamental to establishment and/or progression of these disease processes. As established 
earlier, loss of synaptic pruning has been linked to schizophrenia [115, 310] which suggests 
potential therapeutic strategies would need to reduce (but not completely abrogate) this 
pathway. Ideally biomarkers or risk stratification could inform prophylactic therapies that can 
be used before the onset of disease and loss of neurones. 
Microglia also have been implicated in a wide variety of inherited retinal degenerative diseases 
observed in mice, including in genes such as phosphodiesterase 6b (Pde6b; retinal degeneration 
1 [rd1] model), membrane frizzled-related protein (Mfrp; rd6), Crumbs cell polarity complex 
component 1 (Crb1), Cx3cr1 (polymorphisms of which associate with AMD), and prolyl 3-
hydroxylase 1 (P3h1) [368-373]. In these situations, microglia proliferate and accumulate 
proximal to areas of retinal damage, enabling phagocytosis. They secrete pro-inflammatory 
cytokines including TNF-α, IL-1β, C-C motif chemokine ligand (CCL2), and CCL3 in addition to 
ROS and nitric oxide (NO) [374, 375]. Some of these genes are expressed exclusively in the retina 
by microglia (i.e. Cx3cr1), implying that microglia can initiate and drive degeneration. However, 
in other inherited retinal degenerative diseases it appears that the microglial response is 
secondary to dysfunction. 
In autoimmune situations, TGF-β-activated kinase 1 (Tak1) has been proposed as pivotal in 
causing autoimmunity as microglial-specific knock-out demonstrated significantly suppressed 
disease in the experimental autoimmune encephalomyelitis (EAE) model (EAE models the 
disease multiple sclerosis) [376]. Further experiments have showed that microglial-specific Tak1 
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knock-out reduces TNF production, and that conditional knock-out of TNF in microglia can 
also significantly reduce disease severity in graft-versus-host disease [377]. In addition to studies 
discussed later (within the “Retinal Microglia and Uveitis” section), this implicates a central role 
for microglia in the development of autoimmune disease. 
Beyond surface markers, cytokine production, and gene expression, there is growing evidence 
of a range of microglial phenotypes at the morphological level that are now being realised. The 
simple two-state ramified or amoeboid model of microglia (sometimes described in 3 states: 
compact, longitudinal, and radial [378]) which, whilst useful, is a gross oversimplification. In 
full, microglia exhibit a multi-dimensional spectrum of morphological phenotypes that 
facilitates the need for automated analysis strategies [379]. Currently, two dominant approaches 
for analysing the microglia exist: sholl analysis, and frac-lac [380]. In brief, sholl analysis was 
developed to characterise neurone morphologies and involves counting intersections between 
dendrite processes and expanding concentric circles [381]. Frac-lac involves counting of fractal 
dimensions (which broadly corresponds to complexity) whilst lacunarity helps to describe how 
the fractal dimensions fill space (a larger lacunarity generally means more or larger gaps) [382-
384]. Both approaches can help to describe quantitatively how ramified a microglial cell is, in 
addition to other parameters such as complexity and shape [385, 386]. These approaches, whilst 
useful, tend to rely on manual segmentation of each microglia which limits the numbers which 
can be analysed. However, many more approaches are being developed to increase throughput 
(to more than 20,000 cells i.e. with phenotypic clustering [387]) or by extracting further 
information (59 parameters, 17 of which were highly discriminatory in microglial classification 
on shape [388]) using automated solutions. Despite this, such analyses tend to require technical 
or coding expertise to execute correctly and obtain results which currently limits their reach 
and usage. Furthermore, they will rely on and assume the use of a single marker which is both 
sensitive and specific for microglia along their entire membrane – ergo it tags all microglia, and 
only microglia – which during severe and chronic inflammation has not necessarily yet been 
identified or validated. 
1.5.2 Retinal Microglia and Homeostasis 
Retinal microglia have been shown to reside within both the plexiform layers, forming niches 
dependent on different cytokines for homeostatic function and survival [341]. Around 50% of 
microglia within the inner plexiform layer (IPL) depend on IL-34 (an alternative CSF1R ligand 
[389]) for survival, whilst microglia within the outer plexiform layer (OPL) are IL-34 
independent (but are CSF1-dependent as CSF1R blockade can deplete all microglia from the 
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retina [390]). Furthermore, the IL-34-dependent microglia within the IPL are believed to possess 
sub-specialisations to their niche and are suggested as key contributors to normal visual 
function [341]. 
Retinal microglia constitutively express IL-27 which stimulates photoreceptors to secrete IL-10 
[312]. IL-10 is associated with anti-inflammatory activities and has been shown to metabolically 
reprogram macrophages [391]. This suggests microglia can self-regulate through the IL-27/IL-10 
axis. Unsurprisingly, dysregulation of IL-10 increases the risk of autoimmune diseases [392]. 
Furthermore, microglia can interact with neurones directly, with receptors such as P2RY12, 
CX3CR1, and CD200R assisting with coupling [393]. These localised interactions, like with 
tissue-resident macrophages in other organs, are believed important in conditioning the 
phenotype. 
There are four major types of microglial checkpoint mechanisms which help to establish an 
immunosuppressive/homeostatic or “resting” environment: physical barriers (i.e. the BBB/BRB 
which help to seclude both peripheral immune cells and cytokines or other signalling 
mechanisms), soluble factors (paracrine signalling via neurons and other local cells e.g. TGF-β, 
but also through autocrine mechanisms such as TNF-α signalling via TNF alpha-induced protein 
3 [TNFAIP3] [394]), cell-cell interactions (e.g. through CD200 and C-X3-C motif chemokine 
ligand 1 [CX3CL1]), and microglial-specific chromatin regulators and transcription factors (e.g. 
RUNX1 and SPI1) which promote the expression of immunosuppressive factors (Figure 1.5.3) 
[395, 396]. This complex set of checkpoints and interactions highlights the critical need for well-
controlled microglial activation. 
  




Figure 1.5.3. Major types of microglial checkpoint that help to establish and maintain an 
immunosuppressive environment. Soluble factors can influence microglial activity, and these 
can be via autocrine (e.g. TNF-α), paracrine (e.g. TGF-β), or paracrine loop (e.g. IL-27/IL-10) 
mechanisms. Cell-cell interactions (e.g. CX3CL1-CX3CR1 and CD200-CD200R) can aid with 
microglial localisation. Both soluble factors and cell-cell interactions can influence epigenetic 
regulation of microglia and activation state of transcription factors via cell signalling, reducing 
their propensity towards inflammation. Lastly, physical barriers (e.g. the BRB) hinder peripheral 
immune cells from accessing the retina and their ability to secrete cytokines and interact with 
microglia to promote inflammation. Abbreviation: BRB – blood-retinal barrier. 
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1.5.3 Retinal Microglia and Uveitis 
The role of microglia in EAU and uveitis are less-well understood and more speculative. 
Investigation of microglia within inflammatory disease models has been challenging due to their 
similar phenotype to monocyte-macrophage populations [397]. During early EAU microglia 
migrate from the inner and outer plexiform layers to other regions of the retina [398], and that 
during this early stage they secrete peroxynitrite and TNF-α [398, 399] to recruit and activate 
peripheral immune cells [400]. Microglia also undergo a morphological change from a ramified 
appearance into a more ameboid appearance [401], suggesting their activation as important in 
the early pathogenesis of EAU. The current understanding of microglia during early EAU is 
summarised in Figure 1.5.4. 
Studies have shown that knockout of CD200, an important regulatory glycoprotein expressed 
by neurones, vascular endothelium, and other activated immune cells, results in accelerated 
onset and severity of EAU [402]. Recent work suggests that myeloid cells can transfer 
mitochondria to neurones in a CD200-dependent manner, and this can resolve inflammatory 
pain in mice [403]. Knock-out of CX3CR1, another important microglial checkpoint/regulatory 
receptor also enhances disease severity [404]. Furthermore, IFN-γ (produced by Th1 cells, a key 
mediator of EAU) upregulates IL-27 in microglia which stimulates the production of the anti-
inflammatory cytokine IL-10 by photoreceptors [312]. IL-27 also inhibits RORc expression to 
prevent lineage commitment to Th17 and expression of IL-17 in CD4+ T cells [405, 406]. It is 
possible IL-27 could induce transformation of Th17 cells towards a Th1 phenotype (these are 
termed non-classical Th1 or ex-Th17 cells) [214]; in other contexts Th17 cells could become Treg-
like as well [407]. Moreover, IL-1β has been shown to induce IFN-γ (a typically Th1-associated 
cytokine) in Th17 cells [408]. As IL-1R knockout mice are resistant to EAU but cellular infiltration 
can still occur (expression of IL-1β is an early microglial event) [61, 409], and that IL-27R 
knockout mice exhibit more severe autoimmune disease in brain contexts [410], this suggests 
that reprogramming of T cells by microglia (or a critical role for microglia helping to drive 
uveitis) is plausible. This not only confirms that microglial dysregulation worsens EAU, 
illustrating direct involvement in disease process, but also suggests that they represent an 
excellent cellular target for therapeutics in addition to highlighting the critical role several 
different axes (e.g. IL-27, CD200, CX3CR1), or immune checkpoints, can have in regulating the 
potential inflammatory environment within the eye. 




Figure 1.5.4. The changes between homeostatic ramified microglia and dysregulated 
amoeboid microglia during EAU. Microglia undergo a morphological transition towards a 
more amoeboid state, in addition to migration from plexiform layers to other regions of the retina. 
During this time, the threshold for activation is overcome and a pro-inflammatory environment 
generated. Microglia are known to release factors enhancing vascular permeability (e.g. NO and 
ONOO-) as well as IL-1β to activate peripheral immune cells and help to facilitate their entry into 
the retina. It is currently unknown if microglia can completely reset to their homeostatic state 
following activation in EAU. 
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Microglia are tissue-resident immune cells within the retina, meaning they could be targeted 
locally by a therapy during remission. Nonetheless, following inflammation it is recognised that 
the BRB remains permeable, that immune thresholds are altered, and tertiary lymphoid 
structures may have formed within the eye – these represent other plausible targets during 
remission also [44, 411]. Targeting microglia (and/or other immune cells that have acquired 
residency within the tissue) during remission has the potential, in a patient, to enhance the 
immunosuppressive environment – e.g. in recurrent uveitis, or in drug-induced remission i.e. 
in chronic uveitis brought under control by steroids that need to be tapered due to its adverse 
effects – to ultimately prevent relapse. This represents a preferable approach to treatment 
strategy instead of targeting the peripheral T cells; during relapse, damage and symptoms are 
already being caused and targeting during remission would likely have an increased side effect 
profile as it would affect T cells systemically – and they are responsible for adaptive immune 
responses (in conjunction with B cells) throughout the body. 
Determining the role of microglia during the late stages of EAU has been challenging because 
macrophage infiltration has occurred and reasonable discrimination between these cell types 
has not been possible (until recently). However, it is plausible that microglia could play a key 
role in re-establishing an immunosuppressive environment within the eye; for example, through 
increased secretion of IL-27 (as outlined earlier) but via other mechanisms as well. Overall, this 
suggests that microglia have both a pro- and anti-inflammatory response in EAU, and that 
careful manipulation of them with therapies could have a beneficial effect in uveitis. 
A recent study cemented the vital role microglia play in uveitis by showing their depletion 
(using CSF1R antagonism; described later) inhibited the onset of EAU in both conventional 
immunisation and AT models, yet their depletion during established EAU was relatively 
inconsequential [390]. Using the EIU model (systemic LPS administration), it was also shown 
that CSF1R antagonism could prevent BRB breakdown and subsequent immune cell infiltration 
[412]. This highlights the importance of microglia in enabling immune cell infiltration, through 
direct interaction with leukocytes through the vascular wall and/or indirect effects via the 
vascular endothelium, but how other immune cells (such as monocytes and macrophages) could 
functionally mimic them and compensate for their loss once autoimmunity was established, or 
that they were obsolete by this point. They did not observe the effects of complete microglial 
depletion (e.g. using CSF1R antagonism) long-term, and it would be interesting to see if disease 
continued with a different severity due to their loss, because their potential pro-resolution 
response would no longer be present. However (as discussed in the next section) there is 
potential for myeloid cells to adopt programmed microglial niches of residency, acquire a 
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microglia or microglial-like role, and help to also resolve disease. As this adopted residency and 
functional adaptation takes time to complete, then resolution of disease could still be delayed 
compared to an absence of microglial depletion. 
1.5.4 Monocyte Engraftment and Microglial Depletion 
The understanding of monocyte and microglial dynamics within the brain has been difficult to 
establish due to similarities between the cell types. Nonetheless, it is well-characterised that 
microglia can be replaced by monocytes in the retina and brain by a process termed 
engraftment. The monocytes/monocyte-progenitors differentiate into microglia or microglia-
like cells, adopting their function and niche of residency. Post-engraftment, tissue-resident 
CD11b+ populations have their enhancers shaped by the local microenvironment (tissue- and 
lineage-specific transcription factors in addition to the microbiome) and this enables them to 
acquire the required phenotype for the niche they occupy [192, 413]. This may also explain why 
loss of a homeostatic microglial signal is observed in many microglial cell lines and cultures – 
i.e. because they are removed from this regulatory microenvironment [414].  
It has been shown that infiltration and engraftment of monocytes (for at least 6 months post-
radiation) into the brain only occurs after total body irradiation (TBI) and not after head-
protected irradiation (HPI) [415]; engraftment by monocytes occurs in a dose- and time-
dependent manner [416].  
More recent work, using Cx3cr1CreER/+:Csf1rFlox/Flox (CSF1R signalling is a vital microglial survival 
signal, and therefore its removal results in their death) mice fed tamoxifen-containing chow, 
shows that microglia are capable of self-replication (in the presence of partial loss) to maintain 
their physiological count (as compared to Cx3cr1+/+:Csf1rFlox/Flox controls) [417]. They also showed 
that both sorted and circulating blood monocytes were able to occupy the brain only in the 
CreER heterozygotes after tamoxifen administration (in a chimera with donor cells labelled). 
Engraftment occurred with or without the presence of a CSF1R inhibitor (it was exacerbated in 
its presence) and was confirmed it as genuine through use of the Cx3cr1+/-:Csf1rFlox/Flox:R26yfp 
mouse (where microglia would express yellow fluorescent protein [YFP+] and lose Csf1r 
expression, whilst peripheral cells would be negative). It was also shown that the peripherally-
engrafted cells had a transcriptional signature that was different from microglia; the unique 
signature was similar to intestinal serosal macrophages, lung CD11b+ macrophages, and small 
intestine lamina propria macrophages determined from microarray data acquired as part of the 
Immunological Genome Project (ImmGen) [418]. However, it should be noted that the atlas has 
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a bias towards certain cell types and others are under-represented or not present at-all. For 
example, currently no microglial data is included. Overall, the data suggests that tissue-
residency of microglia or microglia-like immune cells can only occur in predetermined regions 
commonly referred to as niches, and that in the absence of free/available niches this process 
cannot occur. It is suggestive that the spatial distribution of the niches, in conjunction with 
extension/retraction of microglial ramified processes, enables adequate microglial coverage of 
the tissue to both provide total immunosurveillance and enable completion of sub-specialised 
tasks unique to each microenvironment within the CNS. 
Other studies show that wide-scale microglial depletion (using Cre recombinase [Cre]/diptheria 
toxin [DT] receptor systems) results in self-renewal of those which survive. With irradiation, 
engraftment of peripheral cells could occur [419]. Therefore, it was suggested that unless the 
BBB is disrupted (i.e. by irradiation), the “niches” (programmed regions in which a microglia or 
microglial-like cell can reside – as described by [417]) are filled by self-renewing microglia. 
Through blockade of IL-1R, it was showed that microglial renewal is significantly delayed and 
that engraftment does not occur despite the niches being empty long-term, confirming that 
disruption to the BBB to permit cellular entry is required in addition to empty niches [419]. As 
CSF1R is vital for microglia, and they die without it [420], it is suggestive that the cell death 
resulting from experiments targeting CSF1R to deplete microglia could lead to the disruption of 
the BBB through the release of DAMPs or other signals to indicate tissue damage (CSF1 would 
be produced in a typical retina, and absence of its signalling could suggest tissue abnormalities) 
– which could disrupt the BBB and permit engraftment. The mechanism of cell death via DT 
systems is apoptosis as a result of inhibition of protein synthesis [421], meaning that release of 
DAMPs or danger signalling molecules may not occur as they cannot be synthesised, and this 
may explain why engraftment does not occur in this context. Irrespective of the conflicts, both 
studies independently identified microglial unique gene signatures, that were already widely-
believed to be microglial-specific, when compared to the engrafted cells [417, 419] (e.g. P2ry12, 
Tmem119). In agreement, other reports suggest that TMEM119 marks only microglia within the 
human brain and not monocytes [422]. However, in these experiments (performed on human 
tissues post-mortem) it remains unclear whether the monocytes have persisted long-term and 
are engrafted cells or are infiltrating due to inflammation. Furthermore, during disease states it 
is becoming increasingly recognised that downregulation of the microglial transcriptional 
programme occurs, including Tmem119 [353]. Nonetheless, it is understood that engrafted 
monocytes can be morphologically indistinguishable from yolk-sac derived microglia, but that 
it is possible to fate-map them using Ccr2 transgenic mouse lines (i.e. using Ccr2Cre instead of 
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chimeric techniques) as microglia do not express Ccr2 but most monocytes/monocyte 
progenitors do [423]. It is likely that their differential transcriptomes could be due to different 
differentiation pathways and lineages (i.e. origins) leading to epigenetic differences in these 
cells that cannot be fully overcome by the microenvironment and other local regulators. 
Whether these engrafted cells are beneficial or detrimental to tissue homeostasis is likely to be 
context-dependent with research supporting both outcomes [423, 424]; further research is 
required before their role and potential can be realised. Assuming monocyte-engrafted cells 
retain some epigenetic footprint of a monocyte progenitor, it would follow that these cells are 
inherently more predisposed towards a pro-inflammatory state. This could be helpful or 
harmful depending on the context. For example, monocyte-engrafted cells could become better 
at clearing and scavenging as well as dealing with infection (beneficial) whilst at the same time 
predisposing to inflammation in unnecessary contexts that could lead to collateral damage 
(detrimental). In the context of lipid-droplet accumulation, replacement of these microglia 
(LDAMs) by the monocytes could result in a more anti-inflammatory environment; whilst this 
would certainly be context-dependent on the proportion of LDAMs present, there is potential 
for engrafted cells to be beneficial and/or detrimental to the immune state of the retina. 
Furthermore, recent research shows that partial depletion of microglia and subsequent self-
renewal results in reduced neuronal damage in models of traumatic brain injury compared to 
controls which did not perturb the microglia, and that this is an IL-6-dependent process [425]. 
Whilst these experiments were performed on microglia located within the brain, these results 
could explain observations in the retina on partial depletion as they are likely to be similar in 
mechanism. This data suggests it could be repopulation of the retina, and not necessarily a 
specific cell type or progenitor (i.e. microglia or engrafted cell), that associates with protective 
effects. Further work comparing the IL-6 repair process between self-replicating microglia and 
engrafting monocytes, in addition to the context(s) in which this is beneficial would be useful 
in delineating the finer aspects of this phenomenon. 
It should, however, be noted that the experiments involving irradiation and large-scale 
depletion of microglia may not be representative of disease processes in humans. However, 
during inflammation (either locally or systemically) the ability for engraftment to occur, as the 
BBB/BRB is disrupted, is plausible. In humans, engrafted microglia-like cells have been observed 
in AD whilst in the mouse they have been shown to express genes associated with AD DAMs in 
naïve mice (engraftment procedure aside) [426, 427]. 
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Further work to establish whether engraftment is a genuine feature of inflammatory disease 
models of the brain and retina, and the effect this has on a disease course or future inflammatory 
processes, is required. It is, however, well-recognised in ageing that cells exhibiting a microglial 
morphology are more pro-inflammatory (generally primed) compared to their younger 
counterparts – it is unclear if these are general replacement of microglia with engrafted cells 
with time, or genuine changes in the embryonically-derived microglia over the lifetime of an 
organism (such as lipid accumulation and para-inflammation). It is possible that a threshold for 
these changes (i.e. a more pro-inflammatory state) is required before autoimmunity or 
neurodegenerative disease becomes feasible and could explain why the burden of infection, 
LDAM accumulation, immune adaptation, and para-inflammation could be important to its 
onset. 
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1.6 Experimental Techniques: mRNA-Sequencing 
Messenger ribonucleic acid sequencing (mRNA-Seq) is a technique that enables the 
quantification of mRNA inside a cell or group of cells, and has the potential to identify 
differences in expression of any gene, splice variants, and/or mutations (or SNPs) in different 
experimental groups – whether that be physiological and disease groups, treatment groups, 
others, or a combination [428]. The aim is to characterise changes between experimental groups 
in an unbiased manner to determine the changes occurring to cellular behaviour at the 
molecular level. For the study of microglia, this approach has improved our fundamental 
understanding through the identification of specific candidate markers which has enabled the 
generation of transgenic microglial reporter mouse lines, compendiums of key/homeostatic 
microglial transcripts, and meta-analyses of multiple microglial datasets to identify genes 
associated with varying microglial states (e.g. acute vs. primed) in attempts to begin classifying 
different microglial subtypes [158, 308, 346-351, 376, 429] (see the microglial phenotypes section 
of this Chapter and the challenge of microglial identification section within Chapter IV). mRNA-
Seq is a powerful tool for interrogating the whole transcriptome and understanding changes to 
cellular behaviour at a broad level, and has the potential to elucidate mechanisms of action, 
signalling, and side effects induced by therapeutics. The general aspects of experimental and 
analytical pipelines for mRNA-seq are summarised and discussed herein; specifics of the mRNA-
Seq pipeline selected for the experiments conducted as part of this thesis are described within 
Chapter III and Appendix I. 
1.6.1 Experimental Pipelines 
Cell Isolation Methods 
When performing mRNA-Seq on whole tissues derived from organisms, there will inevitably be 
a mixture of cell populations. This poses several challenges, chiefly that the mRNA isolated for 
sequencing would be a mixture of all the cell-types present in that tissue or organ. This causes 
significant problems in that the signal from your population of interest will be diluted by the 
others, and any treatments or other experimental procedures you wish to investigate would 
yield a summary picture of the largest/average changes from the cells types blurred into one – 
as opposed to specific changes at given times within a defined cell population. This can become 
further complicated if there is differential transcriptional amplification between cell types – 
transcriptional amplification being when a cell expresses more mRNA (or in the case of 
repression, less), leading to potential bias in identifying differentially-expressed genes (DEGs) 
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[430]. This may also result if there are changes in the proportions of cells of the different types 
or cellular infiltration (as would be seen in inflammatory models). Despite this, and approaches 
for cell isolation being well established, studies based on whole tissue approaches are being 
published currently [102]. 
To overcome some of these limitations, two main methodologies for bulk mRNA-Seq have been 
widely-adopted: fluorescence-activated cell sorting (FACS) and laser capture microdissection 
(LCM) [431]; the former involves dissociation of cells into a single-cell suspension, staining with 
antibodies conjugated to fluorophores (or use of fluorescent tagging beforehand), and then 
sorting of populations based on a gating strategy (determined by size and fluorescence intensity 
in the channels). LCM involves fixation and sectioning of tissues, optional staining, and use of 
a microscope-guided laser to isolate the region of interest (in this case a cell or group of cells). 
It is argued by many that LCM will be more representative of the mRNA being expressed by the 
cell as fixation “flash freezes” mRNA early-on in the preparation process, whilst there is a greater 
window of opportunity for transcriptional changes to occur with FACS-isolated mRNA due to 
the length of time required for preparatory steps such as staining protocols. However, it is also 
recognised that contaminant mRNA from surrounding areas/cells can also be captured using 
LCM. Nonetheless, both are valid ways of obtaining cells for mRNA-Seq as controls within each 
experiment are likely to be confounded by the same limitations and thus change in a similar 
way – when analysing, these artefacts would then be excluded as noise which would not achieve 
the required statistical threshold, and/or not be observed as different between experimental 
groups. Furthermore, a study investigated the two methodologies head-to-head by profiling 
single cells from chicken embryos; good correlation between samples acquired using the two 
cell isolation methodologies (FACS and LCM) was observed, suggesting the two techniques are 
comparable [432]. Beyond the two initial approaches, it is possible to utilise other technologies 
such as magnetic-activated cell sorting (MACS) for mRNA-Seq [433]. However, this approach is 
less widely adopted due to limitations of lower specificity and reduced sample viability of MACS 
compared to either LCM or FACS [434, 435]. 
Sample and Library Preparation 
Following isolation, cells require careful processing and preparation for sequencing. If not 
performed initially during the isolation step, the cells need to be lysed; this can be performed 
using snap freezing but is commonly performed with a lysis buffer (usually containing an RNAse 
inhibitor). The mRNA is then isolated, stabilised, and sometimes amplified from the mixture of 
cellular contents (the latter step is required in the case of low input amounts from few or single 
cells). This can be performed through polyA selection or ribosomal/transfer RNA (rRNA/tRNA) 
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depletion. The former is considered superior for mRNA-Seq, but rRNA/tRNA depletion helps to 
retain more long non-coding RNAs (lncRNAs) and other small RNAs [436]. Other approaches, 
such as using TRIzol reagent, also exist [437]. The aforementioned approaches are not 
compatible with formalin-fixed and paraffin-embedded samples – which is the way many tissue 
banks preserve and store patient samples – and therefore specialised extraction pipelines for 
these types of samples have also been developed [438]. 
The mRNA is then converted into complementary DNA (cDNA) using reverse transcriptase (RT) 
because cDNA is considerably more stable [439]. Before proceeding to cDNA synthesis, 
protocols often test the quality of the mRNA if it was purified as part of processing; the RNA 
Integrity Number (RIN) is the gold-standard for this [440]. In the original mRNA-Seq pipelines 
developed, random hexamer primers (in addition to d[T] primers specific for the beginning of 
the poly[A] tail) are used to amplify the cDNA first-strands generated by PCR. However, this 
process leads to a strong GC bias. Enhancements to this process now include the use of template 
switching to facilitate introduction of equivalent sequences at the 5’ end of the transcript to 
overcome this limitation [441]. Other pipelines bypass the use of PCR entirely, instead utilising 
a different process called in vitro transcription, which is considered to introduce less bias and is 
used in microarray platforms (the predecessor transcriptomics platform which mRNA-Seq has 
now effectively superseded) [442]. At this point, the cDNA is usually quantified and then 
processed for library preparation (where each sample is barcoded and prepared for sequencing; 
see Appendix I for the intricacies of this process), in addition to quantification post-library 
generation. A variety of techniques are available, such as the conventional nanodrop approach, 
but Qubit and Agilent Tapestation approaches are more sensitive, accurate, and reliable, and 
remain two commonly-used approaches to this end [443]. 
From this point, the samples are then loaded onto the flow cell (sometimes called chip) and 
sequenced. A variety of sequencing machines are available, depending on the throughput or 
technology required; the vast majority of mRNA-Seq is performed using the Illumina 
technology. A small proportion of mRNA-Seq is also performed using the Ion Torrent platform. 
Both perform similarly well, but the choice of sequencing platform affects how the data should 
be processed (for example, some aligners perform better or worse for each technology) [444]. 
1.6.2 Approaches to Data Analysis 
Whilst there is no gold-standard for data analysis approaches, good practice does exist and a 
survey on best practices was recently performed to help compile these in one place [445]. Before 
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detailing the available packages, software, and/or code to carry out analysis functions it is 
important to recognise the infrastructure and technical challenges relating to these tools and 
their use. 
Bioinformatics Tools 
The majority of tools available for use have been released as packages (or plugins) within 
Bioconductor. This is an add-on platform for the open-source R statistical package and is 
specifically aimed at the analysis and visualisation of data generated from high-throughput 
biological assays (e.g. mRNA-Seq, proteomics, flow cytometry) [446, 447]. This platform enables 
anyone to author a package (a plugin/addon for Bioconductor) and holds several advantages 
such as faster and better collaboration opportunities, being open-source so that the code can be 
critiqued and edited/refined by users, and an ability to write custom code if a desired function 
does not yet exist. However, it also holds several disadvantages such as a need for experience 
with command line interfaces (CLI). Packages can also become obsolete and dysfunctional 
within the Bioconductor environment if they are not maintained because Bioconductor itself is 
continually being updated. University computer systems often restrict user permissions and this 
can make troubleshooting or running of certain packages more challenging because the R 
environment defaults to using the C: drive (restricted) and it isn’t usually possible to edit the 
java runtime environment (default installation is also to the C: drive) which R depends on. 
Additionally, writing code for novel tasks/functions is non-trivial and requires expertise with 
coding languages. 
Other tools have also been developed and released in different ways. A large compilation of 
tools have been written by the Bioinformatics group at the Babraham Institute and the Broad 
Institute, whilst many other tools and/or data repositories are integrated on websites including 
the European Bioinformatics Institute (EMBL-EBI; to include the Expression Atlas and many 
more), the Database for Annotation, Visualization and Integrated Discovery (DAVID), the 
ImmGen project, the National Centre for Biotechnology Information (NCBI, to include the Gene 
Expression Omnibus [GEO]), Mouse Genome Informatics (MGI), and Ensembl [418, 448-457]. 
Beyond this, numerous commercial packages for analysis have also been released such as the 
Partek suite of software, Ingenuity Pathway Analysis (IPA) and CLC Genomics Workbench (the 
latter two from Qiagen) – these utilise graphical user interfaces (GUIs) instead of CLIs which 
makes them considerably more user friendly. Open-source all-in-one packages with a GUI, such 
as the Visualization Pipeline for RNA-Seq, a Snakemake workflow for efficient and complete 
RNA-seq analysis (VIPER) have also been released [458]. However, these GUI-based 
applications will have functionality limited to what has been implemented within them already, 
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usually with inaccessible/protected source code meaning that users rely on new versions solely 
from the developers. This can limit the rate of adoption of the latest innovations in the field and 
available options for analysis within these environments. 
It is evident that there are a variety of bioinformatics tools at a scientist’s disposal each with 
benefits and drawbacks. A more exhaustive list of over 100 mRNA-Seq bioinformatics tools, and 
their original papers for further reading, can be found on Wikipedia [459]. A different review 
paper also summarises and discusses many ‘omics tools and their utility in systems immunology 
[460]. 
Analysis of mRNA-Seq Data – Principles and a “Good Practice” Pipeline 
Once data has been acquired, it is first quality-checked and pre-alignment processing 
performed. Tools such as FASTQC are used to check the Phred scores (defined as -10 log10P 
where P is the probability of an error in base-calling [461]), GC content (highlighting PCR bias), 
base distribution across read position (highlighting abnormalities in a sample), and many other 
parameters which can be informative about the quality of the output (e.g. adapter 
contamination) [462]. From here, bases are trimmed – typically to remove adapter sequences, 
but also to remove poor quality reads at the 3’ end – so that alignment to a reference genome or 
de novo assembly would be more accurate and valid; low-quality reads can also be discarded 
[463]. Alignment, especially of small or microRNA molecules, would be highly inaccurate if 
contaminating adapters were still present or base calling was not accurate. Adapter sequences 
are dependent on the library preparation kit used (and hence vary considerably, although a list 
of many Illumina adapters can be found at [464]), but trimming from the 3’ end of a read on a 
Phred score of ≥20 is considered good and ≥30 ideal. 
At this point, dimension-reduction algorithms (such as principal component analysis [PCA]) 
are often performed on the data to enable visualisation of broad patterns. For example, 
segregation of samples would be anticipated based on factors such as experimental group, tissue 
the sample was derived from, time, etc [465]. Samples can also be correlated to one another to 
help identify outliers for exclusion (e.g. R2 ≥0.9 for cell lines of the same experimental group). 
However, in heterogeneous in vivo disease models this is not well understood and no defined 
set of criteria for exclusion exists, possibly because each disease model is unique and could vary 
in correlation due to genuine biological variation [466, 467]. 
The reads are then mapped to an organism’s genome or transcriptome, or sometimes (usually 
in the case of a poorly annotated organism) are used to create a de novo assembly, using an 
aligner. This process associates each read with a specific region (or regions) that it matches 
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within the genome, which itself associates with a specific gene. When mapping to the genome, 
it is also possible to identify new transcripts and splice variants [468]. For the creation of an 
assembly or to identify novel splice variants, considerably more and longer paired-end reads are 
generally required1. A huge variety of different aligners exist including bowtie 2, Burrows-
Wheeler aligner (BWA), genomic short-read nucleotide alignment program (GSNAP), 
hierarchical indexing for spliced alignment of transcripts (HISAT2; a successor to the popular 
TopHat2), Isaac 2, MapSplice, RNA-Seq unified mapper (RUM), and spliced transcripts 
alignment to a reference (STAR) [469-477]. When selecting an aligner for use, the main 
considerations include available random access memory (cRAM) of the processing machine 
(some aligners require large amounts of cRAM, and would not run on smaller systems such as 
desktop personal computers), read length of your data (some aligners are optimal for only 
certain length reads [i.e. ~25, ~75, ~200, or even larger]), mapping accuracy (higher being more 
desirable), splice awareness (if using mRNA-Seq data, this is critical or reads spanning an exon-
exon boundary will align to multiple places within the genome unnecessarily and this can affect 
results), and to some extent the speed at which the algorithm can align. To this end, STAR is a 
prominent and popular aligner because it is splice aware, can be used on reads of any length, is 
comparably accurate in mapping to many other aligners, and has a fast mapping speed – it is up 
to ~55 times faster than TopHat2 [475]. Furthermore, it can utilise only 16 Gb of cRAM in sparse 
mode, which would enable its use on high-end desktop machines and all servers. 
Once alignment has been performed, quality control (QC) steps are carried-out to check various 
basic metrics including alignment rate and unique alignment rate, but also more advanced 
metrics such as coverage uniformity, mapped reads distribution, and splice junction annotation 
[478, 479]. Generally, a total alignment rate of 80–90% is considered ideal, with a unique 
alignment rate of 70–80% also desired – assuming you are mapping to a well-annotated genome 
(e.g. human or mouse). Unique alignments describe where that read mapped to only one 
position within the organism’s genome; because of some repeat sequences and similarity in 
sequence between paralogous genes, some non-unique alignments are anticipated. In some 
organisms, such as the zebrafish, whole-genome duplication events occurred in evolutionary 
history (for the zebrafish, this is termed the teleost-specific genome duplication and represents 
a third-round compared to the two observed in tetrapods) and means that a greater proportion 
 
1 Five to twenty-five million reads are required for gene expression analysis, 50–70 million reads for 
transcript-level analysis, and ≥90 million reads for identifying novel transcripts or de novo assembly. This 
rule applies well to genomes comparable to the mouse or human, but otherwise the required number of 
reads can vary depending on the size of the organism’s genome (fewer for smaller genomes and vice 
versa). 
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of non-unique alignments would be anticipated compared to other organisms [480, 481]. 
Relatively uniform coverage is expected across the genome, so over-representation of sequences 
from one region of the genome can be an indicator of QC issues in the sample or problems with 
processing steps. 
The next step requires quantification of the reads and this can occur at the gene-, transcript-, 
or exon-level. A variety of packages can perform this function, including those such as Cufflinks, 
NOISeq, exploratory data analysis and normalization for RNA-Seq (EDASeq), Sailfish, and 
HTSeq [482-486]. Unfortunately, many (if not all) appear to struggle with reliable and valid 
quantification of reads that map in a non-unique fashion – which typically correspond to 
paralogous genes – as there is no simple (if any) way of differentiating them [487]. After 
quantification, the raw reads require normalisation because normalisation, or lack of, can have 
a profound effect on expression values and the subsequent detection of DEGs [488]. There are 
many normalisation strategies, but some of the commonly-used approaches include: RPKM, 
fragments per kilobase of exon model per million reads mapped (FPKM), transcripts per million 
(TPM), trimmed mean of M values (TMM), PoissonSeq, RNA-Seq by expectation maximization 
(RSEM), eXpress, or through the use of synthetic spike-in controls (e.g. ERCC spike-ins) of 
known concentration before sample processing begins [467, 489-496]. It is also possible to 
normalise using housekeeping genes: this could include the use of one or a set of predefined 
genes. Normalisation models which assume that roughly half of the transcriptome does not 
change across experimental groups have also been developed [497]. 
Quantified reads can then be analysed by differential gene expression analysis (DGEA) to 
identify DEGs. As before, many tools can be used for this (and some provide their own 
normalisation too); two of the best currently available packages include empirical analysis of 
digital gene expression in R (edgeR) and differential expression analysis for sequence count data 
2 (DESeq2) [498-500]. Once DEGs have been identified, it is important to nonetheless validate 
them. Performing quantitative PCR (qPCR) on the samples (if there is leftover material) can 
validate both the mRNA-Seq itself and the analysis as it uses the same original material. This is 
important, because if validation at the protein level was discrepant it would be unclear if the 
mRNA-Seq and/or analysis was valid or not, and discrepancies between proteome and 
transcriptome have already been observed [501]. The best approach to confirm change at the 
protein-level (i.e. with techniques such as Western blotting, fluorescence microscopy, and flow 
cytometry to name a few) will depend on a variety of factors [502]. 
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From here, the list of DEGs can be used for secondary analysis such as gene set enrichment (or 
pathway) analysis (GSEA) [503]. Two databases predominate in this type of analysis: gene 
ontology (GO) terms, and the Kyoto encyclopedia of genes and genomes (KEGG) pathways [504-
506]. This type of analysis can help to group DEGs which are related in a specific pathway, and 
put them through a second statistical test: the proportion of DEGs in that pathway (to those 
not) are compared to the proportion of all DEGs to the list of genes in the database (in essence, 
a repeated version of the Chi-Squared test for each pathway in the list) [507]. It arguably corrects 
for DEGs which may otherwise be noise (i.e. false positives) as multiple DEGs from a single 
pathway will be required before significance is achieved, and the probability of this occurring 
by random chance becomes considerably smaller. Despite this, these approaches are limited 
because they rely on coupling data to annotated databases and pathways primarily determined 
by genes with known functions. It can lead to the loss of information relating to genes which 
have been poorly characterised or are novel. The second main limitation is that it does not show 
directionality of the pathway change and uncertainty as to whether the changes in gene 
expression correspond to activation or inhibition of the pathway, or if there is functional 
antagonism and therefore no overall change to the pathway. However, the IPA tool can perform 
a modified GSEA which predicts activation/inhibition of the pathway to help understand which 
pathways are both significant and have a directionality bias. Despite these shortfalls, GSEA 
remains a very useful tool for filtering results into meaningful changes, mechanistic/signalling 
changes, or for further lines of investigation. It can also confirm at a broad level if the results 
are in general agreement with the known pathways and processes (e.g. you would anticipate 
immune-related processes to be identified as significantly enriched if you were investigating 
transcriptional differences during an autoimmune disease). Further to this, some tools 
(including weighted gene co-expression network analysis [WGCNA]) permit the generation of 
novel clusters/gene sets and statistical comparisons between samples and clusters [508]; the use 
of such tools generally require large datasets, often compiled from multiple sources. 
Lastly, a variety of other tools can also be utilised in conjunction with mRNA-Seq data such as 
genome browsers, generation of Sashimi plots (to visualise splice junctions), gene fusion 
discovery, volcano plots, and many other types of visualisation or investigation. However, these 
are generally limited to specific or a small set of genes [445]. 
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1.7 Thesis Objectives 
Uveitis is a group of autoimmune/autoinflammatory conditions of the eye and is the commonest 
cause of blindness in the working-age, representing a significant health burden. EAU and EIU 
are mouse models of non-infectious uveitis that enables us to manipulate and investigate the 
mechanics and kinetics of ocular autoimmune disease. The interplay of innate and adaptive 
responses, driven by macrophages and T cells, underpins immune-mediated pathology 
associated with non-infectious intraocular inflammation. Additionally, the retina is endowed 
with regulatory networks to maintain tissue homeostasis and neuronal function and to respond 
appropriately to danger. However, when homeostasis is lost immune-mediated inflammation 
and damage can ensue. 
At the current time, it is evident that microglia are more than mere bystanders during uveitis. 
They are suggested to be critical in initiating ocular autoimmunity, with some understanding 
of basic mechanisms by which they can achieve this. Alterations in critical sensing and 
regulatory microglial proteins have been shown to have profound effects on the permissibility 
of autoimmunity and severity of inflammation. Microglia are also known to influence leukocytes 
within the eye and have the potential to restore tissue homeostasis and resolve inflammation. 
However, little is known about their role in the later stages of uveitis, whether it is beneficial or 
detrimental overall, if tissue homeostasis ever returns or how it could be modulated. 
Furthermore, no markers for microglial-specific identification have been validated despite many 
promising candidates. Conventional transgenic models such as the Cx3cr1GFP mouse strain are 
known to tag microglia in addition to subsets of monocytes and other immune cells and this 
limits its utility in microglial investigation. In contrast, the Cx3cr1CreER:R26-tdTomato mouse 
strain holds promise but is currently unclear if it will overcome shortcomings in microglial 
identification during inflammation so that the microglial role could be better investigated. 
Provided it is sensitive and specific, the Cx3cr1CreER:R26-tdTomato mouse strain would permit 
valid usage of established techniques that utilise fluorescence-based detection, and the coupling 
of these to high-throughput techniques such as mRNA-Seq for unbiased characterisation. The 
synthesis of these tools with repeatable in vivo imaging techniques should ultimately enable 
discovery of changes to microglia and more understanding about their role in uveitis. 
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In summary, the hypotheses on which this thesis is based were specifically formulated to focus 
on determining the transcriptional changes that occur in retinal microglia in response to 
inflammation, comprising both a technical and biological question: 
- An enhanced ability to transcriptionally characterise samples acquired from ultra-low 
cell numbers. 
- Use of this platform to ask whether the homeostatic threshold of retinal microglia 
remains perturbed in response to acute and chronic inflammation. 
 
To test these hypotheses, this thesis aimed to: 
- Optimise and validate a FACS-Seq pipeline that would permit isolation and 
characterisation of defined/small numbers of immune cells from a single retina. 
- Characterise whether the Cx3cr1CreER:R26-tdTomato reporter strain was a sensitive and 
specific tool that would permit the isolation of microglia from retinas with intraocular 
inflammation. 
- Determine what changes occur in the microglial transcriptome in response to acute 
challenge using the EIU model. 
- Determine what changes occur in the microglial transcriptome in response to persistent 
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Chapter II: Materials and Methods 
C57BL/6J drug and test naïve 7-week-old SPF female mice were obtained from Charles River 
Laboratories International, Inc. (Oxford, UK). C57BL/6 Cx3cr1CreER:R26-tdTomato mice were 
obtained from Clemens Lange (University of Freiburg, Germany) and re-derived by embryo 
transfer; breeding colonies of homozygotes were established from the offspring, and 
homozygotes were crossed with wild-type (WT) mice to generate heterozygotes for 
experiments. C57BL/6 Cx3cr1GFP/+ mice were obtained from Heping Xu (Queen’s University 
Belfast; the mice were originally obtained from The Jackson Laboratory, Bar Harbor, ME), re-
derived and bred as described for the Cx3cr1CreER:R26-tdTomato mice. Genotyping (via PCR) of 
breeding pairs was performed to validate homozygosity of breeders. Mice were confirmed as 
negative for the Rd8 mutation [509]]. The details of mice used for experiments are listed in table 
2.1.1. 
For genotyping, DNA was extracted from mouse ear notches by overnight digestion in a solution 
containing 100 mM Trisaminomethane (Tris)-Cl, 5 mM ethylenediaminetetraacetic acid 
(EDTA), 0.2% sodium dodecyl sulphate (SDS), 200 mM NaCl, and 100 µg/mL proteinase k 
(P2308-100MG; Sigma-Aldrich, Poole, UK) at 56°C. Samples were then centrifuged and 250 µL 
of supernatant was transferred to a new Eppendorf containing 250 µL ice-cold pure isopropanol. 
This was then washed with 75% v/v ethanol (diluent was distilled water [dH2O]), air-dried, and 
resuspended in 20 µL double-distilled water (ddH2O). A PCR mastermix was made, using 
Phusion Green Hot Start II High-Fidelity PCR Master Mix (F566L; Thermo Fisher Scientific) at 
1:2 and primers at 0.2 µM to a total volume of 11.5 µL per sample (adding ddH2O as necessary). 
Half a microlitre of the DNA solution was added to each sample and mixed. The samples were 
then ran through the thermocycler programme for amplification. All run batches included both 
positive and negative (water) controls for validation. The primer sequences and cycling 
conditions are detailed in Tables 2.1.2 and 2.1.3, respectively. 
After amplification, the product was separated using gel electrophoresis and visualised under 
UV light. Briefly, 1.5% w/v agarose gels (in Tris-acetate-EDTA [TAE] buffer containing 100 
ng/mL ethidium bromide [E7637; Sigma-Aldrich]) were ran for ~22 minutes at 120 V (400 mA). 
A band (using the Cx3cr1CreER primer set) 750 bp in length is observed in a WT mouse (i.e. 
without insert), and a band 304 bp in length if present. In the case of the tandem dimer tomato 
(fluorescent protein [tdTomato]) insert in ROSA, a 297 bp band is observed in a WT mouse, and 
a band of 169 bp is observed if present (Figure 2.1.1). 






Disease Model Strain Gender 
Age (at disease 
induction) 










Table 2.1.1. Details of mice used for experiments. The Cx3cr1CreER:R26-tdtomato mice received a course of 
tamoxifen 4 weeks prior to disease induction. Abbreviations: EAU – experimental autoimmune uveitis, 
EIU – endotoxin-induced uveitis, WT – wild-type. 
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Primer Name Primer Set Forward/Reverse Sequence (5’->3’) 
Cx3cr1CreERF 
For genotyping the 
CreER insert (in the 
Cx3cr1 gene) 
Forward CCTCTAAGACTCACGTGGACCTG 
Cx3cr1CreERR Reverse GACTTCCGAGTTGCGGAGCAC 
Cx3cr1CreERSpec Reverse GCCGCCCACGACCGGCAAAC 
RsTom-F 
For genotyping the 
tdTomato (and stop/ 
locus of X-over p1 
[loxp] sites) insert (in 
the Rosa26 gene) 
Forward CTGTTCCTGTACGGCATGG 
RsTom-R Reverse GGCATTAAAGCAGCGTATCC 
RsTomWT-F Forward AAGGGAGCTGCAGTGGAGTA 
RsTomWT-R Reverse CCGAAAATCTGTGGGAAGTC 
Table 2.1.2. Primer details for genotyping of the Cx3cr1CreER:R26-tdTomato mouse strain. Two 







Stage Temperature (°C) Length (minutes) 
Pre-heat 105 0 
Initial (Heat Activation) 94 5 
Cycles (repeats 
33 times) 
Denaturation 94 0.5 
Annealing 58 0.75 
Extension 72 1 
Final Extension 72 5 
Table 2.1.3. Details of cycling conditions used in genotyping the Cx3cr1CreER:R26-tdTomato 
mouse strain. The same conditions were used for both genotyping sets of primers. 
 
  






Figure 2.1.1. An example gel output from the genotyping protocol for the Cx3cr1CreER:R26-
tdTomato mouse strain. Ladders flanking the samples enable confirmation of expected band 
size. Output from each of the primer mixes is indicated, and these alternate within the gel meaning 
that every 2 lanes represents results from a single biological sample. A wild-type control, positive 
control, and negative (water) control are shown in red, green, and blue, respectively. The ladder 
used has steps 100 bp in size, starting from 100 (the brightest band nearest to the bottom 
represents 500 bp). 
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The Cx3cr1CreER:R26-tdTomato mice were weaned at ~4 weeks of age. All mice were housed in 
groups of 2-5 in Tecniplast 1284L conventional cages (Tecniplast, Buguggiate [VA], Italy) on a 
12-hour light/day cycle at room temperature. They also had access to EURodent Diet 22% food 
(LabDiet, St. Louis, MO) and water ad libitum, and environmental enrichment in the form of 
cardboard play tunnels/huts, wood gnawing blocks and sizzle nests. Welfare-related 
assessments were performed at least daily. The number of mice in each experiment was chosen 
so that, despite variability in disease incidence and severity/development of EAU [110] (EIU has 
a disease incidence of 100%, although there is a rare risk of protocol failure), suitable mice could 
be selected for sequencing to provide adequate power. 
All work was performed within the Animal Services Unit (ASU) at the University of Bristol, 
where the mice are housed, in concordance with the Animals (Scientific Procedures) Act 1986 
(ASPA) and The Association for Research in Vision and Ophthalmology (ARVO) Statement for 
the Use of Animals in Ophthalmic and Visual Research. 
2.2 Tamoxifen Administration 
Tamoxifen (T5648; Sigma-Aldrich) was dissolved in corn oil (C8267; Sigma-Aldrich) to a 
concentration of 21 mg/mL or 5 mg/mL, for subcutaneous injection and topical administration 
respectively. The solutions were freshly prepared by overnight incubation in an orbital shaker 
at 42°C and 300 rpm. Mice were injected with 200 µL subcutaneously (100 µL into both the lower 
[inguinal] left and right quadrants using a 25-gauge [25G] needle) on days 1 and 3; alternatively, 
mice were administered 10 µL (using a Gilson pipette) topically to the eye 3 times daily 
(minimum gap of 2 hours between dosing) for up to 4 days (post-optimisation, a 3-day protocol 
was used). The subcutaneous regime was provided by Clemens Lange (with the Cx3cr1CreER:R26-
tdTomato mice) whilst the topical regime was obtained from a paper using CreER mice and 
induction of recombination within the eye [510]. The local method of administration was 
compared to subcutaneous in case extraocular recombination occurred within long-lived cells 
that entered the eye during inflammation. 
2.3 In Vivo Models 
2.3.1 Induction of EAU 
Female mice were immunised for disease at 8 weeks of age (typical mean weight of 19.3 ±1.0 g), 
with constrained randomisation within blocks (cages, which represent mice from the same 
litter) being performed in Excel (Microsoft, Redmond, WA) to select unimmunised mice as 
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naïve controls. An experimental unit is considered a collection of mice that were all immunised 
(or kept unimmunised) at the same time. 
Mice were immunised by injecting 500 µg/mouse hRBP-31-20 or 400 µg/mouse RBP-3629-643 in 
phosphate-buffered saline (PBS) with 2% v/v dimethyl sulphoxide (DMSO). This was added 1:1 
v/v to CFA; 1 mg/mL supplemented with 1.5 mg/mL Mycobacterium tuberculosis H37 RA (Becton 
Dickinson [BD] Biosciences, Oxford, UK), to a total volume of 100 µL/mouse, subcutaneously. 
Mice were also injected with 1.5 µg Bordetella pertussis toxin (Sigma-Aldrich), diluted to a 
volume of 100 µL in PBS, intraperitoneally. 
2.3.2 Induction of EIU 
Prior to anaesthesia, mouse pupils were dilated using topical tropicamide 1% w/v and 
phenylephrine 2.5% w/v (Minims; Chauvin Pharmaceuticals, Romford, UK). 
The mice were then anaesthetised by intraperitoneal injection of 90 µL/10 g body weight of a 
solution containing 6 mg/mL ketamine (Ketavet; Zoetis Ireland Ltd., Dublin, Ireland) and 2 
mg/mL Xylazine (Rompun; Bayer plc, Newbury, UK; diluent was dH2O). This anaesthetic 
combination and route of administration was used as it is a well-established and safe method of 
anaesthesia, used both within and beyond our group, to provide sufficient sedation for 
imaging/intravitreal injections whilst allowing for relatively quick recovery. 
Mice were selected for injection using randomisation as described before. The eye (left or right) 
was also randomised. 
Intravitreal injections were performed under an operating microscope by Dave Copland [97]. In 
summary, 2 µL volume of PBS containing 10 ng LPS from E.coli 055:B5 (Sigma-Aldrich) was 
delivered into the intravitreal space via the pars planar. The eye was proptosed and held in 
position with a pair of forceps, then carbomer eye gel 0.2 % w/w (Viscotears; Novartis 
Pharmaceuticals, Camberley, UK) was applied and a circular coverslip (7 mm diameter) placed 
over the eye. A 33G hypodermic needle, mounted on a 5 µL Hamilton syringe (CAL7633-01; 
Hamilton, Reno, NV), was inserted approximately 2 mm circumferential to the corneal limbus 
with a ~45° injection angle. The needle bevel was guided into the VB, stopping between the lens 
and the optic disc (from the relative viewpoint of the surgeon, this is above/covering the optic 
disc – approximately 1.5 mm from the site of insertion), and 2 µL of LPS (at 5 ng/µL in PBS) was 
slowly injected. The needle was held in-place briefly (to reduce the amount of reflux of injectate) 
and removed. Post-injection, the site was treated with 1% w/w chloramphenicol ointment 
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(Martindale Pharma, Romford, UK) and the globe reposited by release of the forceps. Post-
injection, mice were monitored for vital signs (breathing, movement, heart rate, reflexes) and 
kept on a heated pad until recovered. 
2.4 In Vivo Imaging Techniques 
Disease progress was monitored using the Micron IV: Retinal Imaging Microscope (Phoenix 
Research Labs, Pleasanton, CA). Imaging was performed in the morning, working in ascending 
mouse number within each cage and by alphabetical cage lettering. 
The Micron IV had the following attachment: OCT1. Prior to imaging, the Micron IV charge-
coupled device (CCD) was calibrated using the auto-white balance, and the OCT attachment 
was calibrated in accordance with the manufacturer’s protocol. For brightfield fundus images, 
the gain was set to +3 dB, frames per second (FPS) to 15, and a 544/211 exciter filter with 700 nm 
shortpass emission filter was used. For fluorescence imaging, the brightness, gain, and FPS were 
adjusted so that (using the log histogram function of the Streampix software) the brightest non-
dead pixels (representing the brightest spots of the fluorescently-labelled cells) were at an 
intensity just above 200: for tdTomato imaging, this typically required maximum brightness on 
the analogue dial, a gain of +11 dB, and FPS of 2 (or a gain of +18 dB and FPS of 4); for green 
fluorescent protein (GFP) or fluorescein imaging this typically required maximum brightness, a 
gain of +15 dB, and FPS of 4. Gain-normalised settings (to the typical parameters – for 
comparison across a time-course) were acquired for each retina, in addition to tuned settings 
for each eye so that images were not under- or over-exposed and would be suitable for 
deconvolution or other image analysis. The exciter/emission filter combinations used for 
fluorescent imaging is detailed in Table 2.4.1. For OCT, the parameters were defined according 
to the manufacturers protocol, and all scans were taken 30 times in rapid succession and 
averaged. Full-length line B-scans were taken horizontally and vertically with the optic disc 
centred; other features of interest, identified through fundal imaging, were also scanned. Full-
length circle B-scans were taken centred around the optic disc. Additionally, 512 half-length line 
B-scans running superiorly (with respect to the target box area; scans obtained without 
averaging) can be acquired in quick succession for acquisition of a 3D, or volume, scan. Images 
were stored in the tagged image file format (TIFF). 
  






Specification Λ Range (nm) Source 
1 
Exciter 544/211 bp 438.5-649.5 
Stock (Phoenix 
Research Labs) 
Emission 700 sp -700 
2 
Exciter 468/35 bp 451.5-486.5 
Emission 488 lp 488- 
3 
Exciter 550/25 bp 537.5-562.5 Edmund Optics 
(Barrington, NJ) Emission 590 lp 590- 
4 
Exciter 715 lp 715- 
Phoenix 
Research Labs 
Emission 512/30 bp 497-527 Edmund Optics 
Table 2.4.1. Filter information for the exciter/emission positions (on the filter wheel) of the Micron 
IV: Retinal Imaging Microscope. Exciter and emission filters can be used independently of each 
other. Common combinations of filters used (x-y, where x is the exciter and y is emission) 
include: 1-1 (brightfield), 3-3 (tdTomato), 2-4 (GFP/Fluorescein). Excitation filters were 25 mm 
in diameter and mounted, with a max thickness of 5 mm; emission filters were 12.5 mm in 
diameter and unmounted, with a max thickness of 3.5 mm. Filters were installed according to 
the Micron IV manual. 
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Prior to imaging (both techniques), mouse pupils were dilated as described previously. 
When using the Micron IV, mice were anaesthetised (as described previously; in some cases, a 
lower dose of the anaesthetic solution was administered in conjunction with isofluorane by 
inhalation), transferred to the animal stage, and carbomer eye gel was administered for coupling 
to the objective lens. The mouse was positioned so the eye was perpendicular and near to the 
lens with the iris roughly equidistant from pupil to sclera on the viewing plane on the computer 
monitor (the ideal position is to have the optic disc centrally-positioned with an unobscured 
view of the retina surrounding – with the space between optic disc and iris equidistant – this 
roughly corresponds to the iris-sclera positioning described above, but can vary slightly based 
on anatomical variation found between mice; some optic discs are found centrally to this 
position, but are usually slightly offset). An image was captured (for QC purposes), and then 
the lens was moved closer to the eye so that the retina occupied the full image space. The focus 
and illumination were adjusted (for brightfield – for fluorescent imaging, the settings are 
described above) to obtain a good colour balance and images were captured. Videos, whilst 
slowly rotating the focus dial (starting from above the focal-plane of the retina until below) were 
also captured to assist in the acquisition of the sharpest/most in-focus images. Post-imaging, 
mice were monitored for vital signs (breathing, movement, heart rate, reflexes) and kept on a 
heated pad until recovered. 
2.5 Flow Cytometry/Fluorescence-Activated Cell Sorting 
2.5.1 Batch Processing 
Mice were euthanised by cervical dislocation, eyes enucleated and spleens dissected, and both 
were placed in PBS on ice. The eyes were dissected under a microscope to isolate the retinas; a 
27G needle was poked through the corneal limbus, 100 µL of ice-cold PBS was added, and then 
micro surgical scissors were used to cut along the remainder of the boundary. The anterior 
fragment, along with the lens, was removed and discarded. The retina was then gently teased 
apart from the RPE and, with the PBS, transferred to an Eppendorf where it was mechanically 
disrupted by scratching along the surface of an Eppendorf rack. The retinas were transferred to 
a 60 µm nylon mesh filter plate and centrifuged at 300 xg and 4°C for 5 minutes. The filtrate was 
then transferred to a V-bottom 96 well plate for staining. Spleens were prepared by mashing, 
transfer through a 70 µm cell strainer and centrifuged at 400 xg and 4°C for 3 minutes 
(subsequent centrifugation steps use these settings, unless otherwise stated). The supernatant 
was discarded, and the pellet was resuspended in 10 mL Ammonium-Chloride-Potassium (ACK) 
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lysing buffer (8.29 g/L NH4Cl, 1 g/L KHCO3, 372 mg/L Na2-Ethylenediaminetetraacetic acid 
[EDTA] in dH2O) for 3 minutes on ice (to lyse erythrocytes), centrifuged and the supernatant 
discarded, re-suspended in 5 mL PBS and 200 µL transferred to the plate. A 200 µL aliquot of 
the spleen cell suspension was killed by heating to 95°C for 15 minutes. 
For staining, the V-bottom plate was centrifuged, the supernatant discarded, and each well re-
suspended in 100 µL 2.4G2 cell supernatant (or 50 µL Fc block [#553142 (BD Biosciences)] at 1:50) 
and incubated at 4°C for 10–15 minutes. 100 µL of an antibody cocktail (or 50 µL if using the Fc 
block) containing fluorochrome-conjugated mAbs (see Table 2.5.1) was added and incubated at 
4°C for 20-30 minutes. One µL of mAbs were also added to one drop of compensation beads 
(OneComp eBeads [Thermo Fisher Scientific], Anti-Rat Ig, κ/Negative Control Compensation 
Particles Set [BD Biosciences], or AbC total antibody compensation bead kit [Thermo Fisher 
Scientific]) to prepare single-stain controls for compensation; for live-dead compensation, a mix 
of live and heat-killed spleen cells were used re-suspended in 7-aminoactinomycin D (7AAD) at 
1:500 (Thermo Fisher Scientific) diluted with staining buffer. Fluorescence minus one (FMO) 
controls were also prepared. Post-staining, the plate was centrifuged and the supernatant 
discarded, re-suspended in 200 µL staining buffer, and centrifuged with supernatant discard as 
a wash step. Cells were re-suspended in 250 µL 7AAD as before and kept on ice until sorting on 
a BD Influx Cell Sorter (in some sorting experiments DRAQ7 [DR77524; Biostatus, Shepshed, 
UK] was added instead – for flow cytometry, the 7AAD was added in conjunction with the 
antibodies); beads were re-suspended in staining buffer. Data was acquired using a BD 
LSRFortessa X-20 flow cytometer. 
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Target (synonym) Fluorophore Clone Supplier 
B220 FITC RA3-6B2 
BD Biosciences 
CD3 APC 145-2c11 
CD45 PE-Cy7 30-F11 
Gr-1 (Ly6C/Ly6G) Alexa-700 RB6-8C5 
CD11b APC-Cy7 M1/70 
Milr1 (Allergin-1) BV421 TX83 
C5ar1 BV510 20/70 
CD44 Super Bright 600 IM7 Thermo Fisher Scientific 
Siglech BV650 440c 
BD Biosciences Fas (CD95) BV711 Jo2 
Mertk (Mer) BV786 108928 
Slamf1 (CD150) FITC 9D1 
Thermo Fisher Scientific 
Bst2 (CD317) PE-eFluor610 eBio927 
Lair1 PE-Cy5.5 113 Novus Biologicals*  
P2ry12 APC S16007D Biolegend 
CD4 FITC RM4-4 BD Biosciences 
CD8 PE H35-17.2 Thermo Fisher Scientific 
Table 2.5.1. A list of monoclonal antibodies used for flow cytometry. *Novus Biologicals 
(Centennial, CO). Abbreviations: Milr1 – allergin-1 precursor, Siglech – sialic acid binding Ig-like 
lectin H, Fas – fas cell surface death receptor, Mertk – tyrosine-protein kinase mer precursor, 
Slamf1 – signaling lymphocytic activation molecule, Bst2 – bone marrow stromal antigen 2 
precursor, Lair1 – leukocyte-associated immunoglobulin-like receptor 1, FITC – fluorescein 
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Cells were sorted (using a BD Influx Cell Sorter) into 0.2 mL tubes containing 0.05 µL RNase 
inhibitor, 0.95 µL lysis buffer, and a variable amount of nuclease-free water depending on the 
number of cells collected – 9.5 − ( 𝑥𝑥
850
∗ 3) µL, where 𝑥𝑥 is the number of cells you are sorting (e.g. 
600 cells occupy 2.1 µL, so 7.4 µL ddH2O is added; components of the SMART-Seq v4 Ultra Low 
Input RNA Kit for Sequencing; Takara Bio USA, Inc., Mountain View, CA) as per the user manual 
(to calculate the volume of nuclease-free water, preliminary experiments determined the 
volume of 850 microglia to be 3.0 µL). Sorting was performed by the University of Bristol Flow 
Cytometry Facility. Samples were sorted in a constrained randomised order in blocks; blocks 
were made as small as possible and consisted of a balance of every tissue type and disease status 
(naïve or immunised) so that observable effects between groups were not due to a time-/order-
dependent effect of when they were sorted. 
Gating strategies for cells are shown and described in the relevant results sections. 
2.5.2 Single Sample (or Small Number Batch) Processing 
In a variation of the above protocol, it is possible to prepare samples as required/in batches to 
minimise mRNA sample degradation when performing FACS. Some sample degradation was 
observed in early experiments, and therefore batches of samples (for cell-surface staining prior 
to sorting) were restricted to a maximum of 8 at a time (with later batches of samples being 
staggered and prepared later [i.e. whilst the first batch was sorting]). 
For samples where sorting was performed purely using fluorescent markers (e.g. tdTomato or 
GFP), it was possible to prepare the samples by dissecting, scratching, spinning through the 
filter plate, adding the DRAQ7 and sorting with minimal preparation time. In these 
experiments, samples could be prepared individually (or a pair if taking both retinas from the 
same mouse) but it was determined that batches of 2-4 retinas worked best as single retina 
preparations were not very practicable, and that these small batches were fast enough to obtain 
high quality cDNA output for all samples. 
2.6 Sample and Library Preparation for Sequencing 
Samples were prepared for sequencing through use of the SMART-Seq v4 Ultra Low Input RNA 
Kit for Sequencing, according to the user manual, to generate cDNA from the mRNA and 
amplify by Long Distance PCR; for the latter step, 16 cycles were used (for 600 cells) as 
determined by an optimisation experiment (see Chapter III; 15 cycles was optimal for 1,000 
cells). Subsequently, the cDNA was isolated using the Agencourt AMPure XP Kit (Beckman 
Chapter II: Materials and Methods 
93 
 
Coulter, Brea, CA) and quantified using the Agilent High Sensitivity DNA Kit on an Agilent 2100 
Bioanalyser (Agilent Technologies, Santa Clara, CA), by the University of Bristol’s Genomics 
Facility, as per the protocols in the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing user 
guide. The library was then prepared by the Genomics Facility using the Nextera XT DNA 
Library Preparation Kit (Illumina Inc., San Diego, CA), following the Nextera kit reference guide, 
using 150 pg cDNA as the starting input. 
2.7 mRNA-Sequencing and Data Analysis 
Samples were sequenced to depths of up to 33.3 million single-end 75 nt length reads per sample 
using the Illumina NextSeq 500/550 High Output v2 kit (75 cycles) on an Illumina NextSeq 500 
Sequencing System. Based on new data, and depth vs. replicates data published elsewhere (as 
described in Chapter III), a sequencing depth of ≥11.1 million reads per sample was determined 
as optimal (the SMART-Seq kits allow for preparation of samples in multiples of 12 [where kits 
can used singly to mitigate the risk of contamination from “double-dipping”], and the 
sequencing flow cell provides up to 400 million reads [400/36 = 11.1], making this choice a 
compromise between depth and kit usage). Image analysis, base calling, and generation of 
sequence reads were produced using the NextSeq Control Software v2.0 (NCS) and Real-Time 
Analysis Software v2 (RTA). Data was converted to FASTQ files using the bcl2fastq2 v2.20 
software (Illumina Inc.). 
Sequencing data was uploaded to a cluster of computers for alignment and initial analysis; the 
cluster consisted of a master (consisting of a 12-core central processing unit [CPU] and 32 Gb 
cRAM) and 2 worker nodes (consisting of a 16-core CPU and 64 Gb cRAM each) running on a 
64-bit linux operating system (v3.13.0-40-generic). The data was then processed through an 
analysis pipeline using the Partek Flow (Build version 6.0.17.0614; Partek Inc., St. Louis, MO) 
software with the following task nodes (non-default parameters are specified in brackets): Trim 
adapters (inputting Nextera XT Index Kit v2 adapter sequences as provided by Illumina [464]), 
Trim bases (From 3’ end, 1 base), Trim bases (from 3’ end with minimum quality score [Phred] 
of 30), Align reads using STAR (2.5.3a using mm10 as the reference index), Quantify to 
transcriptome (Partek E/M using mm10 – Ensembl Transcripts release 89 as the reference 
index). 
The data output from Partek Flow was then downloaded to a local computer, and further 
analysed using Partek Genomics Suite (PGS; version 6.6, Build 6.16.0812). PGS normalises data 
using the RPKM approach and performs differential gene expression analysis using an analysis 
of variance (ANOVA) model; a gene is considered differentially-expressed if it had an FDR step-
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up p value ≤0.05 and fold-change ≥±2. The fold-change and p-values were then imported into 
IPA version 01-13 and analysed according to the manual. PGS and IPA were both used to generate 
figures. A summary of the analytical pipelines is shown in Figure 2.7.1. 
  





Figure 2.7.1. The bioinformatics pipeline for processing and analysing the mRNA-Seq 
data. A) The bioinformatics analysis shown starting with the unaligned reads and pre-alignment 
processing, B) alignment, alignment QC and quantification of reads, and C) differential gene 
expression analysis (DGEA) and filtering/visualisation; Partek Flow was used for pre-processing, 
alignment, and quantification of the data whilst Partek Genomics Suite (PGS) was used to 
normalise the data and perform DGEA. Both PGS and Ingenuity Pathway Analysis (IPA) were used 
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2.8 Quantitative PCR 
The remaining cDNA generated from the sorted cells was used for transcript-level validation. 
qPCR was performed using the TaqMan Universal Master Mix II, with UNG (4440038) and 
TaqMan gene expression probes (4331182) on a Quantstudio 3 Real-Time PCR system (A28137; 
all products from Thermo Fisher Scientific). Samples were run in technical duplicate, using 1 ng 
as the input amount, and analysed using the equation: 2Cq(mean (control))-Cq(sample). 
The probes used were: Bst2 (mm1609165_g1), C5ar1 (mm00500292_s1), Cd44 (mm01277161_m1), 
Fas (mm01204974_m1), Lair1 (mm00618113_m1), Mertk (mm00434920_m1), Milr1 
(mm01242703_m1), P2ry12 (mm01950543_s1), Siglech (mm00618627_m1), Slamf1 
(mm00443317_m1). 
2.9 Confocal Laser-Scanning Microscopy 
Mice were euthanised by cervical dislocation, their eyes nucleated and placed in 4% v/v PFA (in 
PBS) for 1 hour. The anterior components were removed (to isolate the “eyecup”) by dissection 
under a microscope as described previously, with the following modification: the 27G needle 
was poked through the sclera, circumferential to the corneal limbus (as opposed to at the 
corneal limbus), with micro surgical scissors used to cut the remainder. 
 After isolation, the eyecup is carefully placed into an Eppendorf containing 100 µL of a solution 
containing 1% v/v BSA and 3% v/v Triton x-100 (both Sigma Aldrich) in PBS and rocked on a 3D 
rocker at room temperature and 70 rpm for 20 minutes. The retinas were washed two more 
times, before blocking for 2 hours in the same solution containing 5% v/v normal goat serum 
(Vector Laboratories Ltd., Peterborough, UK). Eyecups were then incubated at 4°C overnight 
with a rabbit anti-mouse anti-RFP mAb (600-401-379; Rockland Immunochemicals Inc., 
Limerick, PA) and for target validation experiments a Super Bright 600-conjugated anti-mouse 
CD44 mAb was used in combination. They were washed three times, and then incubated 
overnight (as per primary antibodies) with the secondary antibody goat anti-rabbit Alexa-633 
(A21070; Thermo Fisher Scientific). Eyecups were then washed three more times. 
The retina was then isolated from the eyecup by gently teasing as described before. However, 
micro surgical scissors were used to cut the ON (as opposed to tearing it – careful handling and 
preservation of the structure is necessary for confocal preparations). The retina was then cut in 
four places by incising from the peripheral retina one-third to halfway to the ON (the incisions 
are on imaginary horizontal and vertical lines running perpendicular through the ON). They 
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were then flat-mounted in Vectashield hard-set antifade mounting media (H-1400; Vector 
Laboratories Ltd.) by placing the sample in the centre of a “sticky ring” on a microscope slide or 
coverslip and then attaching a coverslip on top. A secondary seal, using nail varnish, can be 
added to the edge of the interface between slide and coverslip. Slides were kept at 4°C until 
imaged on a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica DM I6000 
inverted epifluorescence microscope (Leica Microsystems Ltd., Wetzlar, Germany). Images 
were acquired with an xy pixel size ≤200 nm, and a z-step size of ≤400 nm. 
2.10 Analysis 
2.10.1 Image Processing 
Huygens professional software (Scientific Volume Imaging B.V., Hilversum, The Netherlands) 
was used to deconvolve the Micron IV fluorescent images and fluorescence microscopy (Figure 
2.10.1). For the Micron images, the following parameters were used: lens immersion = 1.343 
(refractive index of the 0.2% w/w carbomer eye gel [511]), embedding = 1.377 [512], peak emission 
= 581 nm, numerical aperture = 1.25, and xy pixel size of 130 nm; the background was estimated 
at 2 and a signal-to-noise ratio of 15 was used. Hot pixel correction (with a sensitivity of 4) was 
used prior to deconvolution. For fluorescence microscopy, the parameters were imported from 
the microscope and the default settings were used. 
  




Figure 2.10.1. tdTomato fluorescence images of a mouse retina both pre- and post-
deconvolution using Huygens software. A) Fluorescent fundal images were acquired from 
naïve Cx3cr1CreER:R26-tdTomato mice 4 weeks following tamoxifen administration. Paired raw and 
deconvolved images show how the software algorithm improves the image detail quality. Full 
fundal distribution of microglia and close-up images of cells located in B) peri-vascular, C) central 
and D) peripheral retinal regions. Due to the resolution limits of the Micron IV (2 µm) it is not 
possible to readily visualise all but the largest of the ramified processes; ramified processes are 
well-known to be typically 0.5–1.0 µm in diameter. 
  




Microscopy images were processed using the Leica LAS X software (Leica Microsystems Ltd.) 
and FIJI (a distribution of ImageJ [513]). Other images, and figures, were processed using 
Photoshop (Adobe Inc., San Jose, CA) and Powerpoint (Microsoft). 
2.10.2 Statistical Analysis 
Data were analysed using GraphPad Prism 7 software (GraphPad Software Inc., San Diego, CA). 
The One-way ANOVA with Tukey’s multiple comparisons test was used to compare multiple 
groups of data to a control group. FDR step-up correction was also applied. A p value ≤0.05 was 
considered significant. For a comparison between two groups, the t-test was used. For 
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Chapter III: Optimising mRNA- Seq 
3.1.1 The Challenge of Ultra-Low Input RNA 
It has been previously shown that the mouse retina contains approximately 1,500 microglia 
using histological-based approaches [514]. Flow cytometric analysis has indicated it is possible 
to reliably recover 1,000 microglia per retina [413]. However, it is well-recognised that cell 
sorting may recover as low as 30% of the cells present in the original sample, meaning that 
recovery numbers could be as low as 450 microglia per retina [515]. This low number limits the 
use of many mRNA-Seq sample and library preparation kits which typically require much higher 
input amounts of mRNA (corresponding to ≥10,000 cells). Furthermore, pooling of multiple 
retinas (≥10) is not feasible/practicable for several of reasons: 1) the time required isolate these 
high numbers means that the mRNA may be degraded or of poor quality for input, potentially 
resulting in very low numbers of samples obtained and poor statistical power or failure of 
experiments entirely; 2) the use of large numbers of mice to obtain limited data could be 
considered unethical/excessive and not in accordance with the principles of the 3Rs [94]; 3) the 
breeding, handling, and effective monitoring of mice with disease may not be feasible in the 
numbers required; 4) information about disease grading and the ability to associate this with 
the transcriptome will be greatly limited, reducing the utility of the hypothetical dataset. 
After careful consideration and support from the University of Bristol Genomics Facility, the 
SMART-Seq Ultra Low Input RNA kit by Clontech (with Nextera XT DNA Library Preparation 
kit by Illumina) was adopted for our requirements of low cell input mRNA-Seq [516-518]. The 
pipeline (which is recommended by Illumina for single-cell and ultra-low input) is summarised 
in Figure 3.1.1 but is discussed in greater technical detail within Appendix I.  
  





Figure 3.1.1. An overview of the SMART-Seq v4 ultra low input RNA kit pipeline. Firstly, 
cells are prepared for isolation by fluorescence-activated cell sorting (FACS). From the poly(A) 
tail, copying of mRNA is performed in addition to template-switching to incorporate primer 
sequences flanking the mRNA transcript. This is then amplified – to increase yield – utilising long-
distance polymerase chain reaction (LD-PCR), purified utilising magnetic beads (Agencourt), and 
quantified utilising a high-sensitivity gel electrophoresis approach (Agilent). Lastly, the cDNA is 
processed for library preparation using the Nextera XT kit and sequenced on an Illumina machine 
ready for data analysis. This figure was prepared utilising modified images from both the SMART 
Seq v4 kit and Agencourt manuals. 
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3.1.2 Experimental Design Considerations 
Design of mRNA-Seq experiments, but also any experiments involving high-throughput 
techniques, are a subject of intense debate. It is possible (and has indeed happened) for an 
mRNA-Seq experiment to be confounded, and yet nonetheless be accepted for publication after 
vigorous peer review. Later, after replication experiments, these claims have been retracted and 
the experiment identified as confounded in some fashion [519]. More generally, problems with 
reproducibility are common within the biomedical sciences [520]. Fisher’s book on the design 
of experiments notes that the two grounds upon which evidence is disputed are “that the 
interpretation of the experiment is faulty” (i.e. that the Author is “incompetent in statistical 
technique”) or that “the experiment itself was ill designed or… badly executed” [521]. The book 
also discusses three key principles of design: randomisation, replication, and blocking. 
Approaches to data analysis are discussed later, but it holds the advantage of capability to 
repeat/permutate an unlimited number of times. Therefore, if the analysis is believed found 
wanting by reviewers it is relatively easy for an Author to correct this. 
In contrast, a possible confounder in experimental design may be difficult to identify 
(particularly in the absence of information about the experimental design within the 
manuscript), but also impossible to correct without replicating the entire experiment at huge 
cost to the Author. This high cost may have contributed to whether an Author has performed 
repeat experiments of their initial sequencing or high-throughput experiment in the initial 
instance. It is also not practicable (or expected) for an Author to validate all of the findings of 
their experiment (e.g. performing orthogonal validation on 1,000 differentially-expressed genes 
[DEGs] would be far too costly in terms of time and resources for a lab), meaning only a small 
subset of DEGs would be validated (likely the most promising DEGs identified by the high-
throughput technique). A reviewer must therefore have very strong grounds to make an 
objection based on experimental design, and criteria such as the number of replicates is relaxed 
in lieu of the fact that sequencing is both difficult and expensive to perform (for example, the 
encyclopedia of DNA elements [ENCODE] guidelines suggest two replicates for mRNA-Seq 
experiments, but that it is possible to justify only one replicate [522]). This explains how it is 
possible (or perhaps easier) for confounded studies using high-throughput techniques to be 
published. In typical studies, a minimum of three biological replicates is usually expected, and 
for randomisation to be performed. With one or two replicates, and difficult-to-obtain samples 
(e.g. human tissue from a biobank) it may not be possible to randomise or effectively block or 
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even obtain a reasonable estimate of the variation, meaning there can arguably no basis for 
inference [523]. 
Sequencing is a rapidly-developing field, and whilst attempts have been made to suggest 
standardised reporting and design/execution of experiments (e.g. depth) – i.e. the ENCODE 
guidelines [522] – these are far from complete and have become obsolete quickly (for example, 
the field of single-cell [sc-]mRNA-Seq has now emerged and only some of the ENCODE 
guidelines would be applicable/relevant to those experiments). Nonetheless, the best practices 
by other researchers – that will be incorporated into this work where possible – will be described 
herein. 
Batching Effects 
With regards to mRNA-Seq, the multiple sources of variation can be separated into 
biological/experimental variation (i.e. due to the intrinsic variability of organisms and the 
interventions being investigated) and “batch effects” – the sources of variation unrelated to the 
biological/experimental variables of the study (e.g. usage of different batches of reagents, flow 
cells, lanes on a flow cell, litters of organisms [resulting in a different microbiome], a different 
researcher or lab performing the experiment, etc) [524]. Batch effects are the variability that 
well-designed experiments attempt to minimise and/or mitigate. With highly dimensional data 
such as mRNA-Seq, batch effects can be readily identified using dimension-reduction 
visualisations (e.g. PCA, where different “batches” will separate into different regions of the plot 
as it represents a major source of variation). Batch effects can cause significant problems for the 
analysis of data, lead to artefacts, and may render the data relatively meaningless/invalid (in a 
worst-case scenario) with regards to the original biological questions being asked. 
Batch effects can be separated into three main groups: biological variation, technical variation, 
and measurement error [525]. With adequate blocking, randomisation, and replication through 
a well-designed experiment, these effects can be mitigated. Furthermore, it is possible to use 
computational methods to (at least partially) correct for batching effects, but to be successful it 
requires that a form of blocking and replication be incorporated into the experimental design 
prior to data acquisition. These approaches are further discussed later but the basic concept of 
batch effects and correction are shown in Figure 3.1.2. 
  




Figure 3.1.2. Visualisation of batching effects within mRNA-Seq datasets. A) PCA plot of 
original processed mRNA-Seq data (each atlas utilised different processing strategies) highlights 
a batch effect between the two compendiums and represents most of the variability observed 
within the dataset (PC#1; GTEx and TCGA). B) PCA plot of data when processed uniformly helps 
to reduce the batch effect partially but not fully because samples isolated from the same tissue 
map with greater distance than samples isolated in the same lab (reduced variation results in 
batching effects observed on PC#2 as opposed to PC#1). Abbreviations: GTEx – genome tissue 
expression, TCGA – the cancer genome atlas, PCA – principal component analysis. Adapted from 
[526] and used under licence (CC BY 4.0). 
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Biological variation can be caused or introduced when experiments use organisms that may 
have differences prior to the experiment. For example, differences in the microbiome of 
organisms could be caused by organisms originating from different litters, or being kept in 
different cages (in the case of animal research) and this could have different effects on 
organismal response to treatments, induction of disease models (i.e. incidence and/or severity), 
and many other measurements [527]. A simple, but confounded experiment design may involve 
treatment of one cage of mice and use of a different cage of mice as a control. In this situation, 
differences in the data obtained could be due to the treatment, or due to the cage effect, or a 
combination of both; due to the experimental design it would be impossible to delineate. A 
more balanced (but complex) design would involve treatment of 50% of mice from each cage so 
that the potential cage effect is blocked (or mitigated) across the samples. This concept is 
visualised in an experimental design schematic (Figure 3.1.3). In large-scale studies with multiple 
experimental groups, experimental design could become exponentially more complicated and 
impractical (if not impossible – e.g. with organisms in cages of 4, based on litter, any experiment 
with 5 or more experimental groups would be impossible to block in a perfect manner) to 
perform adequately, and highlights a potential major issue when scaling-up. 
Technical variation refers to artefacts that are not due to biological variation but occurs prior to 
acquiring the data (i.e. introduced during mRNA isolation/amplification and other pre-
processing required). This can include a large variety of factors such as the batch of reagent 
used, when and how many times the mice were anaesthetised, and many more. It may also 
include the variability (precision) of inducing a disease model, performing a technique on the 
model organism, or differences in the ability of the researcher to isolate a tissue in a pure 
manner. The simplest way of blocking for these is to allocate samples from each experimental 
group across the various runs/experiments (if running more than one experiment – if running 
one experiment these factors will require less consideration) so that any technical variation is 
equally-spread and successfully mitigated. Where possible, organisms should be treated as 
equally as possible with all handling and interventions. Samples from an experiment could also 
be acquired in a random (or random but balanced) order as well for example. The same 
researcher/team could also be used (where possible) to help minimise the technical variation. 
Measurement error has well-established practices for its mitigation, and delve into the 
intricacies of the sequencing technology and are therefore summarised within Appendix I. 
  




Figure 3.1.3. Examples of good and poor experimental design with regards to treatment 
and cage allocations. In the confounded design, experimental groups are allocated according to 
the cage in which mice reside (this typically represents the litter they were derived from). When 
performing analysis, differences between cage conditions and/or litter microbiomes could 
confound the results. In the balanced experiment, all experimental groups are allocated across 
each cage in a constrained randomised fashion and ensures results obtained are not due to litter 
or cage confounding effects.  




The overall implications are that experimental design and good practices for mRNA-Seq is 
continually evolving, and that there are no formal up-to-date standardised design procedures. 
Nonetheless, there are good principles of experimental design (some adopted from the wider 
field that have been well-known for decades) that can be implemented with careful planning. 
In larger-scale experiments, it becomes increasingly difficult to satisfy all of these requirements 
in a fully balanced manner. Therefore, a compromise between the perfect experimental design 
and practicability may be pragmatic (for example, if a design became too complex the 
probability of mistakes by a researcher may increase – such as which mice receive what 
treatments/dose – which would be more confounding to an experiment than a minor design 
imperfection), and in the case of large-scale studies replication (provided the experiment is 
reasonably designed, i.e. has no major flaws) will help to mitigate these. Overall, experimental 
design should not be overlooked, and should be carefully included in any experiment using 
high-throughput technologies in particular. 
Batching Effects: Can we do Anything about them? 
It is possible to compare results obtained from different laboratories or even different 
experiments, although it should be appreciated there are challenges and limitations to using the 
data in this way. Batch (confounding) effects are effects or results observed in the data due to 
non-biological factors. This could include different reagents, laboratories, experiments, 
researcher/s, lot number of reagents, experimental pipeline used, and many other factors which 
could cause a difference in the data which isn’t due to the independent variable (i.e. 
experimental groups). In some cases, observed differences between laboratories can be larger 
than tissue differences (e.g. when comparing expression data from the same tissues generated 
by the cancer genome atlas and gene tissue expression databases; Figure 3.1.2) [526]. 
The ability to summate different datasets and perform meta-analyses of them is pertinent for 
several reasons: 1) it enables interrogation of large numbers of samples which would be 
impractical and too costly for a single experiment or series; 2) it adds additional utility to 
existing datasets and enables investigation of novel questions, reducing the need to generate 
new data which is both costly and time-consuming; 3) it could enable direct comparison of 
datasets in the same area or field and help to establish where consensus exists (for example, in 
mechanisms and pathways that are altered). This could highlight critical pathways or molecules 
altered in all variants of a disease model, or all dysregulated states of a specific cell type. In fact, 
use of datasets from different labs might be more beneficial in identifying critical pathways as 
biases that may be specific to a strain of model organism, reagents used, or processing pipelines 
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– all of which may be specific to a single research group – will be mitigated by such an analysis. 
Much like meta-analysis of clinical trials or other data, summating mRNA-Seq data could 
provide novel insight and prove to be very powerful if done in an appropriate fashion. 
For analyses wishing to compare samples obtained from multiple experiments (e.g. different 
papers published), it may be possible to compensate for/correct batching effects via different 
strategies. This can be done provided the different datasets contain equivalent samples (e.g. a 
reference sample, such as a naïve sample) and can be performed in several different ways: 1) the 
two datasets could be analysed independently, using their own internal reference/controls, and 
DEGs compared between datasets (this might be useful so that a standardised analysis approach 
– for both alignment and DEG identification – was adopted, as the two datasets may have 
undergone different analytical strategies in the original papers. This type of strategy has been 
used to create, compare, and refine consensus gene lists [158]); 2) the datasets could be analysed 
together, but by using a paired design allowing for comparison of each dataset to their own 
reference sample as part of a conglomerate (particularly useful if the experiments replicated 
conditions between them, as this type of analysis would enhance the power through increased 
numbers of biological replicates); 3) the reference sample can be used in conjunction with a 
batch effect remover (such as ComBat or surrogate variable analysis [SVA] [528-530]) – batch 
effect removers may be particularly helpful on both internal and external large-scale datasets 
that inherently need to be performed in multiple batches (i.e. availability of researchers, model 
organisms, patients, cell isolation machines, etc, may not be possible simultaneously all within 
relevant timescales for mRNA-Seq processing). The use of approaches 2 and 3 would improve 
the power of the analysis (ability to detect DEGs), and arguably increase the validity of results 
obtained. A comparison between uniform processing (1) and batch effect removal (3) can be 
seen in Figure 3.1.4. 
Batch effect removal can also include the use of QC samples (such as sequencing a specific cell 
line to sequence what should in theory produce identical results), although these have been 
shown to provide little benefit [531]. It has been shown that batch effect removers tend to 
generally perform better than analyses which do not use them [532]. Whilst useful, it should be 
noted that batch effect removal can itself lead to false discoveries. The results obtained from 
analyses utilising batch effect removal should be considered as obtained from an imperfect 
study design, and therefore identified DEGs or changes to critical pathways should also be 
validated rather than blind trust placed in the data [533]. 
  




                
Figure 3.1.4. Visualisation of batching effects in mRNA-Seq data and processing 
strategies to normalise for non-biological differences. A) PCA plot of original processed data 
without uniform processing highlights a batch effect between the two compendiums (GTEx and 
TCGA). B) PCA plot of data when processed uniformly helps to reduce the batch effect partially. 
C) PCA plot of data when processed uniformly and normalised using a batch remover algorithm 
helps to greatly reduce the batch effect, allowing for analyses to be performed with increased 
numbers of replicates and therefore power. Abbreviations: GTEx – genome tissue expression, 
TCGA – the cancer genome atlas, PCA – principal component analysis. Adapted from [526] and 
used under licence (CC BY 4.0). 
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Power of mRNA-Seq Experiments 
For mRNA-Seq, the depth (i.e. number of reads per sample) obtained and number of replicates 
is also a topic of hot debate. The ENCODE guidelines suggest a minimum of two biological 
replicates, with a minimum of 30 million reads [522]. However, other research has suggested 
this is not necessary for experiments aiming to identify DEGs. For example, correlation 
coefficients between samples (and their various quartiles of genes based on expression level) 
plateau at 10 million reads per sample in chicken lung RNA preparations [534]. Another team 
showed that all genes fall within a 2-fold change of final expression at 10 million mapped reads, 
and that nearly all of the moderately-expressed genes (~95% – 10-99 reads per kilobase of 
transcript per million mapped reads [RPKM]) and all of the highly-expressed genes (>99 RPKM) 
were quantified within 20% of their final expression value within samples (based on the values 
obtained for the maximum depth of 45 million mapped reads utilised in this experiment), 
suggesting that a higher depth may providing diminishing returns with respect to the ability to 
identify DEGs at a considerably increased cost [535]. Whilst higher depths of sequencing allow 
for improved quantification of splice variants and isoform expression, the relatively short reads 
that Illumina sequencing provides has been superseded by different technologies which can 
sequence whole mRNA molecules without the need for polymerase chain reaction (PCR) steps 
(to introduce potential bias) or fragmentation (e.g. the nanopore technology) [536]. 
In these experiments, the number of replicates is also an important factor to consider. It is 
generally accepted that as many replicates should be used as can be afforded. Investigations 
have performed comprehensive comparisons into various algorithms used to identify DEGs but 
also into the number of replicates and how that alters both the true positive rate (TPR) and false 
positive rate (FPR), or the number of DEGs identified as a proxy. For example, one group used 
both simulated and real mRNA-Seq data to investigate 11 different algorithms and concluded 
that all the algorithms perform poorly on less than 3 biological replicates [537]. Another team 
suggested that at least 6 biological replicates were necessary [538]. However, the real data (in 
both these papers) was concatenated from various sources and may have been confounded by 
batching. Therefore, another group sought to create a high number of biological replicates (n = 
42 or 44 “clean replicates”) in a single experimental system to conclusively address the question 
of biological replicates; they also compared various algorithms for detecting DEGs [498]. They 
performed DEG analysis with each algorithm by bootstrapping the number of replicates per 
condition and making a total of 100 iterations. In agreement with others, they also suggested a 
minimum of 6 biological replicates per condition. However, the TPR for 3 replicates (for a fold-
change of ≥±2; a commonly-used criteria in the absence of calibration using spike-in controls 
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such as those made by the external RNA controls consortium [ERCC]) was close to 0.95 for many 
tools (i.e. α ~ 0.05, a commonly-used statistical threshold) [498]. They also show (within their 
system) that the likelihood of obtaining anomalous samples (when performing 48 replicates) 
was relatively low although not impossible [466]. 
However, both depth and replicates need to be considered together when designing an mRNA-
Seq experiment. Consider a hypothetical flow cell which contains a total of 400 million reads, 
and you wish to conduct an experiment involving 2 experimental groups. You have the ability 
to sequence 4 samples (n = 2) to a depth of up to 100 million reads per sample, 6 samples (n = 
3) to a depth of up to 66.6 million, 12 samples (n = 6) to a depth of up to 33.3 million, and so 
forth. An experiment ideally achieves the “golden” 80% power (β) with significance below 0.05 
(α) but irrespective of this the depth and number of replicates could be optimised to achieve 
the highest cost-efficiency – either to reduce the overall cost of the experiment to achieve power, 
or to maximise attainable power for a given cost. One research group considered the two values 
in tandem and showed that both depth and number of replicates are important; however, they 
indicated that 10 million reads per sample (allowing for more replicates – in this example 6) 
allowed detection of far more DEGs than the other permutations, and attainment of a power of 
0.8 (with a significance threshold of 0.05 after false discovery rate [FDR] step-up correction) 
[539]. Their data shows that 6 replicates at 10 million reads detected ~4,500 DEGs, 4 replicates 
at 20 million reads detected ~3,000, and 2 replicates at 30 million reads detected ~2,500 
(equivalent total numbers of reads sequenced). They also showed, with their experimental 
pipeline for performing mRNA-Seq, that having 10 million reads per sample was the most cost-
efficient for the power it provided between 2-6 replicates (at 7 replicates it was marginally out-
performed by 5 million reads) [539]. 
A major flaw of the aforementioned studies is that much of the analysis is based on cell lines 
where there is likely to be a reduced biological variability than what may be observed within a 
whole organism. Therefore, it may be possible that a higher number of biological replicates is 
required to achieve optimal power in vivo. Nonetheless, the above studies indicate that the 2 
replicates and 30 million reads suggested by the ENCODE guidelines are not optimal with 
respect to detecting DEGs in the most cost-efficient or powerful manner (for a fixed cost). 
Ideally, a pilot study should be performed using the pipeline an experimenter wishes to utilise, 
and a power analysis (as well as a cost analysis) be performed for their individual experiment as 
there are many pipelines with different costs and advantages/drawbacks, and that sequencing 
costs can greatly vary between institutions primarily depending on which sequencer machines 
are available (higher throughput sequencers provide greater cost efficiency but assumes enough 
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samples require sequencing – either within an experiment or compounded between several 
researchers). 
Published data utilising the Smartseq2 pipeline (on which the SMART-Seq v4, the selected kit 
for our pipeline, is based) indicates correlation between samples peaks at around 5 million 
uniquely mapped reads [517]. Cost estimates were compared for mRNA-Seq using the SMART-
Seq 4 kit and internal University Genomics Facility Sequencing versus the power data generated 
by Liu et al. [539]: it indicated that, in the context of the SMART-Seq pipeline (where preparatory 
costs are generally higher than most mRNA-Seq pipelines due to its specialist capabilities), the 
most cost-effective mRNA-Seq experiment overall (£ per power) contained 4 biological 
replicates per group at a depth of 10 million reads per sample. However, as advised by Schurch 
et al., at least 6 biological replicates were also considered to achieve adequate power (β = 0.8) 
[498], noting that this recommendation was based on in vitro cell lines. Ultimately, a pilot study 
and power analysis would best inform experimental design, but nonetheless existing data 
suggested sequencing 5–10 million reads per sample was optimal. 
3.1.3 mRNA-Seq Analysis 
There are no special considerations for mRNA-Seq analysis beyond what was described in the 
first chapter, and the pipeline can be analysed using the gold-standard approaches (i.e. adapter 
trimming, trimming based on quality, use of the appropriate splice-aware aligners, typical 
quantification and normalisation algorithms, etc; see Figure 2.7.1). 
For analysis, the University of Bristol’s Genomics Facility provide access to Partek Flow and PGS, 
software that can perform all aspects of the analytical pipeline (from raw data processing and 
identifying DEGs to pathway analysis and more). 
3.1.4 Summary 
The aims of this chapter were to optimise both the experimental and analytical aspects of the 
mRNA-Seq pipeline, performing QC checks and confirming expression/non-expression of 
expected genes in samples, and to determine whether it would be possible to sequence microglia 
isolated from single retinas. Having identified a pipeline that would be appropriate for the 
research objectives to investigate the transcriptome of the microglia, the results of optimisations 
for ultra-low input mRNA-Seq are presented herein. 




3.2.1 Optimisation of mRNA Isolation and cDNA Generation 
The first experiments required involved optimising the pipeline for sorting the cells, to confirm 
the ability to generate suitable material for mRNA-Seq. For initial experiments, microglia were 
sorted based on their CD45 and CD11b expression (Figure 3.2.1). Informed by the SMART-Seq 
kit guidance, 1,000 microglia were sorted from pooled retinas (comprising the left and right eyes 
from a single mouse) to generate cDNA using a 10-cycle amplification programme with 
subsequent Agencourt AMPure isolation (magnetic beads) and quantification with the Agilent 
Bioanalyser tapestation. The rationale for pooled retinas was to ensure 1,000 microglia were 
accurately sorted into each sample tube (the recovery rate of the cell sorter was not known at 
the time, but based on existing knowledge it seemed unlikely that a single retina would yield 
1,000 sorted microglia) so that large quantities of starting mRNA could be utilised for the cDNA 
generation and amplification steps. Taking this approach allowed experimental risks to be 
mitigated until the sorting and cDNA generation was optimised. 
Unfortunately, cDNA was not detected on the Agilent bioanalyzer in the first experiment 
meaning it was unclear if kit components were functioning correctly or whether there was an 
error in a different part of the pipeline until that point. Therefore, a similar follow-up 
experiment was conducted using sorted microglia from both WT and Cx3cr1-GFP+/- mice (using 
CD45 and CD11b gating; see Figure 3.2.1); conceptually, it would allow comparison of 
hypothetical differences in the transcriptomes caused by the transgenic alteration as it was 
unknown if haploinsufficiency occurred below the detection threshold/sensitivity of 
conventional phenotyping approaches (such as fundal imaging) that had not detected gross 
abnormalities. In this experiment, the positive control RNA (from the SMART-Seq kit) and a 
negative (water) control were both included so that kit components could be validated as 
functional and the absence of contamination also confirmed. Cycle optimisation was also 
performed by running a sample from each strain for 12-, 15-, or 18 cycles, numbers higher than 
recommended in the kit manual (this was done in case low cycle number was the reason for no 
detectable yield in the first experiment). This resulted in cDNA generation from both the 15- 
and 18 cycle conditions and a barely detectable amount with 12 cycles (Figure 3.2.2), confirming 
low cycle number was the primary reason for failure in the first experiment. The cycling 
conditions for the positive control were as expected/indicated as per the manual, suggesting 
them as accurate to the amount of input RNA. In-line with the kit’s guidance, 15 cycles for 1,000 
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sorted cells was selected for subsequent experiments (as opposed to 18) as over-cycling can lead 
to amplification bias and skewing of the cDNA generated (the output from 15 cycles most closely 
resembled the exemplary bioanalyser output figures from the manual). Additionally, sorting of 
residual volumes of the samples into empty tubes indicated it was possible to isolate ~1,200–
1,500 microglia per pool, suggesting that it would be possible to reliably isolate 600 microglia 
per retina for single-eye sorting in the future.
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Figure 3.2.1. Flow cytometric gating strategy for the isolation of microglia by fluorescence-activated cell sorting (FACS) in a naïve retina. 
1) Cells are gated-for on size and granularity; 2) singlets are gated using cell area (size) and height; 3) live cells are gated using 7AAD; 4) microglia are 
gated using CD45 and CD11b. 






















Figure 3.2.2. The gel plot, produced from cDNA generated using the SMART-Seq v4 kit as part of the cycle optimisation experiment, on the 
Agilent 2100 Bioanalyser. The following lanes represent different samples and controls: A1 (ladder), B1 (positive control RNA sample [as provided in 
the kit]), C1 (negative control sample), D1–E1 (12-cycle wild-type and Cx3cr1-GFP+/- microglia respectively), F1–G1 (15-cycle wild-type and Cx3cr1-GFP+/- 
microglia respectively), H1–A2 (18-cycle wild-type and Cx3cr1-GFP+/- microglia respectively). The positive control had a peak around 2,000 nt as expected, 
whilst the samples had consistently sized peaks corresponding to just under 1,000 nt – which falls within the normal anticipated range for a sample 













The cDNA from the second experiment was then sequenced and QC was assessed using FastQC; 
the results demonstrated very low N content, sporadic sequence content for the first 15 bases 
with stabilisation afterwards (normal), a near-normal GC distribution, and sequence 
duplication (expected) as a consequence of the LD-PCR amplification (Figure 3.2.3). 
As there are multiple measures of sequence quality and there is no single parameter which can 
define good-quality mRNA-Seq data, quality assurance (QA)/QC measures were also performed 
using Partek Flow. The average base quality score per position (using Phred scoring) was ~35, 
with the vast majority of reads having an overall quality of 34 or 35 (Figure 3.2.4). 
The above information indicates that the sequencer was very accurate in its base calling (a Phred 
score above 30 indicates an error rate below 0.01%, low N content, expected sequence content), 
but indicates little about the quality of the input material beyond having a near-normal GC 
distribution and that it was able to generate quality reads of at least 75 bp in length. To further 
assess the quality of the input material, the alignment stats were also assessed. The total 
alignment for samples was ~90%, with a total unique alignment rate of ~80% – which are 
generally considered the ideal metrics for mRNA-Seq data (Figure 3.2.5). Comparison of the 
alignment rates between paired-end reads (what was generated in initial experiments) and 
single-end reads demonstrated negligible differences between the two; therefore, future 
experiments utilised single-end reads as an improvement in cost-efficiency. 
 
  




Figure 3.2.3. Key quality control parameters (QC) for a representative mRNA-Seq sample 
calculated by FastQC. A) Percentage N content (y) per base position (x) for all reads (1–76). B) 
Percentage sequence content (y; TCAG) per base position for all reads (x). An unusual sequence 
content is anticipated for the first 12–18 bases, after which stabilisation (as observed) is expected. 
C) GC distribution (x; percentage content) of each read plotted as a line (red; y, number) with a 
theoretical perfect distribution line shown (blue), indicating a near-normal GC content 
distribution. D) Percentage (y) sequence duplication levels (x; duplication level) indicated with a 
blue line compared to a theoretical perfect duplication level line (by random chance; red) which 
indicates sequence duplication occurred in the sample; this was anticipated as cDNA samples were 
amplified by LD-PCR as part of the preparation process before library generation, meaning 
duplication was an inevitable part of the preparation process.    






Figure 3.2.4. Average base score quality for a representative mRNA-Seq sample (as 
generated in Partek Flow). A) The average base quality score per position is shown, with a red 
line to indicate a Phred quality score of 30 (0.1% error rate in base-calling), with the average (and 
SD) falling above this (indicating ideal base-calling). B) The average base quality score per read is 
plotted as a histogram of frequencies; a red line indicates a Phred quality score of 30, which the 
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Figure 3.2.5. A representative selection of alignment statistics for mRNA-Seq data 
generated using the ultra-low input RNA pipeline. Each bar represents a different sample, 
which are colour-coded according to how the reads mapped to the mouse genome. Green 
represents unique alignment (where the read aligned to only one location of the genome), yellow 
represents non-unique alignments (where the read aligned to more than one location of the 
genome), and red represents unaligned reads (where it did not align to the genome). Non-unique 
alignments are possible because many genes may have arisen from a common predecessor via gene 
duplication events (i.e. paralogous genes), meaning that identical (or near-identical) regions of 
two paralogues will inevitably exist. Generally, a unique alignment of ~80% (with total alignment 
of ~90%) is considered the ideal/gold-standard results for mRNA-Seq. The white dots represent 
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Using PGS, analysis indicated expression of “top microglial genes” (e.g. Slfn2, Gpr84, Bcl2, 
Olfml3), expression of many “microglial-enriched genes” (e.g. Olfml3, Siglech, Tmem119, Cx3cr1, 
Slc24a3¸Sparc) and an absence of expression for markers canonical to T cells, endothelium, and 
photoreceptors which otherwise could be suggestive of sample contamination (Cd3, Cd4, Cd31, 
Map2, Tubb3) in the four samples sequenced [158, 308, 346-348]. 
However, it became apparent during analysis that the two experimental groups were very 
similar, as few DEGs were identified and PCA was unable to delineate the groups. Robust final 
checks for QA would require samples obtained from two different experimental groups to 
enable identification of larger numbers of DEGs and run unsupervised analyses (such as PCA) 
to see if delineation between the groups occurs, both of which would indicate the ability to 
detect broad differences between experimental groups using this pipeline. However, until the 
experiment comparing microglia from different transgenic lines was performed, it was unknown 
whether microglia isolated from WT and Cx3cr1GFP/+ mice would be similar or have differences. 
For a follow-up experiment, use of the Cx3Cr1GFP mouse strain would result in samples 
containing mixed-cell populations as the strain does not retain microglial specificity during 
inflammatory contexts [540] and this would limit the utility of a dataset generated with such 
mice. Informed by publications, acquisition of a new reporter line from collaborators was 
initiated to circumvent these issues of microglial specificity (see Chapter IV) [376]. However, 
there were anticipated delays in the acquisition and rederivation process required to establish 
a colony locally. Therefore, investigation of a different cell type during retinal inflammatory 
contexts would provide data most useful in understanding the disease process of uveitis whilst 
allowing for robust final QA checks to further validate the mRNA-Seq pipeline. As EAU is a 
CD4+ T cell-mediated disease [1], investigation into these cells was performed. 
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3.2.2 mRNA-Seq of CD4+ T Cells in EAU 
Based on the preliminary work on microglia, it was evident that isolation of 600 cells per retina 
would be both feasible and reliable; therefore, this was the target for the number of sorted CD4+ 
T cells. This would enable validation of single-retina sequencing for microglia, as a proof-of-
concept, whilst simultaneously providing a representative sample of the CD4+ T cells isolated 
from an inflamed retina for insights to that aspect of disease. WT C57BL/6 mice were 
immunised for disease with the aim of taking retinas and spleens from mice exhibiting peak 
disease at day 25 (Figure 3.2.6); in C57BL/6 mice, peak disease is typically observed around days 
23–25 (following approximately 8–12 days of no clinical features) with a secondary progression 
that can last at least 100 days post-immunisation [541, 542]. Additionally, spleens from naïve 
mice were utilised as controls because CD4+ T cells are not present in large numbers in a normal 
retina. The sorting strategy is highlighted in Figure 3.2.7. The results are generated from two 
independent experiments with experimental groups balanced between them to combat 
hypothetical batching effects.




Figure 3.2.6. Representative fundal and OCT images of a naïve mouse and at peak (D25) 
EAU from the CD4+ T cell mRNA-Seq experiment. Perivascular sheathing, lesions, and retinal 
damage are evident at D25 EAU (fundal image) with signs of cellular infiltrate on the OCT scan 
(circled red; scan line indicated in green). The naïve retina appears as expected. Abbreviations: 
EAU – experimental autoimmune uveitis, OCT – optical coherence tomography, ON – optic nerve, 












Figure 3.2.7. Flow cytometric gating strategy for the isolation of CD4+ T cells by FACS in an EAU retina. Cells are gated initially as per figure 
3.2.1 (live cells). They are then gated for CD45hi (immune cells), CD11b- (non-myeloid cells), CD3+ (T cells), and CD4+ CD8-. Abbreviations: EAU – 
experimental autoimmune uveitis, FACS – fluorescence-activated cell sorting.  
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However, in the first CD4+ T cell experiment a phenomenon we describe as “time-dependent 
RNA degradation” occurred; it describes where cDNA yield is reduced in a time-dependent 
manner across samples (i.e. the order in which they were sorted) and is likely due to RNA 
degradation due to necrotic/apoptotic processes that occur prior to the formation of holes 
within the membrane (which viability dyes could then identify cells as dead). It occurred due to 
a few factors causing time delays such as technical difficulties with the cell sorter that arose 
after mouse termination and a complicated experimental design involving preparation of 
multiple tissues simultaneously; these factors ultimately increased the time taken between 
mouse termination and sorting of cells into lysis buffer (this phenomenon was observed at 
around 3-3.5 hours post-termination) and highlights the fragility of the first protocol step to 
partial failure (Figure 3.2.8, red box). It is noteworthy to mention that the cells (according to 
the viability stain) appeared live and it was not possible to predict this outcome until after 
performing processing steps. Therefore, future experiments used a protocol amendment where 
small batches (containing samples from every experimental group where possible) of 1–5 were 
prepared and sorted in a staggered fashion to mitigate risks from this occurring in future. 
Nonetheless, the data indicates it is possible to generate high quality cDNA from 600 cells 
isolated from an individual retina as a proof-of-concept for single-eye microglial sorting in the 
future. 
The subsequent experiment adopted this refined protocol, and all samples acquired in this 
experiment were of the expected yield and quality (Figure 3.2.9). In total, 2 naïve spleens, 2 EAU 
peak disease spleens, and 8 EAU peak disease retinal samples were sequenced. PCA was able to 
readily delineate the three groups, indicating genuine and broad differences between the 
samples (Figure 3.2.10). Interestingly, retinas obtained from the same mouse clustered more 
closely together on the PCA plot than retinas obtained from different mice. The spleens, 
irrespective of disease status, clustered more closely together. A total of 991 unique DEGs were 
identified by the three comparisons in the ANOVA model (953 from naïve spleen to diseased 
retina, 147 from diseased spleen to diseased retina, and 59 from naïve spleen to diseased spleen). 
These are visualised by hierarchical clustering in Figure 3.2.11, highlighting a dynamic 
transcriptional landscape. In summary, a group of genes upregulated in CD4+ T cells in EAU 
retinas are highlighted in black; genes downregulated in EAU (spleen and retina) compared to 
naïve controls are highlighted in blue; those downregulated in EAU retinas (but not spleen) in 
green; and those upregulated in EAU spleens only in brown. 





Figure 3.2.8. A gel plot from the experiment where time-dependent mRNA degradation of samples was observed. The gel indicates cDNA was 
generated for samples B1–H1 (a mixture of retinal and spleen samples), but a reduction in yield (resulting in almost none detected) was observed for 
samples A2–D2 (red box). The samples on this gel are arranged in the order they were sorted in (with A1 being sorted first, and hence the shortest time 
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Figure 3.2.9. A representative gel plot, produced from cDNA generated from 600 CD4+ T cells (equivalent to single-eye mRNA-Seq of 
microglia) using the SMART-Seq v4 kit, on the Agilent 2100 Bioanalyser. A) The following lanes represent different samples and controls: A1 
(ladder), B1–E2 (16-cycle CD4+ T cells), F2 (water control loaded onto the gel to estimate background signal). B) Single gel trace for a sample, showing 

















Figure 3.2.10. Principal component analysis (PCA) plot for the CD4+ T Cell mRNA-Seq 
data. The first three PCs are plotted which represent 46.7% of the variation between the samples. 
Samples are labelled according to their anatomical origin and disease status: naïve spleen (green; 
n = 2), diseased (EAU) spleen (blue; n = 2), and diseased retina (red; n = 8). Increasing loss of colour 
intensity on a sample indicates a more posterior position on PC#3. Retina pairs (obtained from 
the same mouse) are indicated with red circles. Abbreviations: EAU – experimental autoimmune 
uveitis, PCA – principal component analysis.




Figure 3.2.11. Hierarchical clustering (heatmap) of the DEGs identified from the DGEA on samples of 600 CD4+ T cells. Comparisons were 
made between naïve spleen (yellow; n = 2), diseased (EAU) spleen (orange; n = 2), and diseased retina (red; n = 8) are highlighted with coloured boxes. 
Raw expression values (on a per gene basis) were shifted to a mean of 0 and scaled to an SD of 1 for easier comparability as part of the visualisation 
process. Genes were clustered based on their similarity in expression profile, as were samples – both to create dendrograms illustrating the relationships. 








The main aims of this chapter were to optimise both the experimental and analytical aspects of 
the mRNA-Seq pipeline, and to determine whether it would be possible to sequence microglia 
isolated from single retinas as a proof-of-concept for utilising this pipeline to assess mRNA 
differences in microglia before, during, and after models of uveitis. 
Initial experiments, performed with naïve microglia, highlighted several factors that can alter 
the quality of the output material. Firstly, careful optimisation of cycling conditions for the 
cDNA amplification step is required; secondly, that high-quality output depends on 
streamlining of the experimental pipeline so that optimal timing for the isolation of cells is 
maintained. Preliminary experiments using sorted microglia did not generate detectable 
amounts of cDNA. The hypothesis was that material had been generated, but it was too low a 
yield for detection. To test this, a cycle optimisation experiment was performed where the cycle 
conditions was changed from 10 to 12, 15, and 18. Upping the cycling conditions to 12 generated 
barely detectable amounts of cDNA, with greatly increased yield with 15 and 18 cycles. This 
confirmed the experimental pipeline as functional and indicates that the initial experiment 
likely generated cDNA but at a level below detection thresholds. 
The cycling conditions used were discrepant to the guidance provided in the SMART-Seq kit 
user manual. It is well-known different cell types can express different amounts of mRNA, and 
that transcriptional amplification occurs in immortalised cell lines [430, 543-545]. The SMART-
Seq kit manual indicates that the cDNA synthesis protocol was tested and validated using 
cultured cells, supporting this notion. Whilst cDNA was generated from microglia with 18 
cycles, the output from 15 cycles was sufficient to produce libraries, and the kit’s guidance 
indicates the fewest number of cycles required to construct a library should be used. This is 
because higher cycle numbers can lead to a phenomenon described as “overcycling”, which 
results in a coarse distribution of sizes and can affect downstream results. The output from 12 
cycles was barely detectable and therefore was too low to select for future experiments. 
Therefore, 15 cycles was selected for 1,000 cells henceforth. 
Whilst all care was taken to ensure high-quality mRNA products were obtained, and haste (with 
accuracy) in the protocol, on one experiment a time-dependent degradation of mRNA was 
observed. A variety of factors caused this, such as a complex experiment for preparation (lengthy 
antibody staining protocols, in addition to preparation of retina, spleen, and blood 
simultaneously) and unanticipated technical difficulties with the cell sorter which arose after 
the mice had already been terminated. As an amendment, future work will utilise small-batch 
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preparations of samples to mitigate the risk of this in the future. Experiments utilising the 
Cx3cr1CreER:R26-tdTomato line may permit sorting of microglia using tdTomato alone (provided 
the tdTomato tag is both sensitive and specific for microglia), which would considerably shorten 
the preparation time and streamline the process as no Fc block or antibody staining would be 
required. This might make future experiments at a reduced risk of failure or problems, therefore. 
There is no clear consensus in the literature about the length of time mRNA remains viable 
post-termination, other than that it is a short time and processing should be as rapid as possible. 
A recent publication suggested a maximum processing time of 5 hours for a sc-mRNA-Seq 
method [546]. However, our own findings suggest a time of 3–3.5 hours post-termination 
(following the protocol described in Chapter II with samples on-ice) as a cut-off for an 
experimental sample unlikely to yield high-quality or large amounts of cDNA suitable for 
sequencing. Other approaches that could help bypass this issue include fixation, but for this 
ultra-low input pipeline the kit manual explicitly stated it was incompatible with fixed mRNA 
and therefore fresh preparations are required for this pipeline. 
Addressing both the cycle optimisation and timing issue, the data generated possessed the ideal 
(Gold-standard) QA/QC parameters (low N content, normal base composition per position, 
near-normal GC content to a theoretical, some sequence duplication as a consequence of the 
LD-PCR, high Phred scores, and excellent alignment metrics); data generated from isolated 
microglia also had expression of both highly-expressed microglial genes and enriched microglial 
markers, and an absence of non-microglial gene expression which is suggestive of a valid and 
successful transcriptomics experimental pipeline. The near-normal GC content, in contrast to 
the heavy GC bias observed with historical mRNA-Seq protocols, is enabled due to template 
switching (which incorporates the same, or GC-equal, primer regions for amplification; 
Appendix I), allowing for unbiased selection and coverage of the transcriptome. However, the 
SMART-Seq technology does have certain limitations that should be recognised. For example, 
strand-specificity is not preserved, and the current kit format prevents multiplexing of the 
samples until library preparation – the latter driving up costs associated with an experiment. 
Additionally, in contrast to mRNA-Seq experiments using alternative preparatory approaches, 
there was no loss in Phred score at the 3’ end of the transcript. 
However, one major limitation of these initial experiments on microglia were that the 
experimental groups were too similar, meaning that unsupervised algorithms were unable to 
delineate them. To fully test the platform and validate the pipeline, isolation of cell types under 
different states (or different cell types) were required. Due to known limitations with the 
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Cx3cr1GFP model in specific labelling of microglia, and the time required to establish the 
Cx3cr1CreER:R26-tdTomato strain locally, characterisation of CD4+ T cells at EAU peak disease 
enabled validation of the pipeline whilst simultaneously generating novel and useful data in 
understanding uveitis (as a CD4+ T cell-mediated disease). Performing mRNA-Seq on 600 CD4+ 
T cells also acted as a proof-of-principle for single retina sorting of microglia (the number that 
could be reliably isolated from single-eyes). 
Hierarchical clustering also indicates that many genes are down-regulated when CD4+ T cells 
are present in the retina. Some of these could be explained by tissue factors (i.e. spleen vs. 
retina), although it is difficult to delineate this as CD4+ T cells are not tissue-resident immune 
cells and hence there is no ideal control. However, as ingress to the eye is a part of the disease 
and something inherent to uveitis, whether the changes are caused by activation or the 
microenvironment could be inconsequential provided they can be characterised and assist in 
understanding how the CD4+ T cells are altered in uveitis. Other studies investigating T cells 
also utilise use spleen preparations as controls, but sometimes include an absence of activation 
markers (e.g. CD62L+, CD25/69-, etc) to ensure the T cells are in a naïve state. This indicates a 
line of investigation equivalent to good and currently established practice was undertaken with 
regards to controls for this type of experiment. It is entirely possible there is no perfect control 
for investigating T cells in uveitis. 
Genes that up-regulate in the EAU retina have great variability, and this could be due to two 
factors: there is inherent variability in the EAU disease model itself (in terms of severity), and/or 
that the mice were at different stages of disease severity. A linear, unbiased method of scoring 
retinas for disease would permit the use of parametric correlative statistics and this could 
ultimately identify markers which associate with disease. In the spleen, there were fewer DEGs 
between a diseased and naïve state, although roughly a third of downregulated genes in the 
retina are also downregulated in the spleen simultaneously during EAU. There is also a small 
group of genes that are upregulated only in diseased spleens, indicating active changes 
occurring there in addition to the retina. As the Th1/Th17 axis is pivotal in uveitis [1], a way of 
delineating T cell phenotypes from the mRNA-Seq data (and how they change across EAU) 
would be pertinent. As the spleen samples were prepared from eyes at peak EAU disease, it isn’t 
possible to extrapolate whether these changes preclude infiltration of T cells into the retina or 
represent changes occurring from T cells that recirculated from the retina, or both. However, it 
adds to compounding knowledge that the peripheral lymphoid tissues are altered during 
inflammation, even at distal sites to the inflammation. 
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The further analysis of the experimental groups with PCA and hierarchical clustering also 
support our pipeline for transcriptomic analysis as valid, building a platform which can then be 
used for analysis of the microglial transcriptome. Unsurprisingly, the spleen samples were found 
closer together on the PCA plot than the retinal samples which indicates more similarity to each 
other than to the retinal samples. Paired retinal samples from the same mouse were also closer 
together than samples from a different mouse. This questions whether contralateral eyes are 
true biological replicates, as the peripheral immune cells which infiltrated the retinas are 
derived from the same pool. Furthermore, there is evidence to suggest untreated contralateral 
eyes can experience changes (with regards to the microglia) in the presence of pathology in the 
ipsilateral [547]. However, in both mouse and man it is well-recognised that the two eyes can 
experience different disease kinetics, with complete disease asynchrony in some rare cases 
[548]. This therefore demonstrates that they cannot be technical replicates. Overall, paired 
retinas could be considered neither biological replicates or technical replicates, and there may 
not be an existing term or statistical model that can analyse them in a completely valid manner 
in light of this (statistical models tend to assume different samples are biological replicates as 
technical replicates are commonly employed for evaluation of variability within a model, 
system, or assay). 
In summary, successful optimisation of mRNA-Seq for ultra-low input samples (equivalent to 
single-eye microglial mRNA-Seq) and an analytical pipeline were achieved, both of which will 
be utilised as a robust platform for investigation of the microglial transcriptome in the retina 
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Chapter IV: The tdTomat o Mouse  
4.1.1 The Challenge of Microglial Identification 
Investigating microglia within inflammatory diseases has been historically very challenging. 
Microglia are historically differentiated as CD45lo/CD11b+ [397]. However, there is overlap 
between CD45lo and CD45hi populations, meaning that during inflammation where infiltration 
of monocytes and macrophages (CD45hi/CD11b+) occurs discrimination is poor. 
When activated, microglial expression of CD45 has been argued to increase to CD45hi [549, 550]. 
However, there is evidence suggesting that microglia retain the ability to differentiate into other 
immune cells and this could explain the observed increase [551]. Many other groups have been 
able to modestly discriminate a CD45lo population during inflammation [348, 552, 553]. In other 
studies it has been shown that infiltrating monocytes can differentiate into microglia [554], or 
even that down-regulation of CD45 occurs in monocytes that are CD62L- as compared to 
CD62L+ [555]; CD62L loss is associated with activation of immune cells [556]. A final group used 
chimeric techniques to conclusively show that microglia can up-regulate CD45, and that 
monocytes can down-regulate CD45 [415]. This raises questions about what the population of 
CD45lo cells during inflammation might be, if there is a way to discriminate them with greater 
resolution, and ultimately discriminate microglia from that pool. 
Until recently, there have been no markers that reasonably discriminate microglia from 
monocyte/macrophage populations. One marker, Cx3cr1, is a gene that is enriched in microglia 
within naïve organisms [557]. A transgenic mouse line was generated that replaced the first 390 
bp of exon 2 of the Cx3cr1 gene with GFP (and a single LoxP site) [429] and was believed would 
allow for the isolation of microglia; however many peripheral immune cells are GFP+ in naïve 
organisms, and other immune cell populations up-regulate Cx3cr1 during EAU (and other 
inflammatory processes) making the mouse line an improvement but still 
unsuitable/inadequate for specific microglial identification [540]. CD44 is a newly-discovered 
marker [558, 559] which appears to resolve the CD11b+ CD45lo/hi populations with greater 
resolution [558]. TMEM119 is a second such marker and has been reported by several teams 
using orthogonal methods to indicate it as a promising microglial-specific marker [352, 422, 560] 
that can differentiate them from other immune cells. However, it should be noted that 
infiltrating monocytes have been shown to adopt a microglia phenotype [415, 554] and hence 
TMEM119 may not permit discrimination of microglia derived from different origins (i.e. 
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embryologically-derived [yolk-sac] vs. resident-proliferating vs. monocyte/bone-marrow 
progenitor-derived microglia). TMEM119 has been argued to specifically label embryonically-
derived microglia within the brain [422]. However, some very recent sc-mRNA-Seq data on a 
spontaneous EAU model (Aire-/-) identifies expression of TMEM119 on a subset of 
monocyte/monocyte-lineage cells identified because they mapped separately to microglia using 
dimension-reduction algorithms [561]. Additionally, loss of Tmem119 expression has been 
observed in activated microglia [340]. 
Nonetheless, the ability to label a pure population of tissue-resident microglia prior to the 
induction of inflammation (e.g. EAU/EIU) would be pragmatic and allow one to deconvolve and 
investigate the microglial kinetics. It would also allow for validation of novel microglia markers 
and activation markers, so that WT or other transgenic mouse lines could be used for further 
investigation of microglia in the future. This would bypass potential confounders of transgenic 
models (as you could utilise WT mice) or enable the use of alternative transgenic lines (e.g. 
some disease models are themselves transgenic lines, or other lines could be used to investigate 
how alterations to a molecular target changes both microglia and the model) without the need 
for complex breeding regimes to a line that tags microglia. A novel strain of mouse, called the 
“Cx3cr1CreER:R26-tdTomato” mouse, is considered to allow for binary discrimination of tissue-
resident microglia from other cells [376]. 
4.1.2 Cre/Lox Systems and CX3CR1 
Cre recombinase (Cre) is an enzyme from the P1 bacteriophage. It uses a tyrosine residue within 
the active site to recombine specific DNA sites termed LoxP sites and is used for genetic 
manipulation [562]. It can be placed downstream of DEGs to create conditional gene targeting; 
for example, if placed downstream of Cx3cr1, only cells expressing Cx3cr1 will express Cre and 
undergo recombination events at inserted LoxP sites within the genome. The Cx3cr1Cre mouse 
line has been shown as able to tag microglia, but also many other types of macrophage found 
throughout the body, similarly to the Cx3cr1GFP strain [540]. Cre and Lox systems are 
summarised in Figure 4.1.1. 
CreER is a hybrid of the Cre gene and the oestrogen receptor (ER) gene, which is only activated 
when 4-hydroxytamoxifen (and some other ER partial agonists or antagonists) are bound but 
not oestrogen at physiological concentrations [563]; this allows for control of when 
recombination events occur, rather than occurring constitutively upon Cre expression. In other 
words, recombination only occurs when the ER partial agonists/antagonists are administered, 
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and therefore only cells expressing CreER at that specific point in time will undergo a 
recombination event [563]. However, it has been noted that some tamoxifen-independent 
recombination can occur in CreER (both CreER and CreERT2 [second-generation]) systems 
[564], particularly when CreER is inserted downstream of a highly-expressed promoter by a 
specific cell type [565]. 
Another commonly-used gene in transgenic mouse models is Rosa26 because it is ubiquitously 
expressed in both embryonic and adult cells of the mouse [566]; a stop codon, flanked by LoxP 
sites, followed by the gene for a fluorescent protein are inserted downstream of the Rosa26 
promoter to create a reporter for Cre lines. Rosa26 is commonly used as any target cell will 
express the fluorescent protein (or other insert) after a recombination event because it is 
ubiquitously expressed [566, 567]. It is noteworthy to mention that daughter cells (of those 
which have recombined) formed via mitotic division will also inherit this recombined variant, 
as it is permanent. 
  





Figure 4.1.1. Cre and Lox systems, and their utilisation in conditional gene targeting. 
Homozyous mice for a Cre insert (downstream of a specific promoter) can be bred to LoxP 
homozygous mice (which contain Loxp [recombination sites], typically flanking a stop codon and 
with a fluorescent reporter downstream) to create Cre LoxP mice which enable conditional gene 
targeting. Only cells which express the promoter that Cre was inserted into have the capability to 
excise the region between the LoxP sites, resulting in removal of the stop codon and expression of 
fluorescent reporter (in this example, tdTomato). This system can be very useful in the conditional 
targeting of gene disruption, and/or fluorescent tagging of cells that have expressed a promoter 
for lineage-tracing studies. 
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In the Cx3cr1CreER:R26-tdTomato mouse, CreERT2 replaced the 390 bp of exon 2 of Cx3cr1 [540]. 
Cx3cr1 is a microglial-enriched gene that is also expressed in lower amounts by other myeloid 
cells in naïve organisms [557], and therefore CreER is only expressed by myeloid cells. This 
means that only myeloid cells can undergo a recombination event and only when an ER partial 
agonist/antagonist is present. The CAG “promoter” (CMV early enhancer, chicken β-actin 
transcription start site [TSS], and rabbit β-globin intron), stop codons flanked by LoxP sites, 
and tandem dimer (td) Tomato fluorescent protein was also inserted downstream of the Rosa26 
promoter [568]. Therefore, until a recombination event occurs and the stop codon is excised, 
tdTomato cannot be expressed (in theory, although very low-levels of expression of tdTomato 
in the reporter mice – even in the absence of Cre – have been noted [569]). 
As CreER is located downstream of Cx3cr1, only myeloid cells can potentially undergo a 
recombination event. Upon tamoxifen administration, myeloid cells undergo recombination 
and express tdTomato. Because Cx3cr1 is a microglia-enriched gene [348], this genetic model 
tags microglia most effectively, although other myeloid cells are tagged too initially [376]. As 
myeloid cells are short-lived, with the exception of microglia which are long-lived with self-
replicative potential [570, 571], after 4 weeks the other cells will have perished (as part of 
haematopoietic turnover) leaving microglia as the only cells tagged. In the original describing 
study, they indicate that a large proportion (~85%) of the microglial population are tagged using 
this transgenic model (Figure 2.1.2) [376]. This means that techniques such as FACS or flow 
cytometry, confocal microscopy, or others that use fluorescence-based detection will be able to 
identify tissue-based microglia. With a combination of other markers (e.g. CD44, CD45, 
TMEM119, CD11b, etc) it could allow for discrimination between monocyte/macrophage 
populations, for validation of these cell markers, and to investigate other avenues such as 
whether monocytes can differentiate into microglia (or microglia-like cells) and whether this 
occurs during chronic inflammation (e.g. EAU). 
  




Figure 4.1.2. Recombination and the kinetics of fluorescent reporter positivity in the 
Cx3cr1CreER mouse strain. A) Schematic for inducing recombination in the Cx3cr1CreER:R26-
tdTomato mouse – loxP sites are indicated with grey triangles. B) A time-course highlights 
induction of recombination in a variety of cell types, with progressive loss of all but microglial cells 
by 4 weeks post-tamoxifen in the Cx3cr1CreER:R26-eYFP mouse strain. Recombination persists in 
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4.1.3 The Safety/Toxicity of Tamoxifen, CreER, and tdTomato 
Tamoxifen is a known chloride channel blocker and has been shown to inhibit microglial 
process formation/extension, compromising their neuroprotective function after lesions were 
formed by lasers [572]. Whilst tamoxifen administration is acute, and occurs 4 weeks prior to 
the usage of mice, it is unclear if this would have long-term effects on the microglia and their 
function. Therefore, experiments to confirm a normal disease course/process will be required 
in the Cx3cr1CreER:R26-tdTomato mouse line as altered in vivo kinetics would impact 
experimental time-points at which microglia are isolated for downstream sequencing. It is well-
recognised that CreER mouse lines can also have off-target effects and use of heterozygotes in 
experiments helps to mitigate these as it ensures that there are functional variants of all proteins 
in the organism. Nonetheless, the effect of a haplosufficient heterozygote compared to a WT 
homozygote is unknown as it is specific for each mouse strain. However, as discussed earlier, 
use of this transgenic line represents one of the only currently available approaches of 
specifically isolating microglia (until specific markers are identified, potentially through use of 
this transgenic line) which justifies its use. 
In the literature there are many reports of CreER being toxic and causing severe side-effects on 
mice via the cells they are expressed in, irrespective of whether they had received tamoxifen or 
not [573]. A different study in the eye was conducted to establish the potential toxic or other 
effects that CreER and tamoxifen administration might have. For this study, three different Cre 
mouse lines (CAGGCre-ERTM [which should tag all retinal cells, including microglia], α-Cre, and 
LMOP-Cre) were used to investigate whether Cre expression and/or tamoxifen treatment would 
alter retinal structure/function, neuronal vulnerability or glial reactivity in the mouse eye [510]. 
Ex vivo assessments included confocal laser scanning microscopy of histological tissue sections 
(to visualise potential morphological changes in individual cell types, but to also perform 
measurements of the INL thickness) and qPCR of microglial activation markers, a macroglial 
development factor, and neuroprotective factors. Additionally, clinical in vivo assessments in 
the form of fundal images and ERGs of the retina, and neuronal vulnerability to light damage 
(measured by a TUNEL assay) were performed. In summary, they showed that Cre or CreER and 
tamoxifen did not influence retinal function, expression of neuroprotective factors, macro-
/microglial reactivity, and neuronal vulnerability. This suggests that the eye is not compromised 
by Cre toxicity and/or tamoxifen treatment. There are no known abnormalities in the 
Cx3cr1CreER:R26-tdTomato mouse line, but these studies highlight the need for good controls (i.e. 
at least from the same transgenic line, but ideally littermates) but also confirmation of typical 
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disease kinetics (despite no detectable retinal abnormalities in other Cre lines) as it has been 
shown that perturbation of microglia can inhibit establishment of ocular disease in the EAU 
model [390]. 
Lastly, it is well-recognised that fluorescent proteins have the potential to be both immunogenic 
and toxic to cells [574]. tdTomato is a tandem-dimer, making it in effect a monomer with double 
the molecular weight, that was engineered not to oligomerise which has helped reduce its 
toxicity potential. It is recognised that (detectable) toxicity is rare in currently-used fluorescent 
reporters [575]. tdTomato has a relatively low potential for phototoxicity due to longer-
wavelength excitation (with respect to many other fluorophores) [576]. It is also noteworthy to 
mention that tdTomato is extremely bright and has very high photostability as well, making 
repeated in vivo imaging unlikely to cause issues with respect to our detection of the microglia 
[577]. It would be important to characterise the mice post-tamoxifen to confirm the microglia 
as physiological, and to use equivalent controls so that tdTomato presence/absence does not 
potentially confound experiments. 
The overall emerging picture from the use of transgenic mice (e.g. Cre lines), fluorescent 
reporters, and tamoxifen is that equivalent controls (if not littermates) should be used where 
possible to mitigate any possible (even if not detected) confounding caused by the transgenic 
line, tamoxifen treatment, CreER, and/or fluorescent protein. 
4.1.4 Tamoxifen Administration Routes 
Various routes of tamoxifen administration (for activating CreER systems) have been described 
previously. Research groups commonly employ subcutaneous injection [376] or oral gavage 
[540] (also in food), but topical administration (as a 4-day regime) has also been described 
recently as both safe and effective [510]. Therefore, we sought to compare the subcutaneous and 
topical administration routes of tamoxifen (200 µL of a 21 mg/mL solution on days 1 and 3, and 
10 µL of a 5 mg/mL solution to each eye 3 times daily for 4 days, respectively) – one systemic 
approach compared to the local approach – to identify whether one was superior with respect 
to both the sensitivity of inducing recombination in, and specificity for microglia (i.e. the 
proportion of microglia that are tagged using the approaches, and the frequency of 
recombination events in non-microglial cells and their presence in the retina under 
inflammatory conditions). This would enable us to determine which is the most suitable regime 
for use in our experiments in the Cx3cr1CreER:R26-tdTomato strain. 




The Cx3cr1CreER:R26-tdTomato transgenic mouse offers great potential as a tool for investigating 
microglia, but many questions needed to be asked such as whether the Cre/Lox system alters 
microglial behaviour and disease model kinetics, whether it is indeed sensitive and specific for 
microglia, and if this is universal or biased towards a particular tamoxifen administration route. 
The major aims of this chapter were to characterise the sensitivity and specificity of different 
tamoxifen administration regimes for retinal microglial tagging in the Cx3cr1CreER:R26-tdTomato 
to confirm whether it would be suitable (alone or in combination with antibody staining) for 
retinal microglial isolation and downstream transcriptomic assessment during inflammatory 
states. 
  




4.2.1 Sensitivity of Microglial Tagging 
Firstly, confirmation was sought that the retina in the Cx3cr1CreER:R26-tdTomato mouse line was 
physiological and no perturbations were observed. Secondly, confirmation that it was possible 
to tag retinal microglia using tamoxifen and the Cx3cr1CreER:R26-tdTomato mouse line was 
required. Thirdly, a comparison between the different tamoxifen regimes (topical 3x daily 
lasting for 1–4 days, a subcutaneous approach with injections on days 1 and 3, and no-tamoxifen 
controls) was required to observe if they tagged microglia differentially and if one was superior 
compared to the others for use in continuing work. Brightfield fundal imaging of WT and 
Cx3cr1CreER:R26-tdTomato mice revealed no gross differences between the retinas, suggesting a 
physiological state, in a naïve context at least (Figure 4.2.1). A fluorescent fundal imaging time-
course (with gain-normalised settings) indicates that, following systemic administration, retinal 
tdTomato fluorescence has not stabilised by 2 weeks post-tamoxifen; it reaches a maximum by 
4 weeks however (Figure 4.2.2). Fluorescent imaging of retinal tdTomato undergoing the 
different tamoxifen regimes, 4 weeks post-tamoxifen, suggested (as a qualitative readout) that 
a minimum of 2 days of the topical regime was required for full tagging (Figure 4.2.3). It also 
indicated that a modest proportion of microglia can recombine in the retina independently of 
tamoxifen administration (tamoxifen-independent, or constitutive, recombination). 
However, a quantitative assay that was more absolute and sensitive would confirm whether all 
retinal microglia were tagged (sensitivity) and if other retinal cells were also labelled following 
tamoxifen administration (specificity). To assess this, flow cytometric analysis was performed 
on the retinas using a panel to include the microglial markers CD45 and CD11b (good markers 
of determining microglia in a naïve retina). This demonstrated that a 3- or 4-day topical, or 
subcutaneous (days 1 and 3) regime was required for full microglial tagging and that the other 
regimes (including 2-day topical) were insufficient (Figure 4.2.4). 
As a final confirmation confocal laser-scanning microscopy, performed on retinal flatmounts, 
permitted assessment of the spatial distribution and morphology of the tdTomatohi cells; they 
exhibited the ramified morphology typical of microglia which also suggested that there were no 
gross pertubations in the retina or microglia as a consequence of the transgenic line or 
treatments (Figure 4.2.5). 
  





Figure 4.2.1. Brightfield imaging of wild-type (WT) and Cx3cr1CreER:R26-tdTomato mice 
highlight no gross perturbations as a consequence of gene editing. Representative fundal 
images are shown, where mice exhibit a typical appearance that lacks retinal scarring, 
inflammation, or degenerative phenotypes. 
  
Wild-Type CX3Cr1CreER:R26-tdTomato 
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Figure 4.2.2. Representative fluorescent fundal images of Cx3cr1CreER:R26-tdTomato 
mice before and after tamoxifen administration. A) Images pre- and 2 weeks post 
tamoxifen indicate a slight increase in fluorescence. B) Fluorescence greatly increases between 2- 
and 4-weeks post-tamoxifen. C) Fluorescence intensity does not change after 4 weeks post-
tamoxifen, indicating stabilisation. All mice (different in each panel) received a subcutaneous 
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Figure 4.2.3. Representative fluorescent fundal images of Cx3cr1CreER:R26-tdTomato mice 
undergoing different tamoxifen administration regimes 4-weeks post-tamoxifen. There 
is clear evidence of recombination and tdTomato expression in a no-tamoxifen mouse, but more 
microglia are tagged when tamoxifen is administered; it is difficult to discern differences between 
2D–4D and Sc retinas. The results are representative of two independent experiments, with at least 
4 biological replicates per group. Abbreviations: No – no tamoxifen administered, xD – x-day 
topical tamoxifen regime, Sc – subcutaneous tamoxifen regime.




Figure 4.2.4. Sensitivity of microglial recombination induced in Cx3cr1CreER:R26-tdTomato mice using different tamoxifen administration 
regimes. A) A representative flow cytometric gating strategy used to identify microglia in a naïve retina based on CD45 and CD11b expression. B) 
Representative tdTomato histograms (unit area scaling) on gated microglia from various tamoxifen administration regimes. C) Aggregate data 
demonstrating the percentage of microglia that were tdTomatohi (as quantified by flow cytometry) shows that a 3-day and 4-day topical, in addition to 
subcutaneous, regimes result in full microglial tagging (n = 3–6). Abbreviations: None – no tamoxifen administered, 1D – one-day topical tamoxifen 
regime, 2D – two-days topical tamoxifen regime, 3D – three-days topical tamoxifen regime, 4D – four-days topical tamoxifen regime, Sc – subcutaneous 
tamoxifen regime. For statistical analysis, One-way ANOVA with Tukey’s post hoc test was used. **** = p ≤0.0001, ns = not significant. 




Figure 4.2.5. Representative confocal microscopy maximum-intensity projection of a 
whole naïve retina highlights a physiological morphology. Retinal flatmount prepared from 
a mouse that received the 3-day topical tamoxifen regime. The microglia exhibit a physiological 
ramified morphology, suggesting no gross perturbations in the microglia as a consequence of the 
transgenic model and tamoxifen administration. Scale bar = 30 µm. 
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4.2.2 Specificity of Microglial Tagging 
Having confirmed that a 3- or 4-day topical tamoxifen regime or sub-cutaneous approach was 
required for full retinal microglia tagging, subsequent experiments sought to compare 
differences in the specificity for microglial tagging using these routes (i.e. if extraocular cells 
underwent recombination). This was important for the planned transcriptomic assessments of 
microglia before, during, and after intraocular inflammation as these would require “pure” 
populations of retinal microglia and it is well-known that other cells ingress to the retina during 
inflammation. 
Initial experiments sought to characterise the full extent of tdTomato expression following 
topical and subcutaneous administration. Tissue samples were prepared for flow cytometric 
assessment using an immunophenotyping panel (containing B220 [a B cell marker], CD3 [a T 
cell marker], CD11b [a myeloid cell marker], CD45 [an immune cell marker], and Gr-1 [an 
antibody that binds Ly6C and Ly6G with different affinities to differentiate “resting/patrolling” 
and “inflammatory” monocytes in addition to granulocytes]) to identify whether there were 
tdTomatohi cells present in non-retinal tissues (blood, bone marrow, brain, kidney, liver, lung, 
and spleen), but also whether there was a predisposition to a given cell type – as use of the tag 
in conjunction with other markers may nonetheless permit specific microglial identification. 
The sub-cutaneous approach resulted in full tagging of brain microglia due to the systemic 
administration; in comparison, the topical approach and no-tamoxifen controls resulted in 40–
50% of microglia being tagged (Figure 4.2.6). 
With the sub-cutaneous approach, there were also ~2.2 times more tdTomatohi splenic 
monocytes as compared to a topical approach (Figure 4.2.6). Furthermore, the presence of a 
small number of tdTomatohi cells were observed in other peripheral tissues (Figure 4.2.7). 
Whilst the absolute numerical differences in cells (or percentages) are low, this could be 
pertinent in the context of the eye where only a small number of microglia are found; numbers 
of tdTomatohi cells ranging in the hundreds (if they infiltrate the eye) as observed could greatly 
reduce the specificity of the mouse line. 
  





Figure 4.2.6. Flow cytometric histograms highlight tagging of brain microglia and a 
small number of splenic monocytes following subcutaneous (systemic) tamoxifen 
administration. Histograms for different tamoxifen administration regimes are displayed for 
retinal microglia, brain microglia, and splenic monocytes alongside the percentage positive of each 
cell type for tdTomato. Histograms containing a small number of positive cells are highlighted 
with circles. Abbreviations: No – no tamoxifen administered, 3D – 3-day topical tamoxifen regime, 
4D – 4-day topical tamoxifen regime, Sc – subcutaneous tamoxifen regime (n = 1). 
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Figure 4.2.7. Flow cytometric analysis of peripheral tissues indicates a small, but 
potentially significant, number of tdTomatohi cells. Tissues were gated for cells, singlets, live 
cells, and then for myeloid cells (CD45+, CD11b+). Histograms of tdTomato fluorescence intensity 
from the different tissues are shown alongside the percentage positive for tdTomato. Histograms 
containing a small number of positive cells are highlighted with circles (these samples contained 
a minimum 3-figure number of tdTomatohi cells). Abbreviations: No – no tamoxifen administered, 
3D – 3-day topical tamoxifen regime, 4D – 4-day topical tamoxifen regime, Sc – subcutaneous 
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Nonetheless, the presence of peripherally recombinant cells (including brain microglia) is not 
necessarily of concern (with respect to retinal microglial specificity) if they do not infiltrate the 
eye during inflammation. Therefore, to test this comprehensively a model where immune cell 
infiltration to the eye occurs was required. EIU, as a model of acute endotoxin-induced 
inflammation, was selected for this purpose because it has a robust and reliable onset of disease 
with peak immune cell infiltrate observed within the retina and VB at 18 hours post-induction 
(typically by intravitreal injection of LPS). 
Before testing, it was important to first confirm the EIU model kinetics in the Cx3cr1CreER:R26-
tdTomato mouse line were equivalent to the WT C57BL/6J mouse (see Chapter V, Figure 5.2.1). 
This would allow the isolation of retinas for flow cytometry during the peak cellular infiltrate 
stage of EIU (18 hours post-injection) to test the specificity. 
Flow cytometry was performed on the retinas during peak cellular infiltrate (as confirmed by 
OCT of the retinas; Figure 4.2.8) and the immunophenotyping panel was used so that various 
immune cell populations could be gated and checked for their expression of tdTomato (Figure 
4.2.9). 




Figure 4.2.8. Representative images of a naïve and EIU 18h retina in the Cx3cr1CreER:R26-
tdTomato mouse line. Fundal images (top) show a generalised haze, including over the optic 
disc (nerve), which OCT (bottom) confirms as cellular infiltrate in the vitreous (circled). 
Abbreviations: EIU – endotoxin-induced uveitis, OCT – optical coherence tomography, ON – optic 
nerve, RL – retinal layers, VB – vitreous body. 
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Figure 4.2.9. Flow cytometric gating strategy used to differentiate immune cell 
populations present in the retina at peak EIU. Retinas were gated for cells, singlets, live cells, 
and CD45+ immune cells. They were then separated into tdTomatohi (which we hypothesised were 
microglia) and tdTomato-. The tdTomato- cells were then gated for myeloid cells (CD11b+), T cells 
(CD3+), and other (CD3-, CD11b-), with the myeloid cells further discriminated into Gr-1-, Gr-1lo 
(Ly6C+), and Gr-1hi (Ly6G+) cells. The “other” cells were gated on B220 to identify B cells. 
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To test for specificity, tdTomatohi cells were gated from live cells (as per Figure 4.2.9; Figure 
4.2.10a) and then subsequently back-gated for microglia based on CD45 and CD11b expression. 
In the 4-day topical and subcutaneous approaches, the presence of non-microglial cells in the 
tdTomato gate was observed (Figure 4.2.10b, circled), indicating a slight reduction in specificity. 
Gating for microglia without first gating for tdTomatohi cells results in the inclusion of many 
tdTomato- cells which are not microglia, and greatly compromises the specificity (Figure 4.2.10c, 
blue). The results indicate that a 3-day topical approach had the highest specificity (equivalent 
to a no-tamoxifen control, where incomplete microglial tagging but no peripheral tagging has 
occurred), followed by the 4-day topical approach and lastly sub-cutaneous (Figure 4.2.10d). 
Nonetheless, use of any tamoxifen administration regime considerably trumped the use of 
conventional CD45/CD11b gating. 
However, a possible limitation to this approach for distinguishing the retinal microglia (CD45int 
CD11b+ tdTomatohi) from the tdTomatohi group is that non-retinal microglial or non-microglial 
cells which possess a similar transcriptional profile (e.g. infiltrating monocytes or brain 
microglia) could be falsely identified as retinal microglia. Therefore, the total counts of the 
tdTomatohi group, from naïve and peak EIU retinas (3-day topical tamoxifen regime), were 
compared and no significant difference was observed confirming a pure retinal microglial 
population (Figure 4.2.11). All subsequent experiments used the 3-day topical tamoxifen regime.




Figure 4.2.10. The specificity of different tamoxifen administration regimes for microglial tagging in the Cx3cr1CreER:R26-tdTomato mouse 
strain during active inflammation. A) Peak EIU retinas following different tamoxifen administration regimes were prepared for flow cytometry. 
Live, cell singlets were gated based on tdTomatohi expression. B) tdTomatohi cells were gated based on CD45int and CD11b+ expression, and in the 4-day 
and subcutaneous tamoxifen treated groups, non-microglial cells (CD45hi, CD11b-) were present (circled). C) Gating microglia based on CD45 and CD11b 
expression alone results in the inclusion of infiltrating immune cells (tdtomato-, blue) in addition to retinal microglia (tdTomatohi, orange) but exclusion 
of cells not fitting the microglial expression profile (CD45hi/-, red). D) Aggregate data on the percentage specificity for microglia demonstrates that the 
3-day topical route results in high specificity for microglia using tdTomato. The CD45int/CD11b+ group uses the microglial gating strategy (from live cell 
singlets without using tdTomato) shown in panel B for a comparison of the mouse strain to conventional microglial identification strategies (n = 2–5). 
Abbreviations: None – no tamoxifen administered, 3D – three-days topical tamoxifen regime, 4D – four-days topical tamoxifen regime, Sc – 
subcutaneous tamoxifen regime. For statistical analysis, One-way ANOVA with Tukey’s post hoc test was used. ** = p ≤0.01, ns = not significant. 




Figure 4.2.11. EIU-mediated inflammation does not alter the number of tdTomatohi cells. 
The retinas from naïve and EIU 18h mice were processed for flow cytometry and gated for live 
tdTomatohi singlets. All mice underwent a 3-day topical tamoxifen regime. For statistical analysis, 
the t-test was used. Ns = not significant (n = 6–8). 
  




The Cx3cr1CreERR26-tdTomato mouse line is both highly sensitive and specific for microglia, and 
irrespective of tamoxifen administration routes is a considerable improvement on the 
previously available methods of microglial isolation (whether that be by cell-surface markers 
such as CD45 and CD11b, through use of the CX3CR1GFP/+ mouse line, or other approaches). This 
is especially important as a clear marker to distinguish long-lived, yolk-sac derived microglia 
from infiltrating myeloid cells is critical to our future investigation into the transcriptome of the 
microglia. 
In concordance with previously published work, our results suggest that the Cx3cr1CreER:R26-
tdTomato mouse strain do not possess any gross abnormalities and that the microglial 
morphology (as identified using confocal laser-scanning microscopy) is physiological 
(ramified). The use of appropriate controls (transgenic mice under the same tamoxifen regimen) 
is necessary to mitigate any potential confounding effect of the transgenic line and/or tamoxifen 
treatment; this will be implemented for future experiments as there could be perturbations in 
the mice which are beyond the detection limits of these assays. Further investigation of this 
might be possible through comparison of microglial morphologies (between Cx3cr1CreER:R26-
tdTomato and WT C57BL/6 strains) using Frac-Lac or Sholl analysis on microscopy images. 
Nonetheless, despite this potential caveat other studies that used more sensitive approaches to 
assess functionality within the retina (e.g. ERG, qPCR, and cell death due to a light-induced 
damage model) were unable to detect perturbations due to the presence of CreER and/or 
tamoxifen administration [510]. 
The results showed a high level of tamoxifen-independent (constitutive) recombination in the 
microglia. Whilst this was unexpected, it has been reported in CreER models previously and so 
is certainly not exclusive to this CreER line or investigations – it is suggested that high 
expression of the CreER, dependent on which promoter it is inserted downstream of, can lead 
to tamoxifen-independent (or constitutive) recombination [564, 565]. Constitutive 
recombination is a well-recognised phenomenon within the field of receptor biology [578], and 
in a simple two-state (active or inactive; on or off) model of receptors an equilibrium between 
these two states (with the position, in the absence of an agonist, being far to the inactivated 
side) is present. This means that it is entirely possible for a receptor to be in an active 
conformation even in the absence of a ligand. Therefore, the higher the expression of CreER 
(but also the longer the time the expression persists, or the receptor lasts before recycling, for) 
the greater probability of a tamoxifen-independent recombination event occurring. As 
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microglia highly express Cx3cr1, this explains why we observe this phenomenon. Nonetheless, 
this phenomenon is of no major concern with regards to microglial tagging as full tagging occurs 
after a tamoxifen regime. A more pertinent question is whether chronic inflammation (and 
possible engraftment of monocytes/bone marrow progenitors) leads to sustained expression of 
Cx3cr1 in and survival of other cells (whether this be non-yolk sac-derived microglia – or 
microglia-like cells – or in other immune cell populations) and if this may lower the specificity 
of the Cx3cr1CreER:R26-tdTomato mouse line for microglia. Based on the current observations, 
this does not appear to be the case for the EIU model but remains to be seen for the EAU and 
other disease models and necessitates testing on a per-model basis. It also raises the question 
of what exactly a microglia is, and whether stratification based upon their origin, or clarification 
of their origin (when isolated for downstream assays) may be necessary for future work so that 
studies can be better compared to one another, particularly if conflicting results are obtained 
due to different isolation strategies. 
As indicated by the imaging, the tdTomato fluorescence intensity does not stabilise until 4 
weeks post-tamoxifen in naïve microglia. This suggests that even if non-microglial cells were to 
undergo a constitutive recombination event, they would not necessarily have the tdTomato 
fluorescence intensity equivalent to a microglial cell unless they survived/persisted for lengthy 
periods of time. This assumes expression of the CAG promoter is not greatly altered by 
inflammation (which we have not tested). The only way to conclusively confirm this hypothesis 
would be using a high-throughput method (such as mRNA-Seq, proteomics, etc) with single-
cell resolution, and even this carries the underlying assumption that the yolk-sac derived 
microglia remain different to the infiltrating cells to enable unsupervised delineation of them 
using a dimension-reducing algorithm. 
The 3-day topical regime is fully sensitive and highly specific for microglia during EIU. Whilst 
other approaches also fully tagged the microglia (e.g. 4-day topical and subcutaneous regimes), 
they are associated with a reduced specificity in the context of immune cell infiltration. The 
non-microglial CD45+ tdTomatohi cells identified in the eye were negative for the full panel of 
markers (which covered all the major types of immune cell). They may represent a population 
of innate lymphoid cells (ILCs). ILCs do not express the typical cell-surface markers of other 
lymphocytes (such as B220 or CD3), but some ILC subtypes are known to express high amounts 
of Cx3cr1 and can also be long-lived [579-582]. This may explain how they could be tagged, 
survive more than 4 weeks, and subsequently be observed within the retina during EIU after a 
course of subcutaneous tamoxifen. It is unclear whether the tagging in a 4-day topical regime is 
due to systemic reabsorption of tamoxifen to a concentration above a threshold to activate 
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recombination in a smaller fraction of these cells, or if activation is happening locally to the site 
of administration. 
Whilst the specificity data is calculated based upon back-gating of microglia using CD45 and 
CD11b expression (and it is possible that non-retinal microglial or non-microglial cells could 
have similar levels of expression of these markers and be incorrectly classified), we are confident 
that the 3-day topical regime in this Cre line is specific because the total numbers of tdTomatohi 
cells did not vary from a naïve organism through to the peak cellular infiltrate phase of EIU; it 
is well-known that microglia do not egress from the retina, but can migrate to different retinal 
layers or the subretinal space (which would still allow for isolation using our approach), upon 
inflammation [341]. This data also supports recent studies of microglia that highlight the need 
to confirm the specificity for microglia in their disease model and employ techniques with 
single-cell resolution to resolve the non-microglial cell populations [341, 583]. 
Lastly, this series of experiments have also enabled us to explore the possibility of implementing 
the 3Rs in our work (principles of animal welfare [94]), specifically refinement. We showed that 
the optimal tamoxifen administration regime is both beneficial to the sensitivity/specificity for 
microglia but also for the animal’s welfare via reduced confounders of handling and procedures; 
a topical regime is a sub-threshold technique resulting in only the inherent stress that handling 
brings as opposed to the mild severity that a sub-cutaneous injection would bring. Furthermore, 
we showed it was possible to shorten the originally published regime to 3 days. 
In summary, we show that a 3-day topical tamoxifen regime results in complete and specific 
tagging of microglia in the Cx3cr1CreER:R26-tdTomato mouse line before, during, and after EIU 
that permits valid investigation of them using fluorescence-based detection and isolation 
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Chapter V: Microglia and EIU  
EIU is a self-resolving model of acute TLR4-mediated ocular inflammation, that following a 
single inflammatory insult generates acute immune cell infiltration [52, 584]. It typically has the 
kinetics of an acute short-lived monophasic reaction. 
Microglial activation by LPS has been characterised before, with co-expressional meta-analysis 
identifying a core set of microglial “LPS” genes in addition to generic activation markers of 
microglia in various pathological states [158]. A common microglial transcriptional signature 
has been described by several groups [158, 308, 346-348]. Furthermore, the microglial 
transcriptional signature is well-documented to be disrupted during an activated state – with 
many homeostatic genes downregulated including P2ry12, Siglech, Cx3cr1, and Tmem119 – 
whether that be due to ageing, neurodegeneration, acute responses (such as to LPS), and many 
others [158, 341, 342, 352, 353]. Depending on the context and kinetics, microglia can promote 
or regulate inflammation [390, 585]. 
Developing our understanding further, both inherent and acquired heterogeneity (i.e. during a 
response) are being observed within microglial populations. Microglia are known to exist in two 
distinct niches within the retina and exhibit differential regulation because of inherent 
microglial heterogeneity [341]. Microglial heterogeneity has been observed in LPS responses 
(brain microglia following a systemic dose), AD, and ocular light-damage models in vivo [340-
342, 344, 586]. C5ar1 was identified as a DEG between microglial subtypes during an LPS 
response [342], making it a candidate marker for differentiating microglial subtypes; other 
reports showed that C5AR1 is required for microglial polarisation to a pro-inflammatory state 
with deficiency of C5AR1 signalling resulting in reduced activation/induction of inflammatory 
genes and improvements in outcomes from an AD model [366]. 
Furthermore, it is now recognised that other similar cell types (i.e. macrophages) exhibit a 
highly-plastic transcriptome during an LPS response [587]. The transcriptional kinetics have not 
been investigated in microglia nor the microglial behaviour/activity post-“resolution”, and the 
degree to which homeostatic restoration is achieved or if they remain permanently altered 
(whether this be more pro- or anti-inflammatory) after an insult. 
Therefore, the aims of this chapter were to utilise the knowledge from the previous chapters to 
characterise the plasticity of the microglial transcriptome over time during an LPS response but 
also to see if the homeostatic state was restored after resolution. 
  




5.2.1 The Kinetics of EIU in the Cx3cr1CreER:R26-tdTomato Mouse 
Line 
For investigation of EIU, the kinetics needed to be characterised to observe if they were 
consistent with reports in WT mice so that appropriate timepoints could be selected for 
microglial isolation and sequencing [97]. To this end, imaging was performed on mice to obtain 
a time-course which confirmed the kinetics as typical, with peak cellular infiltrate at 18 hours 
post-injection and resolution by 2 weeks (Figure 5.2.1). Clinical assessment demonstrated few 
changes in the microglia at 4 hours post-injection, although a slight widening of vessels was 
apparent. By 18 hours, the uniform distribution of microglia was altered, cell bodies possibly 
appeared larger suggesting retraction of ramified processes to form a more amoeboid 
morphology, and vessels were larger still. Cognisant that the Micron IV imaging platform does 
not possess the high resolution required to reliably detect changes to the microglial ramified 
processes, retinal flatmounts were prepared for acquisition by confocal laser-scanning 
microscopy to visualise these in high-resolution (Figure 5.2.2). Microglia were observed to have 
a ramified-to-amoeboid transition by 4 hours which persisted through to 18 hours but resolved 
to a ramified state by 2 weeks. With evidence of microglial perturbation at 4 hours post-
injection, we sought to then characterise the microglial transcriptome during the early stages 
of EIU, peak cellular infiltrate, and after resolution. 




Figure 5.2.1. The kinetics of EIU in the Cx3cr1CreER:R26-tdTomato mouse strain. A) OCT images showing disease-course in a single mouse 
demonstrates the presence of infiltrating cells in the vitreous body at 18 hours post-injection with resolution by 2 weeks. B) Deconvolved fluorescent 
fundal images acquired simultaneously show few changes in the distribution of microglial cells at 4 hours post-injection, but clear changes in their 
distribution and brightness (in addition to vessel dilation) at 18 hours which have resolved by 2 weeks. 
 
 






Figure 5.2.2. Confocal laser-scanning microscopy shows changes in microglial morphology over time in EIU. High-resolution images reveal 
retraction of ramified processes (indicator of activation) between a naïve organism and EIU 4 hours, with resolution after 18 hours but by 2 weeks. Scale 
bars = 30 µm. 
 




Initially, a pilot study to include the naïve (no injection), 18 hours EIU, and 2 weeks EIU groups 
in addition to the contralateral (uninjected) eyes was performed so that a power analysis (with 
an α of 0.1 and β of 0.8; standard parameters) could be completed to further inform the 
subsequent experiments and the required numbers per groups. The power analysis indicated 
that to detect changes in 50% of genes with a fold-change of 2, 6.92 samples were required (50th 
percentile of a given fold-change is the most-commonly used metric according to the PGS 
software documentation). This agreed with published reports on power analysis that suggested 
6 biological replicates were required for adequate power when detecting DEGs with a fold-
change criterion of ≥±2 (at a depth of 10 million reads per sample) [498]. Furthermore, 
unanticipated changes in gene expression between the contralateral eyes and naïve controls 
indicated that true naïve controls were more appropriate than using the contralateral eyes. In 
agreement with our findings, a single report in the literature also identified changes to microglia 
in eyes contralateral to a procedure inducing glaucoma, suggesting a mechanism of microglial 
or general communication between eyes [547]. 
Following the pilot study, a new study was initiated that included the 4-hour EIU group and 
utilised naïve eyes as controls. It was split into two independent blocked experiments with the 
aim of at least 6 biological replicates per group; cDNA was generated from samples with a 93% 
success rate, resulting in 5–10 biological replicates per group from these experiments. The 
analysis identified 1,069 unique DEGs (613 at 4 hours, 537 at 18 hours, and 0 at two weeks; all 
compared to naïve controls) visualised by hierarchical clustering that highlights a highly-plastic 
transcriptome with most up-regulated genes being mutually exclusive at different timepoints 
but a common/core set of downregulated genes (Figure 5.2.3). Boxes highlight clusters of genes 
that were normal at 4 hours but up-regulated at 18 hours (yellow), those which were up-
regulated at 4 hours but not 18 hours (brown), those which were up-regulated at both time-
points (green), those which were down-regulated at 4 hours but recovered to pre-EIU levels by 
18 hours (light blue), and those which were down-regulated at both 4- and 18 hours (black). 
Restoration back to a homeostatic signal was observed by 2 weeks because unsupervised 
clustering failed to discern between samples in the naïve and 2-week post-injection 
experimental groups.




Figure 5.2.3. mRNA-Sequencing of microglia during and after EIU reveals transcriptional alterations that fully resolve. Hierarchical 
clustering of DEGs shows differences in the kinetics of the microglial transcriptome during EIU. Boxes highlight clusters of genes with different kinetics, 
and a restoration back to a homeostatic signal by 2 weeks (n = 5–10).
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Despite all of the previous QC checks, it was nonetheless important to compare this dataset to 
the published literature to observe whether this data was concordant or not. Therefore, gene 
lists generated from a co-expression meta-analysis and other consensus lists of microglial 
homeostatic genes were checked against gene expression values from this dataset. Gene lists 
included those representing microglial homeostatic genes (e.g. G protein-coupled receptor 34 
[Gpr34], v-maf musculoaponeurotic fibrosarcoma oncogene family protein B [avian] [Mafb]), 
microglial activation (generic) genes (e.g. C-X-C motif chemokine 10 [Cxcl10]), microglial LPS 
activation genes (e.g. Map3k8), and “primed microglia” response genes (e.g. axyl receptor 
tyrosine kinase [Axl]) [158, 342, 588]. On this basis, downregulation of homeostatic genes, 
upregulation of activation genes, and no expression of primed genes were expected. For 
clarification, the “primed microglia” response genes were observed and characterised in 
neurodegenerative conditions but not in acute activation. The expected changes were observed 
within the dataset; a representative selection of RPKM scatterplots, highlighting this agreement, 
is displayed in Figure 5.2.4. 
Consensus on these select genes was encouraging but it was also important to compare the data 
at a broader level using pathway analysis. This was performed using the GO terms, KEGG 
pathways, and IPA canonical pathways. Enriched canonical pathways when naïve and 4 hours 
EIU groups were compared included: TREM1 Signaling, iNOS Signaling, Th17 Activation 
Pathway, TNFR2 Signaling; for the naïve and 18 hours comparison, enriched pathways included: 
EIF2 Signaling, Interferon Signaling, Gαq Signaling (Figure 5.2.5). No enriched pathways were 
identified between the naïve and 2 weeks EIU groups because it is not possible to perform 
pathway analysis without DEGs. To better represent the time dimension of the dataset a 
heatmap of the significantly-enriched canonical pathways over time was created, highlighting 
how both the p value and z-score (directionality score) change across the timepoints with 
resolution/homeostatic restoration to baseline by 2 weeks (Figure 5.2.6). LPS was found to be a 
“master regulator” by IPA as expected. 
Enriched GO terms (enrichment score) when naïve and 4 hours EIU groups were compared 
included: immune system process (60.9), regulation of cytokine production (56.0), and response 
to stress (52.7). Similarly, the enriched KEGG pathways included: NF-Kappa B signaling pathway 
(34.1), toll-like receptor signaling pathway (31.7), and TNF signaling pathway (25.3). For the 
naïve and 18 hours EIU comparison GO terms included: cytosolic part (89.7), extracellular 
organelle (70.7), translation (65.8), and immune system process (29.8); enriched KEGG 
pathways included: ribosome (58.8) and proteasome (42.9).




Figure 5.2.4. The transcriptome of microglia during EIU identifies expected changes in previously described microglial genes. Scatterplots 
show expression levels of a homeostatic gene (Gpr34), a homeostatic transcription factor (Mafb), a generic microglial activation gene (Cxcl10), an acute 
LPS-response gene (Map3k8), and “primed microglia” gene (Axl). The observed changes in expression (or absence of) are consistent with previously 
published reports (n = 5–10).
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Figure 5.2.5. IPA software identifies canonical pathways that are 
significantly altered in microglia during EIU. A) Significantly altered 
pathways at 4 hours post-injection and B) 18 hours post-injection are shown. 
A p value threshold of ≤0.05 is indicated by the horizontal line. The shading 
intensity of the bars indicates how strongly positive (orange) or negative 
(blue) the z-score (directionality score) was for each pathway. There were no 




















































































































































































































































































































































































































































































































Figure 5.2.6. A heatmap shows changes in both z-score and p value over time for 
significantly-enriched IPA canonical pathways. The pathways are arranged in ascending 
order based on their overall (summary) p value with colour-coding to indicate the magnitude of 
change in z-score (red representing an increase in pathway activity, and blue representing a 
decrease in pathway activity). All pathways resolved to the equivalent of a naïve state by 2 weeks 
post-injection.
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5.2.3 Orthogonal Validation of Selected Markers 
Identification of recognised DEGs and canonical pathways reported in the literature was 
encouraging, but orthogonal validation of the dataset (to include at the protein-level) was 
required as the transcriptome and proteome do not necessarily correlate. A full proteomics 
assessment was not feasible in the current study as very limited numbers of specialised pipelines 
can handle low cell input (<10,000) and require custom-made reagents and/or equipment (e.g. 
microfabrication of glass chips using photolithography) [589, 590]; utilising one of these 
pipelines would have considerably increased the cost of experiments beyond the current budget 
in addition to requiring further extensive optimisation. Whole retinal protein-level analysis 
could identify differentially-regulated proteins but would be unable to distinguish the 
individual contribution of distinct cell types and validate them as altered in microglia [591]. 
Therefore, a limited number of key markers would need to be selected for validation testing. 
Flow cytometry was chosen as the technique of protein-level validation as it has single-cell 
resolution and would enable the assessment of potential microglial heterogeneity that is 
becoming increasingly recognised. Nonetheless, a hypothetical discrepancy between the 
mRNA-Seq data and flow cytometric data could question the accuracy and validity of the 
sequencing, and therefore direct validation of the mRNA-Seq on the same material used to 
generate the libraries was required to confirm if sequencing results were inaccurate or a genuine 
discrepancy between gene-level and protein-level was present. For this qPCR, using highly 
sensitive and specific TaqMan probes, was utilised. As flow cytometry can be performed on 
samples with limited numbers of markers in parallel and low amounts of cDNA remained from 
the original samples for qPCR (limiting the number of runs that could be performed), a selection 
process for determining a small number of key markers for validation was required. 
Furthermore, not all DEGs identified had commercially available antibodies suitable for flow 
cytometric analysis or fluorophore conjugations that were compatible in the same panel. 
Markers were initially screened by systematic assessment based on magnitude of the relative 
change in expression, membrane localisation, and the availability of testing reagents. The final 
markers were selected based on novelty, lack of prior validation at the protein level, whether 
they were a previously suggested microglial marker, and/or were in contrast to or appeared 
crucial in light of other reports. A total of 10 markers were selected (from a total of 44 suitable 
candidates), to include one identified from the pilot study (Figure 5.2.7). 
  




Figure 5.2.7. A flow-chart demonstrating the selection process of markers for orthogonal 
validation. One thousand and sixty-nine DEGs identified (possible targets) were screened for 
membrane localisation (for simple flow cytometric validation), large RPKM difference, and 
availability of conjugated antibodies. Targets were selected based on whether they were novel with 
respect to describing microglial activation (Milr1) or without validation beyond the transcript level 
(Bst2, Fas, Lair1, Slamf1) [592-596], whether they were a previously specific or enriched microglial 
marker (P2ry12, Siglech) [308, 348], whether our data was in contrast to previous reports (Mertk) 
[597], or appeared crucial in light of other reports (C5ar1) [342]. The other marker (Cd44) was 
selected for testing based on results of a pilot study and its previous description as a possible 
microglial marker [558]. This diagram was generated using the PRISMA word document template 
[598]. Abbreviations: DEG – differentially-expressed gene, MAG – membrane-associated gene, 
MAP – membrane-associated protein, FC – flow cytometry. 




In line with published reports and an activated state, pro-inflammatory markers (Slamf1, C5ar1, 
Fas, and Cd44) were all upregulated at 4 hours following LPS challenge. In addition, a novel 
microglial associated transcript, Milr1 (a negative regulator of mast cell activation) and Bst2 (a 
previously validated marker of late activation) were elevated by 18 hours. In contrast, 
constitutively expressed microglial genes, including homeostatic genes, (e.g. P2ry12, Siglech, 
Mertk, and Lair1) were downregulated at the early timepoint. RPKM values for the markers are 
shown in scatterplots within Figure 5.2.8. 
In general, qPCR analysis validated the transcript-level changes observed at each timepoint, 
confirming resolution and return to baseline levels by 2 weeks (Figure 5.2.9). However, markers 
such as C5ar1 and Siglech did not reach statistical significance despite following the same trend 
(with regards to up- or downregulation). 
 
 





Figure 5.2.8. Changes in expression of markers selected for orthogonal validation, as determined by mRNA-Seq of microglia, during EIU. 
RPKM values show how expression of selected markers change during the course of EIU (n = 5–10). *** = p ≤0.001, **** = p ≤0.0001 (comparisons to 
naïve). For statistical analysis, ANOVA (with FDR step-up correction) was performed on the full mRNA-Seq dataset.
*** *** *** 
**** 








Figure 5.2.9. qPCR validates microglial transcriptomic changes, identified by mRNA-Seq, at the gene-level. Remaining cDNA from 600 
microglia used for bulk mRNA-Seq was used for qPCR validation with Taqman probes. Fold-changes (FC) relative to the naïve baseline are shown for 
each of the 10 selected markers, demonstrating changes in expression during the course of EIU. For statistical analysis, One-way ANOVA with Tukey’s 
post-hoc test was used. * = p≤0.05, **** = p≤0.0001, ns = not significant (n = 3).
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With the transcripts validated at the gene-level, validation at the protein level was then required 
by utilising flow cytometric assessment. Increased expression of SLAMF1, MILR1, C5AR1, CD44, 
BST2, and LAIR1 was observed at 18 hours post-injection (Figure 5.2.10). Furthermore, 
differences in the proportion of marker-positive cells were evident, with C5AR1, CD44, and BST2 
upregulated in the majority of microglia (>50%), in contrast to the other markers which were 
elevated in a smaller fraction (<20%) of cells. Whilst P2RY12 was highly expressed in naïve 
microglia (>80%), no change in expression in response to LPS was observed. Similarly, low-level 
SIGLECH, MERTK, and FAS expression in naïve populations remained unchanged and 
restricted to a small percentage of the microglia (<10%). The upregulation of CD44 was also 
confirmed in retinal flatmounts at 18 hours post-injection using fluorescence microscopy 
(Figure 5.2.11). 
Expression of P2RY12 and SIGLECH was compared between microglia and CD45+ cells, as both 
of the former are previously suggested markers that differentiate microglial populations from 
other immune cells [308, 348]. Flow cytometric analysis clearly demonstrates that both markers 
are equally expressed on some CD45+ infiltrating cells and microglia, indicating these markers 
exhibit poor specificity for retinal microglia during the acute response (Figure 5.2.12). 
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Figure 5.2.10. Changes in protein expression of selected markers in microglia, as determined using flow cytometry, over a time-course of 
EIU. A, C) A representative flow cytometric histogram is shown for the 10 selected markers B, D) in-line vertically with matching scatterplots of the 
aggregate flow cytometry data summarising the percentage of microglia positive for each marker at each timepoint. Gates were drawn with the 
assistance of fluorescence minus one (FMO) controls (light blue). For statistical analysis, One-way ANOVA with Tukey’s post-hoc test was used. ** = 
p ≤0.01, **** = p ≤0.0001, ns = not significant (n = 8).




Figure 5.2.11. Confocal-laser scanning microscopy highlights upregulation of CD44 in 
microglia at peak EIU, compared to naïve controls. Separate channel images and a merge 
highlight the upregulation of CD44 and colocalisation with the tdTomato signals from microglia. 
Scale bars = 30 µm. 





Figure 5.2.12. Flow cytometric analysis demonstrates P2RY12 and SIGLECH expression on 
CD45+ tdTomato- non-microglial immune cells (blue) and CD45lo tdTomato+ microglia 
(red) at 18 hours EIU. The gating strategy to generate these plots is as described previously (cells, 
singlets, live cells, CD45+). 
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5.2.4 Stratifying Microglia using C5AR1 Identifies Both Generalised 
and Restricted Microglial Responses 
Recent reports show that C5ar1 was one of several markers that was enriched in a subset of brain 
microglia (identified by sc-mRNA-Seq data) responding to systemic LPS challenge in vivo [342]. 
Furthermore, mounting evidence from numerous reports identify heterogeneity in the 
microglial response during other pathological states [340, 341, 344, 586]. We therefore examined 
whether stratifying microglia based on C5AR1 expression would delineate differences in the 
markers selected for validation, highlighting specificity to this subset of C5AR1-expressing cells 
or generalised expression across the whole population of microglia. 
Microglia were stratified into three main groups: C5AR1neg, C5AR1lo, and C5AR1hi. The C5AR1-
expressing microglia were sub-stratified based on whether the C5AR1 expression was equivalent 
to microglia observed within a naïve mouse (C5AR1lo) or whether expression was elevated 
(C5AR1hi; Figure 5.2.13a). C5AR1hi expression correlated to the extent of immune cell (CD45+ 
tdTomato-) infiltrate within the retinas and represents a potential microglial marker for disease 
scoring (Figure 5.2.13b). 
Flow cytometric analysis compared expression of the other surface markers in C5AR1neg and 
C5AR1hi subsets, as two distinctive populations, in naïve and peak EIU retinas. Delineating the 
two populations on this basis demonstrates elevation of several markers (SLAMF1, FAS, MILR1, 
and LAIR1) which are restricted to the C5AR1-expressing microglia, including a marker that 
previously did not achieve statistical significance (FAS). In contrast, CD44 and BST2 were 
enriched within the C5AR1-expressing population but also expressed by a large proportion of 
the C5AR1neg microglia, thus representing more generalised markers of microglial perturbation 
(Figure 5.2.14).




Figure 5.2.13. Microglia can be stratified based on C5AR1 expression and this correlates with the amount of immune cell infiltrate. A) A 
histogram shows microglial C5AR1 expression in a fluorescence minus one (FMO) control (blue), naïve retina (purple), and at 18 hours EIU (orange). 
Microglia can be subsequently classified on whether they are C5AR1-, C5AR1lo (equivalent to positive populations in the naïve retina), or C5AR1hi 
(expression above the baseline level observed in a naïve retina). B) Immune cell infiltrate correlates with C5AR1hi expression in microglial populations 
(p = 0.0298). For statistical analysis, Pearson’s test was used.




Figure 5.2.14. Stratifying microglia using C5AR1 expression identifies both exclusive and generalised responses to LPS in vivo. A) Stratifying 
microglia into C5AR1- and C5AR1hi identifies changes in cell-surface protein expression that are exclusive to C5AR1-expressing microglia, B) but also 
changes in proteins which are generalised microglial responses (not exclusive to, but somewhat enriched in, the C5AR1-expressing microglia). For 
statistical analysis, One-way ANOVA with Tukey’s post-hoc test was used. **** = p ≤0.0001, ns = not significant.




Having confirmed the EIU kinetics as synonymous to prior work, it was then possible to 
investigate changes to the microglia using a variety of techniques. Confocal microscopy 
demonstrated an amoeboid-to-ramified transition in morphology which broadly corresponds 
(but is not exclusive) to an activated state. This then enabled investigation of the microglial 
transcriptome at different stages of their activation with LPS. 
Single eye mRNA-Seq revealed inflammation-responsive transcriptional changes in retinal 
microglia following LPS simulation which resolve within two weeks, confirming the potential 
for these cells to reset their homeostatic state. Hierarchical clustering of the 1,069 DEGs 
highlights a consensus group of downregulated genes at both 4- and 18 hours EIU (black box) 
but reveals a highly plastic transcriptome of upregulated genes (brown and yellow boxes, Figure 
5.3). It calls into question the validity of curated lists of “microglia activation” genes as their 
expression may be time dependent in addition to stimulus dependent. This highlights a need 
for further stratification of gene groups based on the kinetics of microglial activation in addition 
to existing stratification measures (such as exact model/stimulus, or “acute/primed microglia” 
groups as determined by co-expressional meta-analyses). This is further evidenced by multiple 
examples of altered pathways at only 4- or 18 hours EIU, but not at both timepoints. 
Nonetheless, our data was also in agreement with curated lists for transcript-level data, whether 
these be microglial-specific lists (as published by other groups) or generalised pathways relating 
to changes in immune function or signalling (GO terms, KEGG pathways, and IPA canonical 
pathways). 
As expected, due to the generally promiscuous role of many proteins (or even isoforms), some 
significant pathways were identified which do not necessarily translate perfectly into the 
microglial inflammatory context of our dataset (e.g. dendritic cell maturation, FAT10 cancer 
signaling, and osteoarthritis). However, most of these involve changes in immune cell function, 
which is what our data shows, and highlights why pathway analysis should always be interpreted 
with caution as a broad method of interrogating the data. In support of this, alterations to the 
TREM1 signaling pathway were observed, and published reports already indicate that microglia 
signal via the TREM2 pathway [599-601]; it is likely that overlap between the TREM pathways 
allowed for identification of enrichment of the TREM1 pathway (whereas no such pathway for 
TREM2 currently exists) – it is one example highlighting one of the most pertinent challenges 
surrounding pathway analysis. 
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Orthogonal validation by qPCR of the 10 markers, selected as they represent key and novel 
transcripts, confirmed the mRNA-Seq findings. However, altered expression of some of these 
membrane-associated markers did not translate to changes at the protein level as determined 
by flow cytometry. In part, this may reflect the presence of intracellular protein that our flow 
cytometric approach did not detect or represents genuine discrepancies between the 
transcriptome and proteome as these are not always in direct proportion [602-604]. Our results 
emphasise caution in reading out mRNA-Seq results alone as a true representation of the cell’s 
activity and highlight the need for orthogonal validation. Despite this, the single eye mRNA-
Seq approach identified key and novel transcriptional changes which informed subsequent 
testing on a smaller number of markers via low-throughput approaches. Ideally and for future 
work, use of integrated ‘omics’ (epigenetics, transcript, protein, and other data [e.g. 
phosphoproteomics]) would enable investigation of multiple different levels of cellular state, 
and for cross-comparison to identify key overlapping pathways or discrepancies where the use 
of low-throughput orthogonal approaches for further investigation could be warranted. 
Cutting-edge ‘omics’ techniques can currently couple two or three different assays in tandem, 
with some techniques incorporating single-cell resolution for the most powerful analysis [605-
609]. Single-cell resolution with one or several of these ‘omic’ approaches would greatly enhance 
the understanding of cellular heterogeneity within the tissue. Despite this, ‘omics’ approaches 
currently have limited capacity to decipher information in the time dimension, and as existing 
assays are terminal it is not possible to follow the same cell or tissue across time with these 
techniques. Nonetheless, mRNA-Seq currently remains the most widely used high-throughput 
and sensitive approach used to decipher molecular changes occurring in cells and enables the 
sampling of vast amounts of information about the cellular phenotype. 
Irrespective of when the transcript was perturbed, no significant changes were identified at the 
protein-level by 4 hours EIU. For example, multiple markers (SLAMF1, C5AR1, FAS, CD44, 
LAIR1) were changed at the transcript level by 4 hours EIU, but no change was observed using 
flow cytometry until 18 hours. This is likely explained by the delay between transcript generation 
and translation (and subsequent folding and transport to the plasma membrane). 
Conflicting with previous reports investigating LPS-responses and EAE, we did not find 
significant down-regulation of P2RY12 upon microglial activation [342, 352]. In EAE, the 
microglia exhibit a chronic inflammatory state different to the acute LPS response, whilst the 
report investigating the LPS response used a systemic dose 400 times greater than our own local 
dose and had an endpoint 24 hours post-injection which could explain the discrepancy. We 
suggest microglial loss of P2RY12 as context-dependent, for example when subject to a 
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significant immune stimulus or persistent inflammation – it could be utilised as one of several 
markers to classify the severity/persistence of inflammation. P2RY12 has been classified as 
important in microglial motility and response, so perhaps its downregulation is part of a 
negative feedback mechanism to help inhibit excess and/or persistent inflammation [610]. 
Our report conflicted with previous evidence that suggested MERTK was upregulated in 
microglia following LPS stimulation [597]. This study was performed in the BV-2 microglial cell 
line; it is generally well-recognised that immortalised cell lines are not necessarily 
representative of an in vivo environment because: 1) they have been modified as part of the 
immortalisation process and 2) they grow in culture conditions which are very different to an 
organ where multiple cells and the extracellular matrix (ECM) interact in a dynamic fashion as 
part of a complex microenvironment. Other transcriptomic studies have shown that freshly-
isolated microglia and primary cultures are more similar to one another and that the BV-2 cell 
line, whilst useful, is not completely synonymous in responses to microglia or microglial 
primary cultures [611]; most strikingly, there is loss of TGF-β secretion in the BV-2 cells which 
has previously been characterised as critical to the microglial programme [308]. It should also 
be noted that the study involving BV-2 cultured the cells for 24 hours, as opposed to our 
timepoints of 4- and 18 hours, that BV-2 cells have been characterised as predisposed towards 
more activation generally, and that these factors may also explain the discrepancy [597, 611]. In 
macrophages, expression of MERTK was required for resolution of inflammation at 72 hours in 
a peritonitis model in vivo. MERTK expression was also observed in vivo in microglia but only 
by 3 days post-ischaemia; its blockade resulted in better clinical outcomes [612, 613]. Lastly, 
missense mutations in MERTK can cause a retinal degenerative disease called retinitis 
pigmentosa [614]; this may link to aberrant microglial regulation. Other recent work suggests 
MERTK is important for efferocytosis of dying cells and promoting immune tolerance. Blockade 
of MERTK results in STING activation (a pathway associated with autoinflammation) and IFNβ 
secretion via a purine receptor-dependent process, suggesting an important role in negative 
regulation of an immune response [615]. Overall, this suggests that downregulation of MERTK 
enables greater microglial responses, and that its upregulation may occur at a later stage of 
inflammation (e.g. 3 days EIU) to assist in resolution. Short-term loss of MERTK has been shown 
to enhance neurogenesis [616], although it is evident (as exemplified by the missense mutations) 
that long-term loss is detrimental as MERTK represents an immune checkpoint. 
The data shows that three previously suggested markers (P2RY12, CD44, and SIGLECH) exhibit 
poor specificity for microglia. The studies suggesting P2RY12 as microglial-specific did so based 
on bulk mRNA-Seq data, where different proportions of immune cells positive for P2RY12 would 
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result in differential RPKM (or other normalised count) values. As only a proportion (~30%) of 
various immune cell types were observed as P2ry12+, compared to a large fraction (~80%) of 
microglia, this explains why it was previously identified and suggested as a microglia marker; 
transcript-level work will always identify it as an enriched marker, highlighting why protein-
level validation is essential before it is confirmed as a specific marker. Furthermore, it has 
already been reported that loss of P2RY12 on the microglia can occur in some contexts, making 
it more suitable as a type of activation marker (severe and/or persistent inflammation), even if 
this loss was not observed in our study [342, 352]. 
For CD44, the poor specificity is because the microglia do not retain a CD44lo signature, 
meaning that CD44lo cells in the retina observed during inflammation (that were hypothesised 
as microglia in another report [558]) are infiltrating immune cells and not microglia. 
In the case of SIGLECH, we did not find evidence of expression at the cell surface in more than 
a small proportion of microglia. This could be a reflection of possible intracellular protein not 
measured by our assay, or poor correlation between transcript and protein in this example. It 
could also represent poor binding by the antibody; for example, if the microglia express a 
different isoform to the receptor it was generated against or our positive control to test the 
antibody (spleen preparations containing SIGLECH+ dendritic cells). 
Nonetheless, with the Cx3cr1CreER:R26-tdTomato line, it remains possible to validate potential 
markers assuming the line retains specificity for microglia across disease contexts; the hunt 
continues. 
Flow cytometric analysis confirmed and validated some of the transcriptional changes but also 
found that the differences were enhanced, and an additional marker (FAS) was identified as 
significantly different, when microglia were first stratified based on their C5AR1 expression as 
suggested via a transcripts-led report [342]. The percentage of C5AR1hi-expressing microglia also 
had a moderate positive correlation with the number of infiltrating immune cells, representing 
a potential score for disease – with greater microglial activation comes greater inflammation 
and immune cell infiltration. Conversely, when microglia are depleted inflammation within the 
retina is considerably reduced if not completely prevented [390]. C5AR1 is a G protein-coupled 
receptor (GPCR) for C5a (generated as part of the complement cascade), that enables 
chemotaxis of myeloid cells towards an area of complement activation via one of the three 
pathways [617, 618]. C5AR1 expression is also controversial, with models of spinal cord injury 
showing an absence of C5AR1 resulting in clinical improvements in the early stages, but an 
ultimately worsened outcome later-on [619]; in contrast, C5AR1 loss resulted in clinical 
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improvements in AD models, showing how its expression and the role of microglia (and 
neuroinflammation) in different pathologies can be potentially beneficial, harmful, or both 
depending on context and timing [366]. 
Nonetheless, further work could be performed to validate changes in expression in addition to 
determining the cellular localisation of different proteins (using immunohistochemistry). 
Quantification of fluorescence (in addition to sampling of a greater volume and performing 
statistical analysis) would enhance the validity and robustness of the microscopy data. 
Furthermore, morphological analysis of microglia across EIU would provide insight; 
unfortunately, the tdTomato fluorescence was discontinuous within the microglia and this 
meant that pre-processing required for morphological analyses such as frac-lac and sholl 
analysis (e.g. skeletonisation) was unsuccessful. Without an alternative marker (such as IBA-1) 
it would not be possible to perform this type of analysis in a robust fashion. 
With C5AR1 stratification, markers which were exclusive to the C5AR1-expressing microglia 
were identified (SLAMF1, FAS, MILR1, and LAIR1) in addition to generalised markers which were 
slightly enriched but certainly not exclusive (CD44 and BST2). Other reports suggest that C5AR1 
is needed for microglial polarisation to pro-inflammatory states, with its knock-out improving 
outcomes in an AD model [366]. Polymorphisms in complement components also associate 
with AMD in addition to evidence for complement association with drusen, potentially 
implicating microglia as key players in neuronal loss when homeostasis is perturbed [620]. 
Furthermore, microglial heterogeneity has already been reported in AD disease, light-damage 
models, EAE, and in response to LPS stimulation in vivo [340-342, 344, 586]. Understanding 
microglial heterogeneity, permitting identification of changes which are exclusive to 
subpopulations (which are yet to be fully realised), is critical for developing targeted therapies. 
Further work to understand the differences between C5AR1+ and C5AR1- microglia could 
potentially uncover therapeutic targets but also assist in understanding the mechanisms of 
microglial changes; ergo, whether they are responding to a stimulus or happen to be in the 
microenvironment. 
Expressed by C5AR1+ microglia, the protein SLAMF1 plays a role in activation of lymphocytes. 
In contrast, MILR1 and LAIR1 act as inhibitory receptors for activation. This implies 
simultaneous activation alongside accumulating inhibitory factors which could act as part of a 
negative feedback loop to prevent persistent inflammation. Work in natural killer (NK) cells has 
shown that a lack of inhibitory receptors leads to hyporesponsiveness (to activating factors) as 
a possible mechanism to present or reduce auto-aggression/possible autoimmunity as these 
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cells lack an “off” switch [621]. Furthermore, inhibitory receptors co-localise with the activating 
receptors in the immunological synapse of NK cells [622]; it is plausible that the expression of 
inhibitory receptors by microglia and our observation of them on the cell surface enables greater 
activation of the microglia, akin to that of the NK cell. This could explain their presence during 
the inflammatory response (in addition to the possible negative feedback loop). 
Furthermore, persistent FAS expression could lead to formation of a death-inducing signalling 
complex (DISC), inducing apoptosis in microglia. Contrastingly, other studies have identified 
FAS as important in the resolution of inflammation via apoptosis-independent pathways and 
that these immune cells are resistant to FAS-mediated apoptosis [623]. 
Taken together this suggests that the C5AR1+ microglia are actively engaging with infiltrating 
immune cells, acting as “responders” presumably through direct LPS stimulation to TLR4; this 
is supported by other reports which showed that C5AR1 knock-out prevented lineage 
commitment of microglia to pro-inflammatory states in an AD model [366]. These are likely 
analogous to the DAM/RAM observed in other disease states/models. 
On the other hand, BST2 has functions involved in antiviral responses and is typically associated 
with activation through IFNα/β [624, 625]; IFNβ was upregulated by microglia during EIU, 
implying autocrine/paracrine signalling. There is no data from these experiments to distinguish 
whether the C5ar1+ or C5ar1- microglia (or both) were secreting IFNβ and hence the exact 
signalling process and mechanisms are unclear. 
CD44 is a receptor for hyaluronic acid, osteopontin, collagens (components of the ECM) and 
matrix metalloproteinases [626]; it is associated with lymphocyte activation and homing [627]. 
Therefore, the C5AR1- microglia may represent “active bystanders” that aren’t directly engaged 
with LPS, but due to changes in the microenvironment (ergo paracrine signalling induced by 
the “responding [C5AR1+] microglia”) enhance their general immunological defence and 
surveillance programmes (e.g. through enhanced expression of antiviral proteins (BST2) and 
receptors involved in homing and interaction with the ECM [CD44]) to better detect further 
damage and respond more quickly as a mechanism of ultimately protecting the tissue. 
Unpublished adaptive optics imaging data from my Supervisor, Colin Chu, has shown that 
microglia within the tissue can interact with immune cells adhering to the endothelium of blood 
vessels. It is plausible that molecules such as CD44 permit microglial interaction with the vessels 
and enable them to assist in extravasation of peripheral immune cells into the tissue (but also 
to signal endothelium with much greater efficiency due to spatial proximity) and could at least 
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partially explain why there is considerable perivascular sheathing caused by microglia in models 
such as EAU (see Chapter VI). These are compatible with the notion that active inflammation 
or activation of a region of the retina would result in enhanced surveillance throughout the 
tissue (and possibly beyond) to allow for rapid elimination of infection. 
In summary, the data demonstrates that the homeostatic threshold of retinal microglia is reset 
following an acute inflammatory insult and identifies potential markers for delineating the 
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Chapter VI: Future Direction s 
Prior to the work presented in this thesis, it was known that microglia play a key role in the 
maintenance of homeostasis within the ocular compartment, that a fine balance exists between 
immune activation and regulation, and that new transgenic models had recently emerged which 
were proposed as sensitive and specific for microglial tagging to permit their investigation. 
However, comprehensive validation of the transgenic models and specific investigation into the 
microglial transcriptome in vivo during inflammatory states had not been performed 
comprehensively. Likewise, many proposed/hypothesised microglia markers had yet to be 
tested for validation (or invalidation) at the protein level. Critically, it was unclear whether 
homeostasis was permanently altered in response to autoimmune/inflammatory stimuli, or 
whether it can reset with time as proof-of-concept to reset immune states of uveitis or other 
patients with inflammatory disorders. 
The data presented in this thesis demonstrates how development and optimisation of a low cell 
number mRNA-Seq platform, using FACS isolation, permits transcriptomic assessment of 
immune cells within the retina. Proof of concept validation using naïve microglia, and CD4+ T 
cells isolated during EAU, confirmed this approach could be applied to the sequencing of 
microglia isolated from single inflamed eyes (Chapter III). 
To investigate microglia, use and validation of the latest transgenic models with temporal and 
conditional gene targeting for microglial specific tagging was required (the Cx3cr1CreER:R26-
tdTomato mouse strain). Furthermore, tamoxifen administration regimes for inducing 
recombination were compared and a shortened local (topical) approach was found to be 
superior, validating the sensitivity and specificity of this mouse strain for microglial 
identification during inflammation within the eye (Chapter IV). 
With both the transcriptomic pipeline and microglial identification optimised, it was then 
possible to specifically interrogate the transcriptome of retinal microglia during inflammatory 
states. mRNA-Seq data acquired using the EIU model shows how LPS induces an acute and 
highly-plastic transcriptional response in microglia that resets by 2 weeks. A consistent set of 
downregulated homeostatic microglial genes, in agreement with the literature, was observed 
across the microglial activation stages. Furthermore, microglial subtypes could be stratified 
during the response via C5AR1 expression (Chapter V). 
In summary, the over-arching aim of ultimately determining the transcriptional changes 
occurring in microglia during intraocular inflammation was achieved, highlighting that during 
acute inflammation the microglial homeostatic state is restored post-inflammation.  
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6.1 Single-cell mRNA-Seq 
Before a comprehensive analysis of the microglial transcriptome could be initiated, optimisation 
of a suitable mRNA-Seq pipeline was required. With approximately 1,500 microglia present in 
the mouse retina, and lower recovery when utilising FACS, a specialist pipeline that could 
process ultra-low inputs was required. To this end the SMART-Seq v4 Ultra Low Input RNA Kit 
by Clontech was selected. Several optimisations including cycling conditions, sequencing flow 
cell utilised, and staggered preparations were required to ensure a high success rate for sample 
preparation. Furthermore, as part of other experiments in the lab, the experimental pipeline has 
been scaled to even lower numbers of cells (<50). 
Using various QC/QA metrics, the data highlights both a high accuracy in base calling by the 
sequencer but also quality input material as the results dependent on that (i.e. alignment rates) 
meet the gold standard as well. Furthering this, optimisation of the analytical pipeline and 
methods of data visualisation enabled key data to be displayed in a format more easily 
interpretable to others. Additionally, power analysis was required to inform the suggested 
number of biological replicates beyond the general considerations and suggestions presented in 
various technical papers, many of which were based on cell lines or other in vitro work. In all, 
optimisations were successful and have resulted in the generation of high-quality data and 
publication of our approach, both of which are available in public repositories. 
Nonetheless, mRNA-Seq has the major limitation that it samples the average expression profile 
of the input material and cannot account for heterogeneity. Microglial heterogeneity in 
responses during disease states are becoming increasingly recognised [340-342], and the data 
presented in Chapter V on C5AR1 expression delineating microglia into what we term 
“Responders” and “Active Bystanders” also highlights this. Specific targeting of the microglial 
subsets responsible for disease or damage would be important to help restore tissue 
homeostasis. Two main technologies are used for the in vivo isolation of cells for sc-mRNA-Seq 
pipelines: 1) FACS and 2) specialised microfluidics devices (e.g. Drop-Seq, 10x chromium, and 
the Fluidigm C1) [628]. 
Systematic review of the published literature on scRNA-Seq protocols was performed to identify 
which protocol/s would be suitable for use with locally available equipment. Ultimately, three 
key criteria were used to determine which method to utilise: 1) low cost (utilisation of off-the-
shelf reagents as opposed to kits where there is a large mark-up on price), 2) being FACS-ready 
(i.e. no requirement for the use of a specialist microfluidics device or other equipment currently 
unavailable locally), and 3) barcoding availability (to allow for pooling, which would greatly 
Chapter VI: Future Directions 
197 
 
reduce the time and cost implications of the experiment, allowing for much larger numbers of 
samples to be ran in parallel). Over 30 protocols were identified which allowed for low-level 
mRNA detection (ergo single-cell and ultra-low cell number mRNA-Seq) [629, 630]. 
Of the protocols identified, a number passed the latter two criteria, but many technical papers 
comparing methods highlighted three methodologies which clearly were of enhanced 
sensitivity and correlation (between technical replicates) than the others: cell expression by 
linear amplification and sequencing 2 (CEL-Seq2) [631], QUARTZ-Seq2 [632], and adapted 
versions of the Smart-Seq2 protocol (on which the SMART Seq v4 kit by Clontech, used for the 
mRNA-Seq data presented in this thesis, is based) [518] to include barcoding [633]. Whilst none 
of these were compared head-to-head, CEL-Seq2 was shown to be more sensitive (defined as 
the number of genes detected from single cells) than a non-barcoding version of Smart-Seq2 
[631]. As they all appeared to (nonetheless) be reliable methods that were highly cited (or at the 
least the original versions of these protocols were), the main deciding factor for the protocol 
selected for use was cost. Using a Smart-Seq2 with barcoding or a QUARTZ-Seq2 approach was 
estimated to cost a total of £7,000 for a single run of a 384-well plate for single-cell sequencing 
(based on the best available estimators of cost and internal facility costings) whereas the CEL-
Seq2 protocol was estimated at £3,100 per run. The primary reason for the discrepancy was the 
high cost of commercial library preparation kits (Illumina’s Nextera XT kits) that the former 
two protocols used, whilst CEL-Seq2 used exclusively off-the-shelf reagents. For reference, use 
of the Illumina recommended pipeline for single-cell mRNA-Seq (utilising the Clontech SMART 
Seq v4 kits and Nextera XT DNA Library preparation kits) [516] was estimated at costing £61,000 
for an equivalent experiment which was deemed unaffordable. 
Additionally, the protocols had multiple pros and cons. The main considerations for CEL-Seq2 
were that it possessed strand specificity (which few other protocols did), higher sensitivity, but 
importantly that it would only sequence the 3’ fragment of the mRNA; the latter means that it 
would be unsuitable for sequencing of a poorly-annotated genome or for transcript/splicing 
analysis. The current mouse genome assembly, mm10, is well-refined and based on the C57BL/6 
background meaning this limitation is not an obstacle to this continuing research. Furthermore, 
new technologies such as Nanopore [634] (which is available at the University of Bristol) are 
more suitable for transcript analysis because they provide long reads of direct mRNA molecules 
(as opposed to the short reads and subsequent alignment using Illumina sequencing). 
Therefore, experiments requiring transcript analysis would likely be performed using nanopore 
instead because of its improved validity. 
Chapter VI: Future Directions 
198 
 
Initial experiments wanted to confirm populations that would delineate nicely on a t-distributed 
stochastic neighbour embedding (t-SNE) plot as positive controls to validate the pipeline, in 
addition to generating interesting data on microglial heterogeneity. Barcoded 384-well plates 
were prepared, and CD4+ T cells isolated from spleen, naïve retinal microglia, retinal microglia 
18 hours post-EIU, and GFP+ cells from the liver of a Cx3cr1GFP heterozygote (the majority of 
these cells will be Kupffer cells, but a small proportion of T and other cells was anticipated based 
on previous flow cytometric characterisation of this organ) were sorted into single wells. It was 
hypothesised that the microglia and Kupffer cells would map to a similar 3D space (but 
nonetheless segregate), and the T cells would be located elsewhere but potentially further 
delineated by subset (e.g. naïve, effector, memory, etc). The samples were then barcoded, 
pooled, and then processed for mRNA-Seq. A library of lower than expected yield was generated 
in 1 of the 4 pools (each comprising 96 cells), which means that further optimisations are 
required before performing sequencing (Figure 6.1.1). Discussions are underway with the 
protocol Authors about possible modifications and improvements to improve the yield and 
success rate of the experimental pipeline (e.g. inclusion of a lysis reagent, such as nonyl 
phenoxypolyethoxylethanol-40 [NP-40], and an RNase inhibitor to the first mix cells are sorted 
into). 
Further to sc-mRNA-Seq, as part of systematic review several protocols were identified which 
incorporate multi-omics approaches, such as transcriptomics with methylation (epigenetic) 
status and single-cell resolution [605-609]. It remains possible that once sc-mRNA-Seq is 
optimised that even more advanced techniques could be attempted to broaden the range of 
information on the cellular state that be acquired with single-cell resolution simultaneously. 
  





Figure 6.1.1. Agilent Bioanalyser output of libraries generated through the CEL-Seq2 
protocol. Barcoded single cells, sorted into a 384-well, were pooled (96 cells per pool) into 4 
samples for processing. Post-library generation and cleanup, these were then analysed on an 
Agilent 2100 Bioanalyser high-sensitivity DNA tapestation. (Left) electropherogram image with 
the ladder indicate a small positive peak around 130 bp (expected peak at 200-400 bp) for one of 
the four samples in the experiment. (Right) the gel trace for the positive sample indicates low 
yield. The ladders can clearly be observed at 25 and 1500 bp in green and purple, respectively. 
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We remain hopeful that this pipeline can generate novel and interesting datasets on retinal 
microglia. It will be especially interesting to observe how the two different niches of microglia 
[341] react during disease states, if it is differential due to their inherent differences, and to 
ultimately map the kinetics of microglial activation in uveitis models through pseudotime 
analysis. With reliable and robust models such as EIU, and sampling of microglia (from different 
mice) at different timepoints it may be possible to map the kinetics of microglial activation 
using real time and overcome some of the existing limitations that pseudotime analysis (of a 
sample at a single time-point) currently exhibits, albeit acknowledging that acquired cells from 
different timepoints were not from the same mouse. Furthermore, sc-mRNA-Seq of various 
myeloid cells, in addition to microglia, would help to highlight transcriptional differences 
between these groups and whether they are genuinely different or distinguishable (without fate-
mapping or chimeras) during inflammation to identify possible microglial markers with more 
precision. Genome annotation to include tdTomato transcripts could act as a positive control 
for microglial identification in the context of these datasets. 
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6.2 Digital Cell Quantification and Demultiplexing of 
Cells and Cell Subsets 
A novel analysis strategy, called digital cell quantification (DCQ), was recently described [635]. 
It involves using bulk mRNA-Seq data generated from known specific cell types and then 
applying it to mRNA-Seq data generated from a mixed population of cells. This then enables 
delineation of the gene expression values into an estimated representation of each cell type 
within a given sample. For example, in the original publication it utilises transcriptomic data 
generated by the ImmGen project for 213 different immune cells (grouped into stem cells, B 
cells, monocytes, macrophages, granulocytes, NK cells, Tαβ cells, NKT cells, Tγδ cells, and 
dendritic cells – they originated from a variety of tissues, stimulations, and time-points and were 
isolated using FACS [418]) to show and validate predicted changes in immune cell proportions 
within the lung during influenza infection. It was able to effectively predict changes in immune 
cell subsets that were already known to change but additionally provide novel insight into 
dendritic cell subtypes and their possible roles in the infection response. 
This type of approach holds various advantages. For example, mRNA-Seq on immune cells 
isolated from patient blood could enable a better understanding of how specific immune cell 
subsets change over the course of treatment or disease, and it may assist in disease classification 
if certain subsets or gene expression profiles associate strongly with disease. A simple test of 
robustness could be to ask what cell populations are predicted in a sequenced sample of known 
cell type to observe how the algorithm performs as a form of positive control. In the case of the 
CD4+ T cell data (Chapter III), analysis highlights high predictive scores (on the raw data) for 
developing T cells, a large number of CD4+ T cells, and one CD8+ T cell signature (Figure 6.2.1). 
The over-representation of a CD8+ T cell signature, Tγδ signature, and developing T cell 
signatures is likely due to overlap in their expression signatures with CD4+ T cells. Nonetheless, 
this highlights the algorithm as accurate in identifying the data as derived from CD4+ T cells. 
  




Figure 6.2.1. Digital Cell Quantification (DCQ) highlights an abundance of T cell signals 
in the CD4+ T cell dataset. The DCQ algorithm [635] was ran on the raw data obtained from 600 
CD4+ T cells isolated from naïve spleens, and EAU peak disease (D25) spleens and retinas. Output 
values in red represent high predictive scores; blue represents low predictive score. An abundance 
of Pre-T cell, CD4+ T cell, and one Tγδ and CD8+ T cell signatures were observed. An absence of 
other signals (from major immune cell types and stromal cells) was observed. Output values which 
differ by ≥2 SDs (compared to the overall SD of all samples) are shown. Basic cell types are labelled 
to the right of the corresponding rows. Additional abbreviations: NVE – naïve, LN – lymph node, 
SP – spleen, BM – bone marrow, LV – liver. For a full explanation of the cell type labels, see the 
Immunological Genome Project data files and metadata [418] (n = 2–8). 
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When performing the same analysis but subtracting signals from the control samples (the 
recommended analysis strategy by the Authors; in this case, the naïve samples were the 
controls) this describes how the cells change from the baseline state in comparison to the cell 
types in the reference database. This is because our sample contains a known population of 
CD4+ cells, and not a mixture. Multiple NKT and CD8+ effector signals were overrepresented in 
the EAU retinas but not the EAU spleens (Figure 6.2.2). This suggests a transition within the 
population to NKT and CD4+ cytotoxic T cells (the CD8+ signatures, in what are known/sorted 
CD4+ T cells) – both of which are recognised as associated with autoimmune conditions [636-
639]. It could also be that there is skewed representation of these cellular populations in the 
retinas, and that they for some reason are selectively retained or recruited to the eye during 
EAU and this accounts for the observation. NKT cells appear to be protective against 
autoimmunity in most, but not all, cases of autoimmune disease [640-642]. Additionally, 
somewhat conflicting results were obtained about B cell, dendritic cell, monocyte, and stromal 
cell signatures: some of the signatures appear enriched within EAU spleen samples, and others 
in EAU retinas, and both predictive enrichment and depletion of similar cell types can be 
observed in the same samples. It is unclear what this means but it highlights inherent variability 
and possible noise present within the system – and a lack of clarity about what is or is not 
significant. Nonetheless the DCQ algorithm was able to predict consistent changes to CD4+ T 
cell populations that are already known within the autoimmunity field. 
Despite these strengths, the ImmGen reference dataset currently contains no information on 
microglia for analysis (a compendium bias) and it is coarse in identification because it has little 
ability for subtype discrimination. Additionally, it provides a single readout of representation of 
that given cell-type without any indication of deviation, and there is no clear cut-off for what 
constitutes a significantly different representation (in the dataset an arbitrary cut-off of ≥2 SDs 
from the overall dataset was used). 
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Figure 6.2.2. Digital Cell Quantification (DCQ) highlights over-representation of NKT 
and T effector cell signatures. The DCQ algorithm [635] was ran on the data processed (as per 
the recommended analytical strategy) obtained from 600 CD4+ T cells isolated from naïve spleens 
(A3S, B1S), and EAU peak disease (D25) spleens (A2S, B3S) and retinas (A2L–C1R). Output values 
in red represent high predictive scores; blue represents low predictive score. Output values which 
differ by ≥2 SDs (compared to the overall SD of all samples) are shown. Basic cell types are labelled 
to the right of the corresponding rows. Additional abbreviations: NVE – naïve, MEM – memory, 
LN – lymph node, SP – spleen, BM – bone marrow, LV – liver. Over-representation of multiple NKT 
and CD8+ effector cell signatures were observed, with a loss of multiple naïve CD8+ T cell 
signatures in EAU retinas. The naïve and EAU spleen signatures were found to be highly similar 
through this analysis. For a full explanation of the cell type labels, see the Immunological Genome 
Project data files and metadata [418] (n = 2–8). 
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Nonetheless, DCQ brings several other possible exciting prospects beyond the ImmGen data 
because it is modular and allows provision of your own reference dataset. This hypothetically 
enables quantification of any cell types or subsets present in the reference data provided. 
Unfortunately, there are no well-classified microglial subtypes currently (aside from the 
relatively poorly-fitting M1/M2 classification borrowed from macrophage field [158, 159]) let 
alone mRNA-Seq reference datasets of these hypothetical subtypes, and therefore analysis of 
them is currently not possible. However, CD4+ T cell subtypes are well-classified (primarily into 
Naïve, Th1, Th2, Th17, and Treg cells) and mRNA-Seq datasets on all these subtypes have already 
been generated [643]. Therefore, as the Th1/Th17 axis is critical to the disease mechanisms of 
EAU [1, 644], delineating subsets using the CD4+ dataset could generate novel insight. 
The results with DCQ were difficult to compare and contrast because of arbitrary cut-offs 
(determined by us) for what constitutes significance and an inability to perform robust 
statistical analyses, but it suggested over-representation of Th1, Treg, and Th17 signals in EAU 
retinas with a Th1/Treg signal in EAU spleens as compared to naïve (Figure 6.2.3). Optimisation 
of the number of input reference markers was required (<100 total reference genes worked best 
as a greater number of makers resulted in ceiling scores for many cell types. The markers were 
selected on the best enrichment for each specific group i.e. highest fold-change in favour of that 
subtype versus each of the other subtypes [10 per subtype in the case of the CD4+ subsets]). Due 
to the aforementioned limitations, comparing the data in a different manner to overcome these 
challenges could be helpful. 
Therefore, the DEGs identified previously with the ANOVA model (Chapter III; naïve vs. EAU 
spleen, naïve vs. EAU retina, EAU spleen vs. EAU retina) were taken and classified by which 
subtype upregulated group (i.e. relative specificity to a single CD4+ subset, as identified in the 
original paper generating the CD4+ T cell subset dataset [643]) they associated with. It was then 
possible to use statistical analysis to observe if any subset was over-represented in the DEGs 
through use of Fisher’s exact tests with FDR step-up p value correction (this mimics how 
pathway analysis is performed). The results of this approach generally agreed with the DCQ 
findings (Figure 6.2.4): that Th1, Th17, and Treg signatures were over-represented in EAU retinas 
compared to naïve spleens. It also indicated (in a head-to-head comparison not possible with 
DCQ) that Th1 and Treg were over-represented in EAU retinas compared to EAU spleens but not 
Th17; the Th17 signal was similar between EAU spleens and retinas. As expected, the naïve signal 
was most prominent in the naïve spleen. A lack of enrichment was observed in EAU spleens to 
naïve retinas and this is likely due to poor statistical power rather than lack of genuine difference 
(n = 2 in both groups for comparison). 





Figure 6.2.3. Digital Cell Quantification (DCQ) [635] identifies a prominent Th1/Th17 
signatures in EAU retinas, in addition to a natural Treg signature. EAU spleens and retinas 
were compared to naïve spleens in their expression signature for various CD4+ T cells subtypes 
using a dataset generated by Stubbington et al. [643]. Output values in red represent high 
predictive scores; blue represents low predictive score. nTreg cells were obtained from mice, whilst 
all other subtypes were derived from in vitro culturing conditions. The reference dataset includes 
replicates for each of the subtypes. Abbreviations: nTreg – natural Treg cell, iTreg – induced Treg cell. 




Figure 6.2.4. Differential gene expression analysis (DGEA) of “subtype upregulated” CD4+ 
T Cell subset genes highlights general agreement with Digital Cell Quantification (DCQ) 
results. Head-to-head comparisons between naïve spleen, EAU spleen, and EAU retinas was 
performed. Total numbers of differentially-expressed genes (DEGs) between group comparisons 
are indicated in brackets (all genes), with the percentage overlap into subtype upregulated genes 
indicated on the bars (n = 2–6). * = p ≤0.05, ** = p≤0.01. 
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As the spleen samples were prepared from eyes at peak EAU disease, it isn’t possible to 
extrapolate whether these changes preclude infiltration of T cells into the retina, represent 
changes occurring from T cells that recirculated from the retina, or both. However, the data 
suggests that T cells shift from a more Th17-like phenotype to a Th1-like phenotype in the retina 
at the peak/late stages of disease. In agreement, other recent sc-mRNA-Seq data also suggests 
that Th1 cells dominate the response in a spontaneous EAU model [561]. Whether this is a 
response to the microenvironment, interactions with microglia, both, or other reasons is 
unclear. However, evidence suggests that Th1 cells could differentiate from other CD4+ cell types 
(such as Th17) by inducing IL-27 expression in microglia via IFN-γ (see “Retinal Microglia and 
Homeostasis” Chapter I which describes IL-27 preventing Th17 lineage commitment and the 
formation of ex-Th17 cells). Does commitment to a more Th1-like phenotype help to drive or 
prevent further damage in the retina? As IL-27R knockout exaggerates autoimmune disease 
[410] this suggests that a more Th1-like phenotype might cause reduced damage in comparison 
to a more Th17-like phenotype. Most pertinently, is there a way to enhance the 
immunosuppressive environment? Further work could help to delineate the kinetics and 
changes across the stages of EAU, in addition to validation of the phenotypes using orthogonal 
approaches such as flow cytometry and immunohistochemistry (including iterative staining for 
an increased marker repertoire in stains). 
If in the future microglial subsets are modelled and mRNA-Seq data produced on them, it would 
become possible for retrospective analysis of multiple existing datasets generated from 
microglia. New analysis strategies similar in function to DCQ have since been developed which 
can infer estimated cell proportions in bulk-mRNA-Seq from cell subsets identified using sc-
mRNA-Seq data and may assist in bridging the gap between old and new [645, 646]. This could 
yield both rapid and novel insight into microglial lineage differentiation in various disease states 
and models because it could utilise a pool of readily-available data from mRNA-Seq repositories 
such as the NCBI’s GEO. Ultimately this could result in rapid expansion of microglial knowledge 
and understanding and highlights why DCQ or other similar analyses represent a very powerful 
approach to probe/mine historic datasets for continued utility. 
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6.3 Further Investigation of Microglia in EIU 
Prior to use of the Cx3cr1CreER:R26-tdTomato mouse strain, it was important to validate this as 
both sensitive and specific for microglia. A reduced sensitivity would have meant fewer numbers 
of microglia tagged, resulting in a potentially less representative mRNA-Seq dataset generated. 
Additionally, downstream processing and testing of marker specificity would have been more 
difficult because the tdTomato- fraction of cells would still include microglia. Lastly, lower 
numbers of microglia would have reduced the power and ability to validate changes using flow 
cytometric analysis because data such as percentage positivity would be more susceptible to 
skewing. Conversely, specificity also needed to be high so that cDNA was generated from a pure 
population of microglia and observed differences in the mRNA-Seq dataset were not due to 
infiltrating cells and changing proportions of cell types. Such confounding would have greatly 
reduced the validity of the datasets generated. Whilst validation in each disease context is 
recommended, it is evident that this approach of microglial identification is considerably 
superior to the conventional approaches and will enable more robust analysis of microglial 
changes during disease until a specific marker or set can be identified to reliably differentiate 
them from infiltrating myeloid cells. 
With both the mRNA-Seq pipeline and Cx3cr1CreER:R26-tdTomato mouse strain optimised and 
validated, it was then possible to begin investigation of retinal microglia during inflammatory 
states using the EIU model. After confirming unaltered kinetics to the WT C57BL/6 mouse, and 
that microglial morphological perturbation occurs by 4 hours post-injection, sorting and 
sequencing of microglia before, during, and after resolution of EIU identified a highly-plastic 
transcriptome over time in response to LPS. It also confirmed that the microglia did reset by 2 
weeks and identifies the potential for immune state reset in diseases such as uveitis. 
Importantly, this series of experiments highlights the importance of orthogonal validation of 
both DEGs but also suggested microglial markers. Lastly, a key marker (C5AR1) that helps to 
delineate microglial subsets during the response was identified and validated. 
With the work presented in Chapters III–V now published, there are still many unanswered 
questions and further lines of investigation into microglia during and after EIU: What potential 
treatments could be identified and tested through further bioinformatic analysis, what does the 
flow cytometric panel of validated markers and imaging show when treatments (both novel and 
existing) are administered, and what happens if the retinas are subject to a second LPS stimulus 
during or after the reset period, or how the anti-viral (e.g. TLR3-mediated) and anti-fungal (e.g. 
TLR-2 mediated) response compare to name a few. 
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To this end, work is already underway to test a variety of treatments: dexamethasone (as 
glucocorticoids represent a first-line treatment in uveitis and a treatment known to have efficacy 
– a positive control to observe how the microglia change with treatment), prostaglandin (PG) 
E2 receptor (EP2) agonists and antagonists Butaprost and AH6809 respectively [647] (as IPA 
identified PGE2 as a key regulator), and searching for GPCRs expressed by microglia that signal 
through the Gαq subunit (an IPA canonical pathway identified as greatly altered that could be 
modulated through agonists, antagonists, biased or inverse agonists). Based on an RPKM 
threshold of 5, the existing datasets indicate that only one combination of Gα, Gβ, and Gγ 
subunit isoforms are expressed by retinal microglia: α15, β1, and γ13. In contrast, three 
phospholipase C (PLC) isoforms are expressed: γ2, δ3, and δ4. However, due to the large 
numbers of subunit isoforms and downstream targets little is known about each combination 
could specifically interact and the functional and regulatory consequences this may have in a 
given cell type [648]. It is known however that the Gα15 subunit can couple in a highly 
promiscuous fashion to multiple receptors and may explain why other α subunits are not 
expressed [649]. Key GPCRs expressed by microglia include C5AR1, P2RY12, and CX3CR1, which 
have roles in inflammatory state polarisation, neurone-coupling and responsiveness to injury, 
and neuronal interactions respectively, further highlighting the potential critical role this 
signalling pathway may have [366, 372, 610, 650, 651]. Assays utilising primary murine microglia 
and PLC isoform inhibition have already been described, and may be useful in delineating the 
roles of different signalling molecules expressed by the microglia as identified by mRNA-Seq 
[652]. Furthermore, generalised inactivation of the Gαq subunit could be achieved by using a 
selective inhibitor such as YM-254890 [653, 654]. However, due to Gα15’s promiscuous nature, 
the critical receptors it couples to, and lack of alternate isoforms expressed by microglia for 
partial compensation this may have limited utility in experiments and unlikely to be useful as a 
therapeutic due to wide potential for side effects. It would however confirm if certain functions 
were mediated by a receptor (or receptors) coupling to that signalling pathway. Other avenues 
for possible therapeutics include targeting PLCγ2, a variant of which with a small hypermorphic 
effect on enzyme function associated with a protective effect in AD [655]. Receptor tyrosine 
kinases (such as TREM2, Fc receptors, and CSF1R), acting through the intermediate protein SYK, 
can interact with PLCγ variants and TREM2 signalling/dysfunction has already been identified 
as important in AD [340, 356]. 
In addition to possible therapeutics, it is possible to investigate EIU and microglial responses 
from a more mechanistic viewpoint. Re-stimulation with LPS in other organs leads to a local 
refractory state and it would be interesting to observe and characterise whether the same 
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phenomenon occurs in the eye [656]. Research into different TLR agonists has already been 
performed in the retina, indicating that TLR3- and TLR2-mediated agonisation (e.g. using 
poly(I:C) and zymosan) can induce an immune response [92, 657]. Investigating whether 
microglia exhibit differential responses to simulated infection with different broad classes of 
pathogen would assist in delineating core response programmes and specialised responses to 
specific stimuli – opening the possibility of generalised inhibition of activation or targeted 
inhibition of a specialised response induced under specific circumstances. 
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6.4 Investigating Microglia in EAU 
Beyond EIU, several other models and variants exist. For example, EAU (where CD4+ responses 
are driven against retinal antigens through immunisation) is a widely used model that simulates 
a variety of aspects of uveitis well. It is possible to investigate several variants of EAU including 
conventional peptide immunisation vs. AT and compare the microglial response between them. 
AT would be especially useful in removing the effects adjuvants (i.e. CFA and PTX) have on the 
disease phenotype, enabling delineation between adaptive immune system effects and innate 
immune influences [88, 658]. In short, AT involves conventional peptide immunisation of mice, 
harvesting of lymph nodes during disease, culturing of these for Th17-inducing cytokines and 
peptide, and lastly intraperitoneal transfer into new recipient mice and is a model that has been 
previously optimised by a PhD student within the Ophthalmology group. With various allelic 
markers (such as CD45.1 and CD45.2) but also the arrival of CAG-eGFP mice (where all cells are 
labelled with GFP) to Bristol, it will permit investigation of various hypotheses and already has 
interesting implications such as repeatable in vivo imaging of the microglia and transferred cells 
and their interactions (Figure 6.4.1). The pinnacle version of this experiment would enable 
imaging of endogenous cells, microglia, and transferred cells all with different fluorescent 
markers and is possible using the right combination of transgenic lines: For example, tagging 
microglia with tdTomato in the Cx3cxr1CreER:R26-tdTomato line, subsequently generating a 
chimera (HPI) with a mouse line expressing BFP (e.g. to the CD45 promoter) to label 
endogenous cells, and AT of CAG-EGFP cells would enable visualisation of how each cell 
group/type move and interact with one another in vivo. Furthermore, with new technologies 
such as adaptive optics (repeatable in vivo high resolution imaging) could be performed in the 
mouse and would synergise with this multi-fluorescent tagging approach [659-661]. 
  





Figure 6.4.1. Inducing EAU by adoptive transfer of CD4+ T cells and initial assessment 
with imaging and flow cytometric platforms. A) The adoptive transfer model pipeline is 
summarised, showing how the antigen-specific T cells are generated, cultured, purified (90% 
purity by magnetic-activated cell sorting), and lastly administered to recipient mice by 
intraperitoneal injection. B) Disease is obtained in 80% of recipients by day 10 (a faster onset than 
conventional peptide immunisation). Tissue damage can be imaged in brightfield, C) whilst 
transferred cells can also be visualised using fluorescent filters. D) Flow cytometric analysis can 
be used to identify the GFP+ transfer cells and confirm them as high purity CD4+ T cells. E) 
Brightfield imaging at day 5 post-transfer shows very early signs of disease and F) fluorescent 
imaging highlights the presence of CD4+ T cells (green) in the retina alongside microglial (red) 
perturbations primarily adjacent to the optic disc. The data presented in this figure were generated 
by Dave Copland and Colin Chu.  
E F 
Chapter VI: Future Directions 
215 
 
Work is already underway for analysis of EAU in the Cx3cr1CreER:R26-tdTomato line. Imaging of 
the conventional peptide EAU model shows simultaneous microglial association with both 
lesions and other regions that appear physiological (Figure 6.4.2). This is analogous to some of 
the highly diverse range of pathological appearances in uveitis. Clinically, inflammation can be 
restricted to different anatomical compartments and even within the same ocular tissue as the 
retina can have strikingly varied appearances [662]. Similarly, damage-associated microglia have 
been described in other disease models [340] and microglial heterogeneity is becoming 
increasingly recognised, with reports highlighting heterogeneity in AD, light-damage models, 
EAE and in response to LPS stimulation in vivo [340-342, 344, 586]. 
Additionally, long-term imaging highlights that EAU continues post-peak disease with “flare-
ups” and activation of the microglia – whether this is by recirculation (into and from lymphoid 
tissues) and activation of CD4+ T cells that had already caused disease, or activation of new CD4+ 
T cells by peptide loading (or both) is unclear. What it does highlight is that conventional 
peptide EAU is a disease model which certainly does not resolve in the immediate aftermath 
from peak disease, or for up to 74 days post-immunisation (the latest time-point in imaging in 
these mice), with regards to microglial involvement and perturbation. This means that the 
model exhibits remission and lower-severity (compared to peak) regionality-specific relapse, 
the latter of which may not necessarily be completely representative of relapse in uveitis patients 
(Figure 6.4.2). Nonetheless it could be utilised to characterise changes to microglia after 
repeated activation versus peak disease, but also compared to repeated stimulation EIU 
experiments for both similarities and differences (i.e. a comparison between repeated innate 
stimuli and adaptive responses). Additionally, the tdTomato fluorescence intensity was raised 
considerably, although from the imaging data this is unclear whether it is due to microglial 
migration (e.g. from ON into retina), upregulation of tdTomato by microglia, proliferation of 
microglia, or a combination of these factors. 
  




Figure 6.4.2. tdTomato acquisition-normalised fluorescent fundal imaging time-course 
in a single mouse highlights continuing pathology and microglial association in the EAU 
model long-term. The mouse was immunised for EAU using RBP-3 peptide 1–20 and both eyes 
imaged using the Micron IV. The day of imaging is indicated to the upper left of each image. The 
time-course shows changes occurring in the right eye over time. This particular mouse had a peak 
of disease around day 20, with evidence of some remission at day 25. Resurgence and worsening of 
disease severity is evident at day 28 (but most prominently at days 42 and 52), highlighting ongoing 
disease and changes in this model long-term. This mouse received a 3-day topical tamoxifen 
regime.  
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Flow cytometric analysis highlights a reduced specificity for microglia with a subcutaneous 
tamoxifen regime that negatively correlates with immune cell infiltrate (Figure 6.4.3a–b). These 
experiments were required as the severity and persistence of inflammation are different to EIU. 
This means it is possible that other immune cells may acquire the tdTomato tag through 
constitutive recombination if Cx3cr1 expression was elevated, in addition to surviving long-term 
due to persistent inflammation or possible engraftment into the tissue. In a spontaneous uveitis 
model (Aire-/-) there is evidence for the formation of tertiary lymphoid structures for example 
[561]. Ultimately, use of the same or a similar pipeline for microglial isolation and investigation 
will be critical to future experiments and necessitates confirmation of specificity in this context. 
At peak EAU the microglial count is elevated roughly two-fold during EAU (Figure 6.4.3c), 
although it is currently unclear whether this is due to proliferation, migration of microglia from 
other regions to the retina, or both; it could even be due to engraftment, although this seems 
unlikely as it has already been shown that it takes several weeks to achieve high expression of 
tdTomato (Chapter IV). Research into microglia in other contexts highlights microglial 
proliferation as a feature of neuroinflammation, suggesting that proliferation in EAU (at least) 
is happening [663-665]. The fact that there are regions which appear quiescent during EAU 
suggest that microglia remain within their niche and that it is only microglia local to the damage 
that are proliferating, although this remains yet to be proven. Additionally, CD45 mean 
fluorescence intensity (MFI) was elevated in microglia (Figure 6.4.3d) in agreement with other 
work [415, 549, 550]. tdTomato expression was also elevated and this positively correlates with 
immune cell infiltrate in EAU (Figure 6.4.3e–f), representing another possible flow cytometric 
marker for scoring disease specific to the Cx3cr1CreER:R26-tdTomato mouse line. 
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Figure 6.4.3. Preliminary flow cytometric analysis of microglia during EAU in the 
Cx3cr1CreER:R26-tdTomato mouse strain. The mice were immunised for disease using RBP-3 
peptide 1–20 and were taken for flow cytometric assessment at day 24 (peak disease). A) The 
specificity of microglial tagging in a topical vs. subcutaneous approach indicates a reduced 
specificity with subcutaneous tamoxifen (gating as per Figure 4.2.4). B) The percentage specificity 
correlates with immune cell infiltrate at peak disease in the EAU model of mice that received a 
subcutaneous tamoxifen regime, highlighting a reduced specificity as disease severity increases. 
Further analyses (C–E) utilised mice that had received a topical tamoxifen regime to overcome 
this possible confounding. C) Microglial count is elevated by roughly two-fold during EAU. D) In-
line with published work [415, 549, 550], microglial CD45 expression was increased during 
inflammation. E) tdTomato expression is elevated during EAU. F) tdTomato MFI correlates with 
immune cell infiltrate in the EAU model (n = 5–17). For statistical analysis, both the T test (with 
FDR step-up correction) and Pearson’s test were used. * = p≤0.05, **** = p≤0.0001. 
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Continuing the work beyond basic phenotyping and analysis of microglia in the EAU model 
(e.g. the panel of markers validated as differentially-expressed during EIU and stratification 
using C5AR1; Chapter V), it would be interesting to observe what effects LPS treatment, other 
treatments (such as potential therapeutic interventions), or even other variations of the EAU 
model (such as PMU, a more chronic disease model [85]) have on microglial activation, fundal 
appearance, and transcriptional status. The PMU model, for example, could be important in 
helping to investigate the role of the CD8-microglia interactions observed in the brain [394], 
and delineating that aspect of uveitis due to its chronicity. Ultimately, co-expressional meta-
analysis of these transcriptomes during inflammation would be interesting to identify core sets 
of genes associated to inflammation/immune cell ingress, but also how they compare to 
microglia in other disease states. Ideally, stratifying microglial subtypes or regional damage 
during disease and improvements in disease severity classification will permit more powerful 
and meaningful bioinformatic analysis of the data generated. 
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6.5 Regional Biopsies of Retinas for Analysis of Intra-
Tissue Heterogeneity 
To address the challenge of heterogeneity in retinal tissue damage observed in EAU (Figure 
6.5.1), my Supervisors (Colin Chu and Dave Copland) developed a regional biopsy technique 
whereby these heterogeneous regions can be visualised and excised using microscopy-guided 
dissection (Figure 6.5.2). Preliminary experiments aim to perfect the technique by performing 
regional biopsies on microglia obtained from different anatomical regions in the retina (e.g. ON, 
parenchyma, perivascular), but then progress onto controlled lesion formation through use of 
the laser-CNV model. Performing flow cytometry and mRNA-Seq on these regional biopsies is 
anticipated. By using regional biopsies from the same mouse, the general microenvironment 
could be controlled for and damage-associated signals could be enriched (compared to 
performing bulk mRNA-Seq on whole tissues) leading to better power and detection of 
transcriptional changes in this microglial subpopulation. It may even be possible to identify 
microglial subsets within the same biopsy using C5AR1 stratification. Regional biopsies 
represent a novel and unique opportunity in eye research as part of the synthesis between 
available imaging technologies and their utility in informing other techniques. 




Figure 6.5.1. Fluorescent fundal images of tdTomato (microglia) in the Cx3cr1CreER:R26-
tdTomato mouse line highlights heterogeneity in the microglial response during EAU. 
Regions of microglial activation in parenchymal (blue, circled) and perivascular (grey, circled) 
regions highlights focal points of activation. Other regions possess microglia which, in viewed in 
isolation, could be considered naïve or certainly appear more quiescent with regards to disease 
(purple, circled). 
  




Figure 6.5.2. An overview of the regional biopsy technique. A) In agreement with images in 
the Cx3cr1CreER:R26-tdTomato mouse, heterogeneity in the microglia is also observed in the 
Cx3cr1GFP mouse line. B) Using a curved 21G lacrimal cannula, tissue punches of live full thickness 
retina can be obtained reliably (blue arrow highlights the optic nerve). C) Fluorescent imaging of 
the same retina shown in B (red box). D) Punches can be isolated (circled) and homogenised as 
per standard protocols. E) Flow cytometric analysis shows the presence of 25 GFP+ microglia per 
punch in a naïve retina. The data for this figure, and figure itself, were prepared by Dave Copland 
and Colin Chu. 
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A potentially very powerful synthesis of techniques could be that of regional biopsies and sc-
mRNA-Seq. Regional biopsies could be utilised to ensure representation of all tissue phenotypes 
in fewer cells than at a tissue level (where a rare population may be missed or under-represented 
unless the whole tissue was sequenced) which would permit a greater number of biological 
replicates to be assessed for improved validity and reproducibility (a lack of biological replicates 
is one major flaw of the sc-mRNA-Seq field currently). Additionally, the phenotype of the 
biopsies (identified by imaging pre-mortem) could be cross-correlated to the sc-mRNA-Seq data 
and enable the prediction of signal (and cell) localisation without the need for microscopy or 
techniques such as fluorescence in situ hybridisation (FISH) – but may inform where these 
techniques would be best-placed to validate the findings nonetheless. Furthermore, with 
imaging over a time-course it may be possible to retrospectively analyse early microglial changes 
and signals that preclude later changes, and ultimately guide targeted therapies. 
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6.6 Three-Dimensional OCT Disease Scoring 
Research into the eye carries the advantage of in vivo imaging, a repeatable and non-terminal 
procedure. Disease models carry inherent variability and this decreases statistical power of 
analyses. However, in the eye it is possible to image and score/grade eyes for disease severity 
and then associate this to downstream assays – a major advantage of this field. With the mRNA-
Seq data currently generated, one pertinent question which could be asked is: does disease 
severity correlate well to any expression patterns? This could serve as an approach of identifying 
novel biomarkers in addition to potential therapeutic targets by identifying those genes which 
are critical and robust in expression across samples which have been delineated based on 
disease severity/stage. 
The currently available approaches for scoring disease (based on brightfield fundal imaging) are 
useful but have limitations [104]. For example, the measures are subjective and therefore subject 
to bias, they are unlikely to be linear (meaning use of more powerful parametric statistics is not 
possible), and are not particularly sensitive in grading scale. Other, conventional approaches for 
scoring (i.e. histology) prevent use of samples for other analyses. 
However, a different method utilising OCT and measurement of particles in the VB was recently 
described [109]. In theory, this approach is linear, objective, and could be more sensitive than 
current approaches. Despite this, the method utilises a small sampling region (one or a few OCT 
line scans) and could be argued as less representative because of this. Nonetheless, with the 
OCT it is possible to sample larger regions of the retina by acquiring 512 B-scans adjacent to one 
another (each B-scan is 0.9 mm in length horizontally, scans have a spacing of ~1.75 µm, and a 
depth of ~1.3 mm leading to acquisition of a 0.9*0.9*1.3 mm region of space; Figure 6.6.1a), 
termed a volume scan, that can be reconstructed into a three-dimensional render (Figure 6.6.1b–
d). They can be acquired with the optic disc located centrally, ensuring the same mouse is 
sampled in the same location (i.e. posterior retina) at different time-points, but also that 
equivalent regions are sampled between different mice for better comparability. 
  






















Figure 6.6.1. Three-dimensional projections of the retina using OCT. A) The OCT can 
rapidly acquire 512 horizontal b-scans running superiorly within the target box area (green) to 
enable sampling of the retina and vitreous in a larger, more representative region. These can then 
be used to create different projections, such as B) en-face, C) slices similar to those obtained with 
single line b-scan acquisition (with extended depth of view), and D) oblique images that help to 
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An analysis strategy that can quantify parameters from these volume scans was recently 
optimised using Imaris software (Bitplane, Belfast, UK). Manual boxes are drawn from the 
NFL/GCP/IP to the upper boundaries of the scan (this was usually within the VB) every 75 scans 
which can then be used to create a surface (similar to a layer in photo-editing programmes) of 
this region. This will capture the inner retinal regions (before the INL), which on the OCT 
appears as a continuous region of high intensity. Imaris can then automatically detect surfaces 
on absolute intensity, and size filters can be applied to remove the very small objects (noise) 
and the large objects (continuous inner retina and hypothetical corneal/lens artefacts). From 
here, the number of objects, their volume, and other parameters can be extracted for further 
analysis (Figure 6.6.2). With calibration, the voxel count can be attributed to exact size/volume 
of identified objects. It would also be possible to introduce a standardised metric, such as score 
per volume (to normalise for differences in the volume of space sampled), or measurement of a 
standardised volume size. 
Whilst the Imaris protocol could represent a potential improvement over previously described 
approaches, it requires validation. Future work aims to score and characterise disease in retinas 
(running comparisons to both fundal image analysis and flow cytometric scoring approaches) 
of mice with EAU and/or EIU. It may be possible to intentionally induce differential disease 
severities in EIU through dosing with LPS or use of different TLR agonists, and this could 
represent a powerful way to validate this approach because you could predictively know the 
order of severity in the eyes measured. Once validated, it could then be correlated to mRNA-
Seq data (either acquired post-validation or through retrospective analysis). 
Nonetheless, this analytical approach is not without shortfalls. The approach is not fully 
automated, meaning that it could be labour-intensive to utilise. It might be only pragmatic to 
use on limited numbers of samples, such as mRNA-Seq datasets, rather than large experiments. 
Additionally, it utilises proprietary software for which the code running it is unavailable, which 
also limits customisation of analysis to the hardcoding in the application; these former points 
will limit its potential adoption and use by others. It also makes the underlying assumption that 
the disease course has linear kinetics that are equivalent in each mouse; existing data already 
indicates that the loss of P2RY12 is context-dependent and could be differential to the amount 
of cellular infiltrate for example (Chapter V). However, if the same disease model and induction 
approach were compared then results would be comparable as variability in cellular infiltrate 
due to disease model would be controlled. Additionally, in the early stages of disease there are 
very few changes in the VB, meaning this approach may be unable to quantify early disease 
scores unlike existing methods. Lastly, in a mouse with very severe disease (such as white-out), 
Chapter VI: Future Directions 
228 
 
it is likely that the number of objects (cells) in the eye would be too great for analysis – they 
may be in contact with the retina and each other, resulting in exclusion by the size filter. 
Conventional scoring is unable to score retinas with this severity of disease either, providing 
them with a ceiling score. 
Work is already underway to potentially improve and optimise this approach. A PhD student 
has recently started in our group, and her project aims to design code which can extract these 
and other parameters in an automated fashion through the use of registration and other image-
processing techniques in MATLAB. This would allow for customisation, faster processing, and 
freely available code which could be more widely adopted in the field. In summary, continuing 
developments in image analysis could provide further insights and novel findings, especially 
when correlated to other datasets including mRNA-Seq. 
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Figure 6.6.2. A series of images showing the key stages of analysis of OCT volume scans 
using the Imaris software. A) The series of 512 images are loaded and rendered. B) Manual 
segmentation of the vitreous and inner retinal layers in a single scan (NFL/GCP/IP). C) Summary 
of key locations where manual segmentation was performed (every 75 scans was the maximum 
spacing in which a reliable result was obtained). D) A blue box represents the mask created from 
the segments drawn in C, with red shapes highlighting identified objects that passed the size 








The synthesis of imaging and image analysis, regional biopsies, AT with labelling of disease-
inducing cells, and sc-mRNA-Seq using the Cx3cr1CreER:R26-tdTomato mouse line has the 
potential to generate novel insight and understanding into both uveitis and the role of microglia 
far greater than what has been previously possible. It would enable us to begin answering many 
pertinent questions about microglia and uveitis on the quest for a “microglia marker” and novel 
targeted therapeutics, ideally one which could reset the microglial transcriptome – confirmed 
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Appendix I: mRNA- Seq Technicalitie s 
Appendix I covers more detailed aspects of the mRNA-Seq pipeline utilised to generate data as 
part of this thesis. For an overview and rationale behind this pipeline, see Chapter III. 
Cell Isolation and cDNA Generation 
Initially, cells are isolated by sorting or direct harvesting (if cultured). The cells are lysed and 
the first-strand of cDNA is generated using oligonucleotide and Moloney murine leukaemia 
virus RT (MMLV-RT). The oligonucleotides (the “Oligo-dT primer”) contains a 30-length T 
sequence, two terminal 3’ nucleotides, and a 5’ 25 bp terminal sequence (containing a primer 
site). The T sequence ensures anchoring to the polyA tail, whilst the two terminal 3’ nucleotides 
ensure specific annealling at the beginning of the polyA tail. This means that cDNA generated 
using this pipeline will not include very long sequences of the polyA tail and waste reads, instead 
enriching the associated mRNA sequence upstream. The terminal sequence (5’ end) is used for 
amplification in later steps [518]. When the end of the mRNA strand is reached, addition of 
nucleotides beyond the original transcript’s 5’ end occurs via template-switching (a property of 
MMLV-RT [666]). Template-switching uses a template-switching oligonucleotide (TSO) that 
has a 3’ terminal sequence of rGrG+G (where rG represents ribosomal guanylate and +g 
represents a locked nucleic acid) which enhances the thermal stability to the DNA strand and 
therefore yield [441]. The TSO (in this pipeline) also contains a primer site, allowing for 
replication independent of the nucleotide composition of the strand sequence, thus eliminating 
GC bias often observed in mRNA-Seq datasets. Once the initial cDNA strand is generated, LD-
PCR is performed (using the newly-incorporated primers that flank the mRNA strand) to 
increase the yield – the hallmark feature of this technology which enables use of low input 
amounts. A summary, highlighting template-switching to generate processed cDNA strands, is 
shown in Figure A1.1. 
  




Figure A1.1. The initial cDNA generation using reverse transcriptase and template-
switching, as utilised in the SMART-Seq v4 ultra low RNA input kit. First, oligo(dT) primers 
(labelled 3’ SMART-Seq CDS Primer II A) anneal to the 3’ poly(A) tail of the mRNA transcript and 
is copied utilising reverse transcriptase (RT). These primers also incorporate a primer binding site 
downstream of the transcript (highlighted in light green). Secondly, RT utilised adds additional 
nucleotides to the 5’ end of the transcript which can anneal with the SMART-Seq v4 
Oligonucleotide. RT can then switch templates and copy the remaining sequence present on the 
Oligonucleotide, integrating it into the cDNA strand. Thirdly, primers specific to the newly-
incorporated regions enable the amplification of the full-length transcript by long-distance 
polymerase chain reaction (LD-PCR) to generate double-stranded cDNA at increased yield. Taken 
from Takarabio Inc.’s website. 
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cDNA Purification and Quantification 
Once the cDNA has been generated, it requires purification from the remaining reaction 
components and subsequent quantification so that input amounts between samples can be 
normalised for library preparation and sequencing. Provided that the input number of cells is 
known, this also allows for an estimation of the average amount of mRNA per cell (with some 
underlying assumptions such as 100% reaction efficiency of the LD-PCR, and that the cell 
viability and mRNA content between samples remains constant – meaning that observed 
differences could represent genuine transcriptional amplification or repression). 
Isolation of cDNA is performed using the Agencourt AMPure XP DNA beads, which are the 
gold-standard in nucleotide isolation for maximal recovery and minimal contamination [667]. 
It involves the use of paramagnetic beads to selectively bind nucleic acids by type and size (≥100 
bp). The beads initially bind to the cDNA, are separated from the solution using a magnet, and 
retained (by the magnet) whilst the solution is aspirated. After wash steps, the cDNA is then 
eluted from the beads and aspirated whilst the beads are held by the magnet. The workflow for 
this stage is summarised in Figure A1.2. 
Once the cDNA has been isolated and purified, it is ready for downstream applications such as 
mRNA-Seq (but also other applications including qPCR). However, normalisation of input 
cDNA amount is required and therefore requires quantification of the cDNA output. This step 
is performed using the Agilent TapeStation system, which represents a very precise method of 
quantification [668]. Nucleic acids are separated using electrophoresis and quantified under UV 
light (similarly to many other DNA applications) using especially sensitive equipment and 
reagents; they are stained using a highly sensitive fluorescent stain called “SYBR Gold”. The 
system is very sensitive at quantifying both the abundance (detects as low as 100 pg/uL peaks) 
and size (25-10,000 bp with an accuracy of ±10%) of nucleic acids, whilst using considerably 
reduced input volumes compared to conventional methods such as detecting ethidium bromide 
intercalation using a UV transilluminator. In synthesis, it allows for the quantification of the 
low outputs expected from the ultra-low input RNA kit and uses minimal volume to retain as 
much sample as possible for downstream steps. Representative figures of output gels produced 
by the Agilent Bioanalyzer are presented within the results section Chapter III. 
  




Figure A1.2. The workflow steps required for successful pure isolation of cDNA using the 
Agencourt AMPure XP beads. The beads are incubated with the cDNA (1) to enable binding (2). 
Then the beads (containing the bound cDNA) are separated from the solution using a magnet (3). 
They are washed (4), and then the cDNA is eluted from the beads (5) before transfer to a new tube 
as a purified preparation (6). Taken from the Agencourt AMPURE XP beads manual.  




Tagmentation and Library Preparation 
After purification removal of the original primer sites, in addition to insertion of new primer 
binding sites (for sequencing on the flow cell), an index (to enable multiplexing of samples on 
the flow cell), and a complementary region to the flow cell (for annealing) is required. For 
cleavage of the double-stranded cDNA and insertion of primer binding sites, a hyperactive and 
nonspecific variant of the Tn5 transposase is used [669, 670]. 
However, this inevitably results in the insertion of the primer binding sequences to all cDNA 
fragments generated. This includes terminal regions which contain artefacts such as the original 
primer binding sites, but also undesirable regions such as the polyA tail. PCR cycling (low 
number) using the new inserts will result in exponential replication of all fragments containing 
a primer binding site, including the artefacts/undesirable cDNA. The primers used for the 
cycling contain an index and a region complementary to the flow cell upstream of the primer 
binding site, which enables their integration into the cDNA fragments. Whilst undesirable 
regions will be amplified, because they contain only one region complementary to the flow cell 
(terminal regions would receive only one insert) they will be unable to generate clusters (see 
later). The end result (of desired regions) is a cDNA fragment containing a portion of the 
original mRNA strand (excluding artefact or undesirable segments, and assuming a 0% error 
rate of DNA polymerase) with the required indices (unique to each sample), primer binding 
sites, and both complementary regions to the flow cell required for cluster generation and 
subsequent sequencing (Figure A1.3). 
From here, the libraries are cleaned using the Agencourt AMPure XP beads (Figure A1.2), with 
quantification on the Agilent Bioanalyser, as described earlier. Lastly, the libraries are 
normalised using beads to ensure they all have the same concentration prior to sequencing on 
the flow cell. This helps to ensure similar number of clusters are generated (and therefore reads) 
by each sample. 




Figure A1.3. An overview of the mRNA-Seq library preparation steps utilised in the 
SMART-Seq v4 pipeline. Firstly, transposase is used to cleave dsDNA whilst incorporating novel 
primer binding sites (adapters). These can then be utilised for polymerase chain reaction (PCR) 
with a low number of cycles required. New sequences that are complementary to the flow cell (for 
sequencing) and an index are introduced upstream of each primer and are integrated with cycling. 
This results in the production of a DNA insert containing the original mRNA sequence and other 
sequences required for successful annealing to the flow cell, successful identification of sample 
source (i.e. index utilised for demultiplexing post-acquisition), and successful amplification as 
part of sequencing. This figure was made utilising parts of a video on the Illumina website that 
describe the mRNA-Seq process.  




Sequencing is performed without modifications to the usual Illumina protocols; the library is 
treated as a small genome library for the purposes of processing. It is performed on a flow cell, 
which contains millions (or billions) of covalently-attached forward and reverse 
oligonucleotides (universal and complementary to the libraries generated); more recent 
versions of flow cells (patterned flow cells) contain nanowells etched into a glass substrate 
coated with a metal or metal compound. The nanowells are between 1 nm2 and 1 mm2 in size 
with spacing of between 0.5 and 100 µm; the former depends somewhat on the size of the 
transcript, and the latter depends on the density (how many reads) a flow cell might contain 
[671]. All flow cells possess a continuous gel layer (such as agarose, gelatin, or polyacrylamide 
covering all regions of the flow cell) and a glass top. The cDNA is amplified by solid-phase 
amplification (PCR with the use of surface-bound primers [672]) which enables clonal expansion 
of the cDNA fragments containing both complementary regions (and hence both primer 
binding sites) to generate clusters of up to 1,000 identical copies of an original strand. This 
ensures that fluorescent signals generated from the cDNA strand during sequencing are greatly 
enhanced so they can be detected much more easily and have improved signal-to-noise ratios. 
Different clusters are randomly spaced but spatially separated (for patterned flow cells they are 
found within the nanowells and therefore clusters will be both at a specified size and interval), 
being up to 1 µm in diameter. The spacing between clusters is generally determined by how the 
libraries were loaded and their concentration and is optimised per individual machine and type 
of flow cell used. An overview of cluster generation is shown in Figure A1.4. Furthermore, most 
flow cells will contain between 4–10 segmented regions known as lanes. They contain discrete 
boundaries and assist in controlling cluster generation. As each lane (relative to others) may be 
susceptible to technical bias, they will typically contain clusters generated from every sample 
being ran on the flow cell. 
After cluster generation, the flow cell is ready for sequencing. This is performed by repeated 
cycles of polymerase-directed single base extension through the use of reversible terminators 
(3’-O-azidomethyl 2’-deoxynucleoside triphosphates), each labelled with a different removable 
fluorophore [673]. To improve the efficiency of phosphodiester bond formation between the 
nucleotide analogues, the polymerase also has modifications to its active site [674]. This 
approach enables simultaneous incorporation of any base to limit the potential for non-specific 
or competitive binding (if different bases were added in different steps) but also enhance the 
speed of sequencing. It also enables control of extension base-by-base, which enables imaging 
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of the conjugated fluorophores a single nucleotide at a time, with fluorophore dissociation and 
exposure of the 3’ on the pentose sugar for further extension (repeat of the prior steps) post-
imaging until a new image is ready for acquisition. As the fluorophores are different for each of 
the four bases (A, T, C, G), this enables base-calling for every cluster on the flow cell in a 
simultaneous fashion and registration back to the specific location of the signal to generate a 
read (Figure A1.5). The extension reaction, imaging, and dissociation can be repeated to 
determine the base sequence for short reads (typically between 75 and 300 bp). 
The index (a 3 base code unique to the biological sample – one for the forward read, and one for 
reverse read where applicable) is also sequenced which enables association of a particular read 
(cluster) to an original sample; use of paired indices like this enables multiplexing of up to a 
large number of samples on a single flow cell (typically ≥96) which is highly beneficial for many 
applications, through greatly enhancing the cost-efficiency, where the full depth (number) of 
reads isn’t required for a single sample (e.g. mRNA-Seq). It would also block for any technical 
artefact caused by the flow cell or lane. 
  




Figure A1.4. Cluster generation on Illumina flow cells. A) A flow cell typically contains 4–10 
segmented regions termed lanes. B) Within the flow cell are millions or billions of covalently-
attached oligonucleotides (one of two sequences) complementary to a region on the cDNA in the 
libraries. C) The libraries can anneal to the oligos, and D) be copied by DNA polymerase to create 
a strand complementary to the original that is immobilised on the flow cell. The signal from a 
single strand is too weak to be easily imaged, and therefore E) the other terminal section of the 
strand can anneal to and F) be copied onto a different oligo, enabling clonal expansion (i.e. cluster 
generation) to greatly enhance the signal produced when sequencing. This figure was made 
utilising parts of a video on the Illumina website that describes the mRNA-Seq process.  




Figure A1.5. Illumina sequencing overview highlights how it is possible to sequence 
millions of reads in parallel with accuracy. A) Primers complementary to terminal regions of 
cDNA enable copying of strands. B) Immediately succeeding this is the 3-nucleotide index code 
that enables demultiplexing in analysis. Bases are added in a stepwise fashion using reversible 
terminators with tags. C) The tags can be visualised and registered to specific locations on the 
flow cell which correspond to the different clusters present. This enables construction of sequence 
reads in a parallel fashion. D) Once the read is complete (typically 75 or 150 bp), a primer is 
annealed near to the terminus which E) enables sequencing of the second 3-nucleotide index. 
Pairing indices like this allows for exponentially more samples to be ran in parallel. Lastly, after 
denaturation of the copied strand, it is possible to F) anneal the original strand terminus to the 
flow cell. This allows the process to repeat, generating a sequence from the other end of the mRNA 
transcript to generate paired reads. This figure was made utilising parts of a video on the Illumina 
website that describes the mRNA-Seq process. 
  
Appendix I: mRNA-Seq Technicalities 
291 
 
Measurement Error within Illumina Sequencing 
Measurement error refers to errors or artefacts introduced as part of obtaining reads when 
sequencing. It is well-recognised that differences can occur between flow cells but even lanes 
on the same flow cell. A balanced study design ideally multiplexes samples across all lanes of a 
flow cell to mitigate this (i.e. technical sequencing replicates) and, if using multiple flow cells, 
balances samples of the different experimental groups across them (or in an extremely 
complicated fashion balance all samples equally across all flow cells) [523]. An experimental 
concept schematic is shown in Figure A1.6 and highlights the differences between good and bad 
practice in this context. Illumina provide comprehensive instructions for sequencing that help 
to minimise measurement error: these include multiplexing samples across lanes, controlling 
the concentration of libraries added to the flow cell (this is machine-specific but is often 
determined when initially using the sequencer), and many more as part of their supplied 
protocols and standard operating procedures. 
  




Figure A1.6. Examples of good and poor experimental design with regards to sequencing 
flow cells and lane allocation. In the confounded design, each sample is sequenced on a 
different lane of the flow cell. When performing analysis, differences between lanes could confound 
the results. In the balanced design, all samples are split and allocated across each lane (as 
technical replicates) to mitigate this potential effect. 
